0000883975 2025-01-01 2025-12-31 0000883975 2025-06-30 0000883975 2026-03-24 0000883975 2025-10-01 2025-12-31 0000883975 2025-12-31 0000883975 2024-12-31 0000883975 2024-01-01 2024-12-31 0000883975 us-gaap:CommonStockMember 2023-12-31 0000883975 us-gaap:AdditionalPaidInCapitalMember 2023-12-31 0000883975 us-gaap:RetainedEarningsMember 2023-12-31 0000883975 2023-12-31 0000883975 us-gaap:CommonStockMember 2024-12-31 0000883975 us-gaap:AdditionalPaidInCapitalMember 2024-12-31 0000883975 us-gaap:RetainedEarningsMember 2024-12-31 0000883975 us-gaap:CommonStockMember 2024-01-01 2024-12-31 0000883975 us-gaap:AdditionalPaidInCapitalMember 2024-01-01 2024-12-31 0000883975 us-gaap:RetainedEarningsMember 2024-01-01 2024-12-31 0000883975 us-gaap:CommonStockMember 2025-01-01 2025-12-31 0000883975 us-gaap:AdditionalPaidInCapitalMember 2025-01-01 2025-12-31 0000883975 us-gaap:RetainedEarningsMember 2025-01-01 2025-12-31 0000883975 us-gaap:CommonStockMember 2025-12-31 0000883975 us-gaap:AdditionalPaidInCapitalMember 2025-12-31 0000883975 us-gaap:RetainedEarningsMember 2025-12-31 0000883975 2023-01-01 2023-12-31 0000883975 MBOT:AtTheMarketOfferingProgramMember 2025-01-01 2025-12-31 0000883975 us-gaap:PrivatePlacementMember 2025-01-01 2025-12-31 0000883975 srt:MinimumMember MBOT:ResearchEquipmentAndSoftwareMember 2025-12-31 0000883975 srt:MaximumMember MBOT:ResearchEquipmentAndSoftwareMember 2025-12-31 0000883975 MBOT:FurnitureAndOfficeEquipmentMember 2025-12-31 0000883975 us-gaap:LeaseholdImprovementsMember 2025-12-31 0000883975 MBOT:ResearchAndDevelopmentExpensesMember 2025-01-01 2025-12-31 0000883975 MBOT:ResearchAndDevelopmentExpensesMember 2024-01-01 2024-12-31 0000883975 us-gaap:CashMember 2025-12-31 0000883975 us-gaap:CashMember 2024-12-31 0000883975 us-gaap:MoneyMarketFundsMember 2025-12-31 0000883975 us-gaap:MoneyMarketFundsMember 2024-12-31 0000883975 us-gaap:MoneyMarketFundsMember 2025-12-31 0000883975 us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel1Member 2025-12-31 0000883975 us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel2Member 2025-12-31 0000883975 us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel3Member 2025-12-31 0000883975 us-gaap:FairValueInputsLevel1Member 2025-12-31 0000883975 us-gaap:FairValueInputsLevel2Member 2025-12-31 0000883975 us-gaap:FairValueInputsLevel3Member 2025-12-31 0000883975 us-gaap:MoneyMarketFundsMember 2024-12-31 0000883975 us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel1Member 2024-12-31 0000883975 us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel2Member 2024-12-31 0000883975 us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel3Member 2024-12-31 0000883975 us-gaap:FairValueInputsLevel1Member 2024-12-31 0000883975 us-gaap:FairValueInputsLevel2Member 2024-12-31 0000883975 us-gaap:FairValueInputsLevel3Member 2024-12-31 0000883975 2025-03-01 2025-03-31 0000883975 2025-07-01 2025-07-31 0000883975 MBOT:ResearchEquipmentAndSoftwareMember 2025-12-31 0000883975 MBOT:ResearchEquipmentAndSoftwareMember 2024-12-31 0000883975 us-gaap:LeaseholdImprovementsMember 2024-12-31 0000883975 MBOT:FurnitureAndOfficeEquipmentMember 2024-12-31 0000883975 MBOT:TwoThousandThirteenToJuneThirtyTwoThousandTwentyTwoMember MBOT:IsraeliInnovationAuthorityMember 2025-01-01 2025-12-31 0000883975 MBOT:IsraeliInnovationAuthorityMember 2025-12-31 0000883975 MBOT:CardioSertLtdMember MBOT:IsraeliInnovationAuthorityMember 2023-10-06 2023-10-06 0000883975 srt:MinimumMember MBOT:IsraeliInnovationAuthorityMember 2025-01-01 2025-12-31 0000883975 srt:MaximumMember MBOT:IsraeliInnovationAuthorityMember 2025-01-01 2025-12-31 0000883975 MBOT:MinistryOfEconomyMember 2025-12-31 0000883975 srt:MinimumMember MBOT:TechnionResearchAndDevelopmentFoundationLimitedMember 2012-06-01 2012-06-30 0000883975 srt:MaximumMember MBOT:TechnionResearchAndDevelopmentFoundationLimitedMember 2012-06-01 2012-06-30 0000883975 MBOT:AtTheMarketOfferingAgreementMember MBOT:HCWainwrightAndCoLLCMember 2021-06-10 0000883975 us-gaap:CommonStockMember MBOT:AtTheMarketOfferingAgreementMember 2024-07-01 2024-07-01 0000883975 2022-10-03 2022-10-03 0000883975 MBOT:HCWainwrightAndCoLLCMember 2022-10-03 2022-10-03 0000883975 MBOT:AtTheMarketOfferingAgreementMember MBOT:HCWainwrightAndCoLLCMember 2022-10-06 2022-10-06 0000883975 MBOT:DeviceMember srt:MinimumMember 2022-10-06 2022-10-06 0000883975 MBOT:DeviceMember srt:MaximumMember 2022-10-06 2022-10-06 0000883975 MBOT:IntegratedProductMember 2022-10-06 2022-10-06 0000883975 MBOT:SecuritiesPurchaseAgreementMember 2025-01-01 2025-12-31 0000883975 2024-01-26 2024-01-26 0000883975 MBOT:LitigationSettlementMember 2024-01-26 2024-01-26 0000883975 MBOT:LitigationSettlementMember 2023-12-31 0000883975 MBOT:LitigationSettlementMember 2024-01-01 2024-03-31 0000883975 us-gaap:CommonStockMember MBOT:LitigationSettlementMember 2024-01-01 2024-03-31 0000883975 MBOT:ChiefExecutiveOfficerAndExecutivesAndCertainEmployeesMember 2025-12-31 0000883975 us-gaap:CommonStockMember MBOT:SeriesAPreferredInvestmentOptionsMember 2022-10-25 2022-10-25 0000883975 us-gaap:CommonStockMember MBOT:SeriesAPreferredInvestmentOptionsMember 2022-10-25 0000883975 us-gaap:CommonStockMember MBOT:SeriesCPreferredInvestmentOptionsMember 2023-06-06 0000883975 us-gaap:CommonStockMember MBOT:SeriesDPreferredInvestmentOptionsMember 2023-06-26 2023-06-26 0000883975 us-gaap:CommonStockMember MBOT:SeriesDPreferredInvestmentOptionsMember 2023-06-26 0000883975 us-gaap:CommonStockMember MBOT:ExistingPreferredInvestmentOptionsMember 2023-12-29 2023-12-29 0000883975 us-gaap:CommonStockMember MBOT:ExistingPreferredInvestmentOptionsMember 2023-12-29 0000883975 us-gaap:CommonStockMember MBOT:InducementInvestmentOptionsMember 2023-12-29 2023-12-29 0000883975 us-gaap:CommonStockMember MBOT:InducementInvestmentOptionsMember 2023-12-29 0000883975 2023-12-29 2023-12-29 0000883975 MBOT:PreferredInvestmentOptionExerciseInducementOffersLetterMember MBOT:HCWainwrightAndCoLLCMember 2023-12-29 2023-12-29 0000883975 MBOT:PreferredInvestmentOptionExerciseInducementOffersLetterMember MBOT:HCWainwrightAndCoLLCMember 2023-12-29 0000883975 us-gaap:CommonStockMember MBOT:SecuritiesPurchaseAgreementMember 2024-06-03 2024-06-03 0000883975 us-gaap:CommonStockMember MBOT:SecuritiesPurchaseAgreementMember 2024-06-03 0000883975 us-gaap:CommonStockMember us-gaap:PrivatePlacementMember 2024-06-03 2024-06-03 0000883975 us-gaap:CommonStockMember us-gaap:PrivatePlacementMember 2024-06-03 0000883975 us-gaap:CommonStockMember MBOT:SeriesFPreferredInvestmentOptionsMember 2024-06-03 2024-06-03 0000883975 us-gaap:CommonStockMember MBOT:SeriesFPreferredInvestmentOptionsMember 2024-06-03 0000883975 us-gaap:CommonStockMember MBOT:HCWainwrightAndCoLLCMember 2024-06-03 2024-06-03 0000883975 us-gaap:CommonStockMember MBOT:HCWainwrightAndCoLLCMember 2024-06-03 0000883975 us-gaap:CommonStockMember MBOT:SecuritiesPurchaseAgreementMember 2025-01-06 2025-01-06 0000883975 us-gaap:CommonStockMember MBOT:SecuritiesPurchaseAgreementMember 2025-01-06 0000883975 us-gaap:CommonStockMember us-gaap:PrivatePlacementMember 2025-01-06 2025-01-06 0000883975 us-gaap:CommonStockMember us-gaap:PrivatePlacementMember 2025-01-06 0000883975 us-gaap:CommonStockMember MBOT:SeriesGPreferredInvestmentOptionsMember 2025-01-06 2025-01-06 0000883975 us-gaap:CommonStockMember MBOT:SeriesGPreferredInvestmentOptionsMember 2025-01-06 0000883975 us-gaap:CommonStockMember MBOT:HCWainwrightAndCoLLCMember 2025-01-06 2025-01-06 0000883975 us-gaap:CommonStockMember MBOT:HCWainwrightAndCoLLCMember 2025-01-06 0000883975 us-gaap:CommonStockMember MBOT:SecuritiesPurchaseAgreementMember 2025-01-07 2025-01-07 0000883975 us-gaap:CommonStockMember MBOT:SecuritiesPurchaseAgreementMember 2025-01-07 0000883975 us-gaap:CommonStockMember us-gaap:PrivatePlacementMember 2025-01-07 2025-01-07 0000883975 us-gaap:CommonStockMember us-gaap:PrivatePlacementMember 2025-01-07 0000883975 us-gaap:CommonStockMember MBOT:SeriesHPreferredInvestmentOptionsMember 2025-01-07 2025-01-07 0000883975 us-gaap:CommonStockMember MBOT:SeriesHPreferredInvestmentOptionsMember 2025-01-07 0000883975 us-gaap:CommonStockMember MBOT:HCWainwrightAndCoLLCMember 2025-01-07 2025-01-07 0000883975 us-gaap:CommonStockMember MBOT:HCWainwrightAndCoLLCMember 2025-01-07 0000883975 us-gaap:CommonStockMember MBOT:SecuritiesPurchaseAgreementMember 2025-02-09 2025-02-09 0000883975 us-gaap:CommonStockMember MBOT:SecuritiesPurchaseAgreementMember 2025-02-09 0000883975 us-gaap:CommonStockMember us-gaap:PrivatePlacementMember 2025-02-09 2025-02-09 0000883975 us-gaap:CommonStockMember us-gaap:PrivatePlacementMember 2025-02-09 0000883975 us-gaap:CommonStockMember MBOT:SeriesIPreferredInvestmentOptionsMember 2025-02-09 2025-02-09 0000883975 us-gaap:CommonStockMember MBOT:SeriesIPreferredInvestmentOptionsMember 2025-02-09 0000883975 us-gaap:CommonStockMember MBOT:HCWainwrightAndCoLLCMember 2025-02-09 2025-02-09 0000883975 us-gaap:CommonStockMember MBOT:HCWainwrightAndCoLLCMember 2025-02-09 0000883975 2025-06-10 0000883975 us-gaap:CommonStockMember MBOT:SeriesIPreferredInvestmentOptionsMember 2025-06-10 2025-06-10 0000883975 us-gaap:CommonStockMember MBOT:SeriesIPreferredInvestmentOptionsMember 2025-06-10 0000883975 us-gaap:CommonStockMember MBOT:PlacementAgentPreferredInvestmentOptionsMember 2025-06-10 2025-06-10 0000883975 us-gaap:CommonStockMember MBOT:PlacementAgentPreferredInvestmentOptionsMember 2025-06-10 0000883975 us-gaap:CommonStockMember MBOT:AtTheMarketOfferingAgreementMember 2024-01-01 2024-12-31 0000883975 MBOT:AtTheMarketOfferingAgreementMember 2024-01-01 2024-12-31 0000883975 us-gaap:CommonStockMember MBOT:AtTheMarketOfferingAgreementMember 2025-01-01 2025-01-31 0000883975 MBOT:AtTheMarketOfferingAgreementMember 2025-01-01 2025-01-31 0000883975 MBOT:SeriesEGHIAndSeriesFPreferredInvestmentOptionsMember 2025-10-01 2025-12-31 0000883975 MBOT:SeriesEGHIAndSeriesFPreferredInvestmentOptionsMember 2025-12-31 0000883975 us-gaap:PrivatePlacementMember 2025-01-01 2025-12-31 0000883975 us-gaap:PrivatePlacementMember 2025-07-01 2025-09-30 0000883975 2025-06-09 0000883975 MBOT:SeriesFPreferredInvestmentOptionsMember MBOT:TheLetterAgreementMember 2025-09-14 2025-09-14 0000883975 MBOT:SeriesFPreferredInvestmentOptionsMember MBOT:TheLetterAgreementMember 2025-09-14 0000883975 MBOT:SeriesGPreferredInvestmentOptionsMember MBOT:TheLetterAgreementMember 2025-09-14 2025-09-14 0000883975 MBOT:SeriesGPreferredInvestmentOptionsMember MBOT:TheLetterAgreementMember 2025-09-14 0000883975 MBOT:SeriesHPreferredInvestmentOptionsMember MBOT:TheLetterAgreementMember 2025-09-14 2025-09-14 0000883975 MBOT:SeriesHPreferredInvestmentOptionsMember MBOT:TheLetterAgreementMember 2025-09-14 0000883975 MBOT:SeriesIPreferredInvestmentOptionsMember MBOT:TheLetterAgreementMember 2025-09-14 2025-09-14 0000883975 MBOT:SeriesIPreferredInvestmentOptionsMember MBOT:TheLetterAgreementMember 2025-09-14 0000883975 MBOT:TheLetterAgreementMember 2025-09-14 2025-09-14 0000883975 srt:MinimumMember MBOT:TheLetterAgreementMember 2025-09-14 0000883975 srt:MaximumMember MBOT:TheLetterAgreementMember 2025-09-14 0000883975 MBOT:SeriesJPreferredInvestmentOptionsMember MBOT:TheLetterAgreementMember 2025-09-14 2025-09-14 0000883975 MBOT:SeriesJPreferredInvestmentOptionsMember MBOT:TheLetterAgreementMember 2025-09-14 0000883975 MBOT:PreferredInvestmentOptionsMember MBOT:TheLetterAgreementMember 2025-09-16 2025-09-16 0000883975 MBOT:PreferredInvestmentOptionsMember MBOT:SecondClosingMember MBOT:TheLetterAgreementMember 2025-09-29 2025-09-29 0000883975 MBOT:PreferredInvestmentOptionsMember MBOT:ThirdClosingMember MBOT:TheLetterAgreementMember 2025-10-06 2025-10-06 0000883975 MBOT:WainwrightMember 2025-01-01 2025-12-31 0000883975 srt:ChiefExecutiveOfficerMember us-gaap:CommonStockMember 2024-01-01 2024-12-31 0000883975 srt:ManagementMember us-gaap:CommonStockMember 2024-01-01 2024-12-31 0000883975 MBOT:ChiefExecutiveOfficerAndOtherExecutivesMember 2024-12-31 0000883975 MBOT:ChiefExecutiveOfficerAndOtherExecutivesMember 2024-01-01 2024-12-31 0000883975 MBOT:ChiefExecutiveOfficerAndExecutivesMember 2024-01-01 2024-12-31 0000883975 MBOT:CertainEmployeesMember 2024-01-01 2024-12-31 0000883975 MBOT:CertainEmployeesMember 2024-12-31 0000883975 MBOT:AdvisorsMember 2024-01-01 2024-12-31 0000883975 MBOT:AdvisorsMember 2024-12-31 0000883975 srt:ChiefExecutiveOfficerMember 2024-02-01 2024-02-29 0000883975 srt:ChiefExecutiveOfficerMember 2024-02-29 0000883975 MBOT:BoardMember 2025-02-01 2025-02-28 0000883975 MBOT:TwentyTwentyOmnibusPerformanceAwardPlanMember 2025-06-10 0000883975 srt:ChiefExecutiveOfficerMember 2025-01-01 2025-12-31 0000883975 MBOT:ExecutivesMember 2025-01-01 2025-12-31 0000883975 MBOT:CertainEmployeesAndCertainBoardMembersMember 2025-01-01 2025-12-31 0000883975 MBOT:EmployeesAndDirectorsMember 2024-12-31 0000883975 MBOT:EmployeesAndDirectorsMember 2025-01-01 2025-12-31 0000883975 MBOT:EmployeesAndDirectorsMember 2025-12-31 0000883975 MBOT:EmployeesAndDirectorsMember 2023-12-31 0000883975 MBOT:EmployeesAndDirectorsMember 2024-01-01 2024-12-31 0000883975 srt:MinimumMember MBOT:ExercisePriceOneMember 2025-01-01 2025-12-31 0000883975 srt:MinimumMember MBOT:ExercisePriceOneMember 2024-01-01 2024-12-31 0000883975 srt:MaximumMember MBOT:ExercisePriceOneMember 2025-01-01 2025-12-31 0000883975 srt:MaximumMember MBOT:ExercisePriceOneMember 2024-01-01 2024-12-31 0000883975 MBOT:ExercisePriceOneMember 2025-12-31 0000883975 MBOT:ExercisePriceOneMember 2024-12-31 0000883975 MBOT:ExercisePriceOneMember 2025-01-01 2025-12-31 0000883975 MBOT:ExercisePriceOneMember 2024-01-01 2024-12-31 0000883975 srt:MinimumMember MBOT:ExercisePriceTwoMember 2025-01-01 2025-12-31 0000883975 srt:MinimumMember MBOT:ExercisePriceTwoMember 2024-01-01 2024-12-31 0000883975 srt:MaximumMember MBOT:ExercisePriceTwoMember 2025-01-01 2025-12-31 0000883975 srt:MaximumMember MBOT:ExercisePriceTwoMember 2024-01-01 2024-12-31 0000883975 MBOT:ExercisePriceTwoMember 2025-12-31 0000883975 MBOT:ExercisePriceTwoMember 2024-12-31 0000883975 MBOT:ExercisePriceTwoMember 2025-01-01 2025-12-31 0000883975 MBOT:ExercisePriceTwoMember 2024-01-01 2024-12-31 0000883975 srt:MinimumMember MBOT:ExercisePriceThreeMember 2025-01-01 2025-12-31 0000883975 srt:MinimumMember MBOT:ExercisePriceThreeMember 2024-01-01 2024-12-31 0000883975 srt:MaximumMember MBOT:ExercisePriceThreeMember 2025-01-01 2025-12-31 0000883975 srt:MaximumMember MBOT:ExercisePriceThreeMember 2024-01-01 2024-12-31 0000883975 MBOT:ExercisePriceThreeMember 2025-12-31 0000883975 MBOT:ExercisePriceThreeMember 2024-12-31 0000883975 MBOT:ExercisePriceThreeMember 2025-01-01 2025-12-31 0000883975 MBOT:ExercisePriceThreeMember 2024-01-01 2024-12-31 0000883975 srt:MinimumMember MBOT:ExercisePriceFourMember 2025-01-01 2025-12-31 0000883975 srt:MinimumMember MBOT:ExercisePriceFourMember 2024-01-01 2024-12-31 0000883975 srt:MaximumMember MBOT:ExercisePriceFourMember 2025-01-01 2025-12-31 0000883975 srt:MaximumMember MBOT:ExercisePriceFourMember 2024-01-01 2024-12-31 0000883975 MBOT:ExercisePriceFourMember 2025-12-31 0000883975 MBOT:ExercisePriceFourMember 2024-12-31 0000883975 MBOT:ExercisePriceFourMember 2025-01-01 2025-12-31 0000883975 MBOT:ExercisePriceFourMember 2024-01-01 2024-12-31 0000883975 srt:MinimumMember MBOT:ExercisePriceFiveMember 2025-01-01 2025-12-31 0000883975 srt:MinimumMember MBOT:ExercisePriceFiveMember 2024-01-01 2024-12-31 0000883975 srt:MaximumMember MBOT:ExercisePriceFiveMember 2025-01-01 2025-12-31 0000883975 srt:MaximumMember MBOT:ExercisePriceFiveMember 2024-01-01 2024-12-31 0000883975 MBOT:ExercisePriceFiveMember 2025-12-31 0000883975 MBOT:ExercisePriceFiveMember 2024-12-31 0000883975 MBOT:ExercisePriceFiveMember 2025-01-01 2025-12-31 0000883975 MBOT:ExercisePriceFiveMember 2024-01-01 2024-12-31 0000883975 srt:MinimumMember 2025-01-01 2025-12-31 0000883975 srt:MaximumMember 2025-01-01 2025-12-31 0000883975 srt:MinimumMember 2024-01-01 2024-12-31 0000883975 srt:MaximumMember 2024-01-01 2024-12-31 0000883975 MBOT:WarrantToUnderwritersOctoberTwoThousandTwentyTwoMember 2025-12-31 0000883975 MBOT:WarrantToUnderwritersOctoberTwoThousandTwentyTwoMember 2024-12-31 0000883975 MBOT:WarrantToUnderwritersOctoberTwoThousandTwentyTwoMember 2025-01-01 2025-12-31 0000883975 MBOT:WarrantToUnderwritersMayTwoThousandTwentyThreeMember 2025-12-31 0000883975 MBOT:WarrantToUnderwritersMayTwoThousandTwentyThreeMember 2024-12-31 0000883975 MBOT:WarrantToUnderwritersMayTwoThousandTwentyThreeMember 2025-01-01 2025-12-31 0000883975 MBOT:WarrantToUnderwritersMayTwoThousandTwentyThreeOneMember 2025-12-31 0000883975 MBOT:WarrantToUnderwritersMayTwoThousandTwentyThreeOneMember 2024-12-31 0000883975 MBOT:WarrantToUnderwritersMayTwoThousandTwentyThreeOneMember 2025-01-01 2025-12-31 0000883975 MBOT:WarrantToUnderwritersJuneTwoThousandTwentyThreeMember 2025-12-31 0000883975 MBOT:WarrantToUnderwritersJuneTwoThousandTwentyThreeMember 2024-12-31 0000883975 MBOT:WarrantToUnderwritersJuneTwoThousandTwentyThreeMember 2025-01-01 2025-12-31 0000883975 MBOT:WarrantToUnderwritersJuneTwoThousandTwentyThreeOneMember 2025-12-31 0000883975 MBOT:WarrantToUnderwritersJuneTwoThousandTwentyThreeOneMember 2024-12-31 0000883975 MBOT:WarrantToUnderwritersJuneTwoThousandTwentyThreeOneMember 2025-01-01 2025-12-31 0000883975 MBOT:WarrantSeriesEJanuary2024Member 2025-12-31 0000883975 MBOT:WarrantSeriesEJanuary2024Member 2024-12-31 0000883975 MBOT:WarrantSeriesEJanuary2024Member 2025-01-01 2025-12-31 0000883975 MBOT:WarrantToUnderwritersJanuaryTwoThousandTwentyFourMember 2025-12-31 0000883975 MBOT:WarrantToUnderwritersJanuaryTwoThousandTwentyFourMember 2024-12-31 0000883975 MBOT:WarrantToUnderwritersJanuaryTwoThousandTwentyFourMember 2025-01-01 2025-12-31 0000883975 MBOT:WarrantSeriesFJune2024Member 2025-12-31 0000883975 MBOT:WarrantSeriesFJune2024Member 2024-12-31 0000883975 MBOT:WarrantSeriesFJune2024Member 2025-01-01 2025-12-31 0000883975 MBOT:WarrantToUnderwritersJuneTwoThousandTwentyFourMember 2025-12-31 0000883975 MBOT:WarrantToUnderwritersJuneTwoThousandTwentyFourMember 2024-12-31 0000883975 MBOT:WarrantToUnderwritersJuneTwoThousandTwentyFourMember 2025-01-01 2025-12-31 0000883975 MBOT:WarrantToUnderwritersJanuaryTwoThousandTwentyFiveMember 2025-12-31 0000883975 MBOT:WarrantToUnderwritersJanuaryTwoThousandTwentyFiveMember 2024-12-31 0000883975 MBOT:WarrantToUnderwritersJanuaryTwoThousandTwentyFiveMember 2025-01-01 2025-12-31 0000883975 MBOT:WarrantToUnderwritersJanuaryTwoThousandTwentyFiveOneMember 2025-12-31 0000883975 MBOT:WarrantToUnderwritersJanuaryTwoThousandTwentyFiveOneMember 2024-12-31 0000883975 MBOT:WarrantToUnderwritersJanuaryTwoThousandTwentyFiveOneMember 2025-01-01 2025-12-31 0000883975 MBOT:WarrantToUnderwritersJanuaryTwoThousandTwentyFiveTwoMember 2025-12-31 0000883975 MBOT:WarrantToUnderwritersJanuaryTwoThousandTwentyFiveTwoMember 2024-12-31 0000883975 MBOT:WarrantToUnderwritersJanuaryTwoThousandTwentyFiveTwoMember 2025-01-01 2025-12-31 0000883975 MBOT:WarrantToUnderwritersFebruaryTwoThousandTwentyFiveTwoMember 2025-12-31 0000883975 MBOT:WarrantToUnderwritersFebruaryTwoThousandTwentyFiveTwoMember 2024-12-31 0000883975 MBOT:WarrantToUnderwritersFebruaryTwoThousandTwentyFiveTwoMember 2025-01-01 2025-12-31 0000883975 MBOT:WarrantToUnderwritersSeptemberTwoThousandTwentyFiveMember 2025-12-31 0000883975 MBOT:WarrantToUnderwritersSeptemberTwoThousandTwentyFiveMember 2024-12-31 0000883975 MBOT:WarrantToUnderwritersSeptemberTwoThousandTwentyFiveMember 2025-01-01 2025-12-31 0000883975 MBOT:WarrantToUnderwritersSeptemberTwoThousandTwentyFiveOneMember 2025-12-31 0000883975 MBOT:WarrantToUnderwritersSeptemberTwoThousandTwentyFiveOneMember 2024-12-31 0000883975 MBOT:WarrantToUnderwritersSeptemberTwoThousandTwentyFiveOneMember 2025-01-01 2025-12-31 0000883975 MBOT:WarrantToUnderwritersSeptemberTwoThousandTwentyFiveTwoMember 2025-12-31 0000883975 MBOT:WarrantToUnderwritersSeptemberTwoThousandTwentyFiveTwoMember 2024-12-31 0000883975 MBOT:WarrantToUnderwritersSeptemberTwoThousandTwentyFiveTwoMember 2025-01-01 2025-12-31 0000883975 MBOT:WarrantToUnderwritersSeptemberTwoThousandTwentyFiveThreeMember 2025-12-31 0000883975 MBOT:WarrantToUnderwritersSeptemberTwoThousandTwentyFiveThreeMember 2024-12-31 0000883975 MBOT:WarrantToUnderwritersSeptemberTwoThousandTwentyFiveThreeMember 2025-01-01 2025-12-31 0000883975 MBOT:WarrantToUnderwritersSeptemberTwoThousandTwentyFiveFourMember 2025-12-31 0000883975 MBOT:WarrantToUnderwritersSeptemberTwoThousandTwentyFiveFourMember 2024-12-31 0000883975 MBOT:WarrantToUnderwritersSeptemberTwoThousandTwentyFiveFourMember 2025-01-01 2025-12-31 0000883975 MBOT:WarrantToUnderwritersSeptemberTwoThousandTwentyFiveFiveMember 2025-12-31 0000883975 MBOT:WarrantToUnderwritersSeptemberTwoThousandTwentyFiveFiveMember 2024-12-31 0000883975 MBOT:WarrantToUnderwritersSeptemberTwoThousandTwentyFiveFiveMember 2025-01-01 2025-12-31 0000883975 MBOT:WarrantToUnderwritersSeptemberTwoThousandTwentyFiveSixMember 2025-12-31 0000883975 MBOT:WarrantToUnderwritersSeptemberTwoThousandTwentyFiveSixMember 2024-12-31 0000883975 MBOT:WarrantToUnderwritersSeptemberTwoThousandTwentyFiveSixMember 2025-01-01 2025-12-31 0000883975 MBOT:WarrantToUnderwritersSeptemberTwoThousandTwentyFiveSevenMember 2025-12-31 0000883975 MBOT:WarrantToUnderwritersSeptemberTwoThousandTwentyFiveSevenMember 2024-12-31 0000883975 MBOT:WarrantToUnderwritersSeptemberTwoThousandTwentyFiveSevenMember 2025-01-01 2025-12-31 0000883975 MBOT:WarrantToUnderwritersSeptemberTwoThousandTwentyFiveEightMember 2025-12-31 0000883975 MBOT:WarrantToUnderwritersSeptemberTwoThousandTwentyFiveEightMember 2024-12-31 0000883975 MBOT:WarrantToUnderwritersSeptemberTwoThousandTwentyFiveEightMember 2025-01-01 2025-12-31 0000883975 MBOT:WarrantToUnderwritersSeptemberTwoThousandTwentyFiveNineMember 2025-12-31 0000883975 MBOT:WarrantToUnderwritersSeptemberTwoThousandTwentyFiveNineMember 2024-12-31 0000883975 MBOT:WarrantToUnderwritersSeptemberTwoThousandTwentyFiveNineMember 2025-01-01 2025-12-31 0000883975 MBOT:WarrantSeriesJSeptemberTwoThousandTwentyFiveMember 2025-12-31 0000883975 MBOT:WarrantSeriesJSeptemberTwoThousandTwentyFiveMember 2024-12-31 0000883975 MBOT:WarrantSeriesJSeptemberTwoThousandTwentyFiveMember 2025-01-01 2025-12-31 0000883975 MBOT:WarrantSeriesJOneSeptemberTwoThousandTwentyFiveMember 2025-12-31 0000883975 MBOT:WarrantSeriesJOneSeptemberTwoThousandTwentyFiveMember 2024-12-31 0000883975 MBOT:WarrantSeriesJOneSeptemberTwoThousandTwentyFiveMember 2025-01-01 2025-12-31 0000883975 MBOT:WarrantSeriesJOctoberTwoThousandTwentyFiveOneMember 2025-12-31 0000883975 MBOT:WarrantSeriesJOctoberTwoThousandTwentyFiveOneMember 2024-12-31 0000883975 MBOT:WarrantSeriesJOctoberTwoThousandTwentyFiveOneMember 2025-01-01 2025-12-31 0000883975 MBOT:WarrantSeriesJOctoberTwoThousandTwentyFiveTwoMember 2025-12-31 0000883975 MBOT:WarrantSeriesJOctoberTwoThousandTwentyFiveTwoMember 2024-12-31 0000883975 MBOT:WarrantSeriesJOctoberTwoThousandTwentyFiveTwoMember 2025-01-01 2025-12-31 0000883975 MBOT:SalesGeneralAndAdministrativeExpensesMember 2025-01-01 2025-12-31 0000883975 MBOT:SalesGeneralAndAdministrativeExpensesMember 2024-01-01 2024-12-31 0000883975 country:IL 2025-12-31 0000883975 country:IL 2024-12-31 0000883975 country:US 2025-12-31 0000883975 country:US 2024-12-31 0000883975 MBOT:USTaxAuthorityMember 2025-01-01 2025-12-31 0000883975 MBOT:USTaxAuthorityMember 2024-01-01 2024-12-31 0000883975 MBOT:USTaxAuthorityMember 2025-12-31 0000883975 MBOT:USTaxAuthorityMember 2024-12-31 0000883975 MBOT:PreTwoThousandSeventeenMember 2025-12-31 0000883975 MBOT:PostTwoThousandSeventeenMember 2025-12-31 0000883975 us-gaap:IsraelTaxAuthorityMember 2025-01-01 2025-12-31 0000883975 us-gaap:IsraelTaxAuthorityMember 2024-01-01 2024-12-31 0000883975 us-gaap:IsraelTaxAuthorityMember 2025-12-31 0000883975 us-gaap:IsraelTaxAuthorityMember 2024-12-31 0000883975 srt:ChiefExecutiveOfficerMember us-gaap:SubsequentEventMember 2026-02-01 2026-02-28 0000883975 MBOT:ExecutivesAndCertainEmployeesMember us-gaap:SubsequentEventMember 2026-02-01 2026-02-28 0000883975 srt:ChiefExecutiveOfficerMember us-gaap:SubsequentEventMember 2026-03-01 2026-03-31 0000883975 us-gaap:ExecutiveCommitteeMember us-gaap:SubsequentEventMember 2026-02-01 2026-02-28 0000883975 us-gaap:ExecutiveCommitteeMember us-gaap:SubsequentEventMember 2026-03-01 2026-03-31 0000883975 MBOT:EmployeesMember us-gaap:SubsequentEventMember 2026-02-01 2026-02-28 0000883975 MBOT:EmployeesMember us-gaap:SubsequentEventMember 2026-03-01 2026-03-31 0000883975 us-gaap:SubsequentEventMember 2026-02-01 2026-02-28 iso4217:USD shares iso4217:USD shares pure iso4217:ILS MBOT:Segment false FY 0000883975

http://fasb.org/us-gaap/2025#UsefulLifeTermOfLeaseMember

10-K true 2025-12-31 --12-31 2025 false 000-19871 MICROBOT MEDICAL INC. DE 94-3078125 175 Derby St. Bld. 27 Hingham MA 02043 (781) 875-3605 Common Stock, Par value $0.01 MBOT NASDAQ No No Yes Yes Non-accelerated Filer true false false false false 95655000 67158044 Item 1C. CybersecuritySince our formation, <span class="xdx_phnt_RGlzY2xvc3VyZSAtIEN5YmVyc2VjdXJpdHkgUmlzayBNYW5hZ2VtZW50IGFuZCBTdHJhdGVneSBEaXNjbG9zdXJlAA__" id="xdx_90C_ecyd--CybersecurityRiskManagementProcessesIntegratedFlag_dbT_c20250101__20251231_zlJw7XVXbJM3">we have been primarily focused on research and development activities and pursuing FDA approval of our planned products, and only recently commenced building our commercial team and focusing on the commercialization of LIBERTY®. <span class="xdx_phnt_RGlzY2xvc3VyZSAtIEN5YmVyc2VjdXJpdHkgUmlzayBNYW5hZ2VtZW50IGFuZCBTdHJhdGVneSBEaXNjbG9zdXJlAA__" id="xdx_907_ecyd--CybersecurityRiskManagementProcessesIntegratedTextBlock_c20250101__20251231_znVS9zXqfggk" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We have 42 full-time employees and 1 hourly employee, of which 24 are based in the United States and 19 are based in Israel, and currently use third-party vendors and service providers for certain product development and regulatory approval activities.<span class="xdx_phnt_RGlzY2xvc3VyZSAtIEN5YmVyc2VjdXJpdHkgUmlzayBNYW5hZ2VtZW50IGFuZCBTdHJhdGVneSBEaXNjbG9zdXJlAA__" id="xdx_902_ecyd--CybersecurityRiskManagementThirdPartyEngagedFlag_dbT_c20250101__20251231_zJIIMqOwUiK8">We use a third-party sub-contractor to manage all Information Technology (IT) issues, including protection against, detection, and response to cyberattacks. The measures that are taken to ensure proper protection include: <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: center">●</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">All computers are protected using a cloud-powered endpoint security solution that helps enterprises prevent, detect, investigate, and respond to advanced threats on their networks. It offers endpoint protection, endpoint detection and response, mobile threat defense, and integrated vulnerability management. It also provides, among other things, malware and spyware detection and remediation, rootkit detection and remediation and network vulnerability detection.</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">●</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">All Company computer hard drives are automatically encrypted.</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">●</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">All Company e-mails are protected by a cloud-based email filtering service designed to protect the Company against advanced threats related to email and collaboration tools.</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">●</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Periodically, all users on the Company’s computer network are required to perform multi-factor authentication.</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">●</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">The Company uses a cloud-based identity and access management service that enables access to external resources.</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">●</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Backup is performed using a secure, automatic cloud-based backup and restore service.</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">●</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">From time to time, the Company considers and evaluates, and adopts if appropriate, additional cyber security procedures and tools.</td></tr> </table> Additionally, we believe that our third-party vendors and service providers have their own respective cybersecurity protocols which our management believes to be adequate for protecting any of the Company’s data that might be in their possession from time to time; however, having such protocols is not necessarily a condition for us using or not using the services of any such vendors or providers. <span class="xdx_phnt_RGlzY2xvc3VyZSAtIEN5YmVyc2VjdXJpdHkgUmlzayBNYW5hZ2VtZW50IGFuZCBTdHJhdGVneSBEaXNjbG9zdXJlAA__" id="xdx_907_ecyd--CybersecurityRiskBoardOfDirectorsOversightTextBlock_c20250101__20251231_zditRBReNuy5">Our IT service provider assesses and manages cybersecurity risks on our behalf, who provides updates and proposals as appropriate, and who reports to our Chief Technology Officer and General Manager, who does not have specific cybersecurity expertise. The Company has an Information Technology Policy that, among other things, governs and provides for cybersecurity policies and processes, including to define safety measures to protect the Company’s confidentiality, integrity and availability of data and other intellectual property, as well as to define the manner in which information is stored, saved and routed in the Company’s network. Additionally, the Board and management believe cybersecurity represents an important component of the Company’s overall approach to risk management and oversight, especially as the Company has commenced commercialization of its first product. Historically, cybersecurity threats have not materially affected the Company, including its business strategy, results of operations or financial condition, while it was focused on pursuing FDA approval and had pre-commercial operations. <span class="xdx_phnt_RGlzY2xvc3VyZSAtIEN5YmVyc2VjdXJpdHkgUmlzayBNYW5hZ2VtZW50IGFuZCBTdHJhdGVneSBEaXNjbG9zdXJlAA__" id="xdx_90D_ecyd--CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag_dbF_c20250101__20251231_zjBYQwA5Duka">The Company is not aware of any material security breach to date. Accordingly, the Company has not incurred any material expenses over the last two years relating to information security breaches. The Company is considering how its evolving business operations could result in a greater risk of a cybersecurity incident, and potential responses and actions to take as a result. The occurrence of cyber-incidents, or a deficiency in our cybersecurity or in those of any of our third-party service providers could negatively impact our business by causing a disruption to our operations, a compromise or corruption of our confidential information and systems, or damage to our business relationships or reputation, all of which could negatively impact our business and results of operations. There can be no assurance that the Company’s third-party vendors’ and service providers’ cybersecurity risk management processes, including their policies, controls or procedures, will be fully implemented, complied with or effective in protecting the Company’s systems and information. true We have 42 full-time employees and 1 hourly employee, of which 24 are based in the United States and 19 are based in Israel, and currently use third-party vendors and service providers for certain product development and regulatory approval activities true Our IT service provider assesses and manages cybersecurity risks on our behalf, who provides updates and proposals as appropriate, and who reports to our Chief Technology Officer and General Manager, who does not have specific cybersecurity expertise. The Company has an Information Technology Policy that, among other things, governs and provides for cybersecurity policies and processes, including to define safety measures to protect the Company’s confidentiality, integrity and availability of data and other intellectual property, as well as to define the manner in which information is stored, saved and routed in the Company’s network. Additionally, the Board and management believe cybersecurity represents an important component of the Company’s overall approach to risk management and oversight, especially as the Company has commenced commercialization of its first product. false false false false false true 1197 Brightman Almagor Zohar & Co. Tel Aviv, Israel

3912000

3114000

74680000

2356000

2000

49000

584000

644000

300000

79822000

5819000

59000

737000

93000

80000

833000

132000

81544000

6031000

511000

165000

296000

70000

2614000

2225000

3421000

2460000

569000

41000

3990000

2501000

0.01

120000000

60000000

67158044

19399513

672000

195000

180968000

94279000

-104086000

-90944000

77554000

3530000

81544000

6031000

6283000

6630000

8460000

4995000

-14743000

-11625000

1285000

182000

316000

-13142000

-11443000

-0.29

-0.73

45790362

15644511

11707317

118000

83884000

-79501000

4501000

3252351

33000

4386000

4419000

1005965 10000 1101000 1111000 3433880 34000 3483000 3517000

1425000

-11443000

19399513

195000

94279000

-90944000

3530000

19399513

195000

94279000

-90944000

3530000

27880955

279000

52452000

52731000

842606 8000 989000 997000 18987752 190000 32190000 32380000

47218

1000

1057000

-13142000

67158044

672000

180968000

-104086000

77554000

67158044

672000

180968000

-104086000

77554000

661000

239000

5155000

101000

65000

2370000

-13142000

-11443000

47000

91000

1000

1057000

1349000

584000

182000

-69000

495000

873000

737000

-1335000 -1100000

-13046000

-8827000

60000

25000

2500000

82926000

5120000

10602000

4182000

-72384000

1537000

86239000

7936000

1000

86240000

7936000

810000

646000

3163000

2517000

3973000

3163000

101000

1111000

893000

98000

76000 30000

NOTE 1 – GENERAL A. Description of business: Microbot Medical Inc. (the “Company”) is a medical device company specializing in the research, design and development of next generation robotic endoluminal surgery devices targeting the minimally invasive surgery space. The Company is primarily focused on leveraging its robotic technologies with the goal of redefining surgical robotics while improving surgical outcomes for patients. Using the Company’s LIBERTY® technological platform, the Company has developed the first-ever fully disposable robot for various endovascular interventional procedures. The LIBERTY® Endovascular Robotic Surgical System is designed to maneuver guidewires and over-the-wire devices (such as microcatheters) within the body’s vasculature. It is intended for the remote delivery and manipulation of guidewires and catheters, and remote manipulation of guide catheters to facilitate navigation to anatomical targets, with the current intention to focus on the peripheral vasculature market. It is designed to eliminate the need for extensive capital equipment requiring dedicated Cath-lab rooms as well as dedicated staff. The Company and its subsidiary are sometimes collectively referred to as the “Company” as the context may require. B. Risk Factors: Through December 31, 2025, the Company has not recognized any revenues, and cannot make any assurances of generating significant revenues in the future. As of December 31, 2025, the Company had cash equivalents and marketable securities balance of approximately $78,592, excluding restricted cash. The Company expects to incur significant losses for the foreseeable future as it conducts marketing activities for its current product and continues its research and development of any other future product candidates and all other work necessary to obtain regulatory clearances or approvals for its products or product candidates. Notwithstanding these conditions, the Company’s management has concluded that the available funds as of the balance sheet date are sufficient to fund the Company’s operations for more than twelve months from issuance date of these consolidated financial statements. The Company will seek to raise additional funds through future issuances of either debt and/or equity securities and possibly additional grants from the Israeli Innovation Authority and other government institutions in order to fund further growth and expansion of the Company. The Company’s ability to raise additional capital in the equity and debt markets is dependent on a number of factors, including, but not limited to, the market demand for the Company’s stock, which itself is subject to a number of development and business risks and uncertainties, as well as the uncertainty that the Company would be able to raise such additional capital at a price or on terms that are favorable to the Company. MICROBOT MEDICAL INC. NOTES TO CONSOLIDATED FINANCIAL STATEMENTS U.S. dollars in thousands (Except share and per share data) NOTE 1 – GENERAL B. Risk Factors: Middle East Conflict The ongoing risks of operating in Israel have been exacerbated as a result of the October 7, 2023 surprise attack by hostile forces from Gaza, which led to Israeli military operation at first in Gaza, then in Lebanon, Syria, Yemen and Iran. These include security and economic risks, risks relating to the Company’s ability to sell or buy internationally, risk of economic instability, risk of exchange rate fluctuation negatively affecting operating costs, and the risk of employees leaving to perform military service. These military operations and related activities are on-going as of the filing date of these consolidated financial statements. Subsequent to the reporting period, on February 28, 2026, a military operation referred to as “Epic-Fury” commenced with a large-scale attack on Iran carried out in coordination with the United States. In response, Iran launched a counterattack that included the firing of ballistic missiles and unmanned aerial vehicles toward military and civilian targets in Israel. Additionally, Hezbollah, a terrorist organization in Lebanon, joined the attacks against Israel and Israel has started military operations in Lebanon. As a result, a special state of emergency was declared in Israel, which included, among other things, the closure of Israel’s airspace, restrictions on public gatherings, temporary closures and/or reduced operating hours of businesses, and the mobilization of military reservists, which have resulted in reduced economic activity. The Company has considered various ongoing risks relating to these and other military operation and related matters, including: <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="width: 0.75in"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify">●</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">That some of our Israeli subcontractors, vendors, suppliers and other companies in which the Company relies, may not be fully active and operational, as instructed by the relevant authorities; </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">●</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">A slowdown in the number of international flights in and out of Israel;</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.75in"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in">●</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">The decreasing international regard for Israeli-based companies in certain quarters, including as a result of the Israeli government’s policies in Gaza and the West Bank; and</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">●</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Possible and actual boycotts of Israel and Israeli-based companies, which may adversely affect our ability to do business in certain jurisdictions or with certain industry groups or potential customers, among others.</td></tr> </table> The Company closely monitors how these and other military operation and related activities could adversely affect its anticipated milestones and its Israel-based activities to support future commercial, clinical and regulatory milestones, including the Company’s ability to import materials that are required to construct the LIBERTY® devices and to ship them outside of Israel. As of the filing date of these consolidated financial statements, the Company has determined that there have not been any materially adverse effects on its business or operations.

78592000

NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES The significant accounting policies applied in the preparation of the financial statements are as follows: A. Basis of presentation: The financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America (“US GAAP”). B. Financial statement in U.S. dollars: The functional currency of the Company is the U.S. dollar (“dollar”) since the dollar is the currency of the primary economic environment in which the Company has operated and expects to continue to operate in the foreseeable future. Transactions and balances denominated in dollars are presented at their original amounts. Transactions and balances denominated in foreign currencies have been re-measured to dollars in accordance with the provisions of Accounting Standards Codification (“ASC”) 830-10, “Foreign Currency Translation”. All transaction gains and losses from re-measurement of monetary balance sheet items denominated in non-dollar currencies are reflected in the statements of comprehensive loss as financial income or expenses, as appropriate. C. Use of estimates: The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions pertaining to transactions and matters whose ultimate effect on the financial statements cannot precisely be determined at the time of financial statements preparation. Although these estimates are based on management’s best judgment, actual results may differ from these estimates. MICROBOT MEDICAL INC. NOTES TO CONSOLIDATED FINANCIAL STATEMENTS U.S. dollars in thousands (Except share and per share data) NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES D. Principles of consolidation: The consolidated financial statements include the accounts of the Company and its wholly owned subsidiary. Inter-company balances and transactions have been eliminated in consolidation. E. Cash and cash equivalents: Cash and cash equivalents consist of cash and demand deposits in banks, and other short-term liquid investments (primarily interest-bearing time deposits) with original maturities of three months or less at the date of purchase. F. Restricted cash: Restricted cash serves as collateral for the Company’s lease agreements and are classified as either current or long-term depending on when the anticipated use of these funds will be required. G. Long-term deposit: Long-term deposit represents cash advances paid to a vendor as security for the performance of the Company’s payment obligations. The Company does not expect these deposits to be utilized in the normal course of business. H. Fair value of financial instruments: The carrying values of cash and cash equivalents, prepaid expenses and other current assets, accounts payable and accrued liabilities are stated at their carrying value, which approximates fair value due to the short-term maturity of these instruments. The Company measures the fair value of certain of its financial instruments (such as marketable securities) on a recurring basis. The method of determining the fair value of marketable securities is discussed in Note 4 below. A fair value hierarchy is used to rank the quality and reliability of the information used to determine fair values. Financial assets and liabilities carried at fair value will be classified and disclosed in one of the following three categories: Level 1 - Quoted prices (unadjusted) in active markets for identical assets and liabilities. Level 2 - Inputs other than Level 1 that are observable, either directly or indirectly, such as unadjusted quoted prices for similar assets and liabilities, unadjusted quoted prices in the markets that are not active, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities. Level 3 - Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities. I. Concentrations of credit risk: Financial instruments which potentially subject the Company to credit risk consist primarily of cash and cash equivalents and marketable securities. The Company holds these investments in highly rated financial institutions. These amounts at times may exceed federally insured limits. The Company has not experienced any credit losses in such accounts and does not believe it is exposed to any significant credit risk on these funds. The Company has no off-balance sheet concentrations of credit risk, such as foreign currency exchange contracts, option contracts, or other hedging arrangements. MICROBOT MEDICAL INC. NOTES TO CONSOLIDATED FINANCIAL STATEMENTS U.S. dollars in thousands (Except share and per share data) NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES J. Property and equipment: Property and equipment are presented at cost, less accumulated depreciation. Depreciation is calculated based on the straight-line method over the estimated useful lives of the assets, at the following annual rates: SCHEDULE OF ESTIMATED USEFUL LIVES OF PROPERTY AND EQUIPMENT <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%; margin-left: 0.75in; margin-right: 0.5in"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">%</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="2" style="text-align: center"> </td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Research equipment and software</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_90A_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20251231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--ResearchEquipmentAndSoftwareMember__srt--RangeAxis__srt--MinimumMember_zBbFDxKqVUNj" title="Property, plant and equipment, useful life">25-<span id="xdx_901_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20251231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--ResearchEquipmentAndSoftwareMember__srt--RangeAxis__srt--MaximumMember_zApP10aRKaF8" title="Property, plant and equipment, useful life">33</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="width: 80%; text-align: left">Furniture and office equipment</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 16%; text-align: right"><span id="xdx_904_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20251231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--FurnitureAndOfficeEquipmentMember_z0dFuBS5QzMe" title="Property, plant and equipment, useful life">7</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Leasehold improvements</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_903_eus-gaap--PropertyPlantAndEquipmentUsefulLifeDescriptionOfTermExtensibleEnumeration_iI_dxL_c20251231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--LeaseholdImprovementsMember_zoO7VPM3UrF3" title="::XDX::http%3A%2F%2Ffasb.org%2Fus-gaap%2F2025%23UsefulLifeTermOfLeaseMember">Over the lease period</td><td style="text-align: left"> </td></tr> </table> The Company assesses property and equipment impairment whenever events or changes in circumstances indicate that the carrying amount of the asset may not be recoverable. If such circumstances are determined to exist, an estimate of undiscounted future cash flows produced by the property and equipment assets, or the appropriate grouping of assets, is compared to the carrying value to determine whether impairment exists. If an asset is determined to be impaired, the loss is measured based on the difference between the asset’s estimated fair value and its carrying value. For property and equipment assets, the estimate of fair value is typically based on a discounted cash flow model. As of December 31, 2025 and 2024, no impairment charges were recorded. K. Liabilities due to termination of employment agreements: Under Israeli employment laws, employees of Microbot Israel are included under Article 14 of the Severance Compensation Act, 1963 (“Article 14”). According to Article 14, these employees are entitled to monthly deposits made by Microbot Israel on their behalf with insurance companies. Payments in accordance with Article 14 release Microbot Israel from any future severance payments (under the Israeli Severance Compensation Act, 1963) with respect of those employees. The aforementioned deposits are not recorded as an asset in the Company’s balance sheets. As for the U.S. employees, the Company has certain defined contribution plans, including a 401(k)-retirement plan in the U.S., whereby contributions made by eligible employees are matched by the Company with certain limitations. L. Common stock warrants: The Company accounts for warrants issued to investors as either equity-classified or liability-classified instruments, based on an assessment of the warrant’s specific terms and the applicable authoritative guidance in Financial Accounting Standards Board (“FASB”) ASC 480 and FASB ASC 815, “Derivatives and Hedging” (“ASC 815”). The assessment considers whether the warrants are freestanding financial instruments pursuant to ASC 480, meet the definition of a liability pursuant to ASC 480, or meet all of the requirements for equity classification under FASB ASC 815, including whether the warrants are indexed to the Company’s own shares of common stock and whether the warrant holders could potentially require “net cash settlement” in a circumstance outside of the Company’s control, among other conditions for equity classification. This assessment is conducted at the time of warrant issuance and as of each subsequent quarterly period end date while the warrants are outstanding. M. Basic and diluted net loss per share: Basic net loss per share is calculated by dividing net loss attributable to common stock shareholders by the weighted average number of shares of common stock outstanding during the year without consideration of potentially dilutive securities. For purposes of the diluted net loss per share attributable to common shareholders calculation, stock options and warrants are considered to be common stock equivalents. All common stock equivalents, as detailed in Notes 2P, 11H and 11I, have been excluded from the calculation of the diluted loss per share for the years ended December 31, 2025 and 2024, as their effect would be anti-dilutive. Therefore, basic and diluted net loss per share were the same for both years presented. In the calculation of the basic and diluted net loss, the Company included warrants that would be exercised for no or little consideration and are exercisable with no contingencies. N. Research and development expenses, net: Research and development expenses are charged to the statement of comprehensive loss as incurred. Grants for funding of approved research and development projects and others are recognized at the time the Company is entitled to such grants, on the basis of the costs incurred and applied as a deduction from the research and development expenses. See Note 2U below. Reimbursement of expenses for research and development projects is recognized as the costs are incurred and is netted against research and development expenses in the statement of comprehensive loss. Research and development reimbursements of $0, and $83 were offset against research and development costs in the years ended December 31, 2025 and 2024, respectively O. Sales, general and administrative expenses: Sales, general and administrative expenses are charged to the statement of comprehensive loss as incurred. MICROBOT MEDICAL INC. NOTES TO CONSOLIDATED FINANCIAL STATEMENTS U.S. dollars in thousands (Except share and per share data) NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES P. Share-based compensation: The Company applies ASC 718-10, “Share-Based Payment” (“ASC 718-10”), which requires the measurement and recognition of compensation expenses for all share-based payment awards made to employees and directors including stock options under the Company’s stock plans based on estimated fair values. ASC 718-10 requires companies to estimate the fair value of stock options using an option-pricing model, which is recognized as an expense over the requisite service periods in the Company’s statement of comprehensive loss, based on a straight-line method. The Company recognizes compensation cost for an equity classified award with only service conditions that has a graded vesting schedule on a straight-line basis over the requisite service period for the entire award, provided that the cumulative amount of compensation cost recognized at any date at least equals the portion of the grant date fair value of such award that is vested at that date. The Company recognizes the expense for an equity classified awards subject to performance-based milestone vesting over the remaining service period when management determines that achievement of the milestone is probable. Management evaluates when the achievement of a performance-based milestone is probable based on the expected satisfaction of the performance conditions at each reporting date. If no explicit service period is determined, the Company estimates the implicit service period based on the timing the employee is expected to achieve the related performance condition. When no future services are required to be performed by the grantee in exchange for an award of equity instruments, and if such award does not contain a performance condition, the cost of the award is expensed on the grant date. The Company estimates the fair value of stock options granted as share-based payment awards using a Black-Scholes options pricing model. The option-pricing model requires a number of assumptions, of which the most significant are expected volatility and the expected option term (the time from the grant date until the options are exercised or expire). Expected volatility is estimated based on the standard deviation of the Company’s closing prices according to the expected life (SAB107) for each of the grants. The Company has historically not paid dividends and has no foreseeable plans to issue dividends. The risk-free interest rate is based on the yield from governmental zero-coupon bonds with an equivalent term. For stock options that qualify as “plain-vanilla,” the expected term is calculated using the simplified method. For stock options that do not qualify as “plain-vanilla”, the Company’s management estimated that the expected stock option term is the contractual term of the options. Changes in the determination of each of the inputs can affect the fair value of the stock options granted and the results of operations of the Company. Q. Income taxes: The Company provides for income taxes using the asset and liability approach. Deferred tax assets and liabilities are recorded based on the differences between the financial statement and tax bases of assets and liabilities and the tax rates in effect when these differences are expected to reverse. Deferred tax assets are reduced by a valuation allowance if, based on the weight of available evidence, it is more likely than not that some or all of the deferred tax assets will not be realized. As of December 31, 2025, and 2024, the Company had a full valuation allowance against deferred tax assets due to the uncertainty as to whether the Company’s deferred tax assets will ever be realized in future periods. MICROBOT MEDICAL INC. NOTES TO CONSOLIDATED FINANCIAL STATEMENTS U.S. dollars in thousands (Except share and per share data) NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES R. Marketable securities: The Company invests in equity securities. Equity securities consist of a mutual fund. The Company records these investments in the consolidated balance sheet at fair value. Unrealized gains or losses for the equity security are reflected in the statements of comprehensive loss as financial income or expenses, as appropriate. The Company classifies its investments as current based on the nature of the investments and their availability for use in current operations. S. Leases: The Company determines if an arrangement is a lease at inception. Operating lease assets are presented as operating lease long-term right-of-use assets (“ROU”), and corresponding as lease liabilities (current portion), and as operating long-term lease liabilities, on the Company’s consolidated balance sheets. Operating lease ROU assets and operating lease liabilities are recognized based on the present value of the remaining lease payments over the lease term at commencement date. The Company’s leases do not provide an implicit interest rate. The Company calculates the incremental borrowing rate to reflect the interest rate that it would have to pay to borrow on a collateralized basis an amount equal to the lease payments in a similar economic environment over a similar term and considers the Company’s historical borrowing activities and market data in this determination. The operating lease ROU asset also includes any lease payments made and excludes lease incentives and initial direct costs incurred. The Company’s lease terms may include options to extend or terminate the lease when it is reasonably certain that it will exercise that option. Lease expense for minimum lease payments is recognized on a straight-line basis over the lease term. The Company has lease agreements with lease and non-lease components, which it accounts for as a single lease component. The Company has elected not to recognize ROU assets and lease liabilities for short-term leases that have a term of 12 months or less. The Company’s lease agreements do not contain any material residual value guarantees or material restrictive covenants. In addition, the Company does not have any related party leases. MICROBOT MEDICAL INC. NOTES TO CONSOLIDATED FINANCIAL STATEMENTS U.S. dollars in thousands (Except share and per share data) NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES T. Contingencies: Management records and discloses legal contingencies in accordance with ASC Topic 450 Contingencies. A provision is recorded when it is both probable that a liability has been incurred and the amount of the loss can be reasonably estimated. The Company monitors the stage of progress of its litigation matters to determine if any adjustments are required. The Company carries liability insurance to mitigate its exposure to losses, including litigation losses. The Company records the estimated amount of expected insurance proceeds for litigation losses incurred as an asset (typically a receivable from the insurer) and offset to losses up to the amount of the losses incurred when the amount is determinable and approved by the insurance company. U. Government grants: Government grants which are received from the Israeli Ministry of Economy and Israel Innovation Authority (“IIA”) by way of participation in research and development that is conducted by Microbot Israel, are received in installments as the program progresses based on qualified research spending. Grants received are recognized when the grant becomes receivable, provided there was reasonable assurance that Microbot Israel will comply with the conditions attached to the grant and there was reasonable assurance the grant will be received. The grants are deducted from the research and development expenses as the applicable costs are incurred. Research and development expenses, net, for the years ended December 31, 2025 and 2024, include participation in research and development expenses in the amount of approximately $496 and $149, respectively. V. Inventory Inventories primarily consist of raw materials, work-in-process and finished goods produced by our third-party contract manufacturer. Inventories are stated at the lower of cost, determined using the first-in, first-out (FIFO) method, or net realizable value. Inventory costs include the purchase price of materials and other manufacturing costs, including overhead and personnel costs for employees involved in production planning. The Company regularly evaluates its inventory for excess and obsolescence. The Company considers the expiration of sterilization dates where applicable. When the carrying value of inventory exceeds its estimated net realizable value, the Company records a write-down. The Company considered regulatory approval of its product candidate to be uncertain and product manufactured prior to regulatory approval could not have been sold unless regulatory approval was obtained. The Company began recognizing inventory related to the manufacture of the Company’s LIBERTY® Endovascular Robotic Surgical System in October 2025, after FDA approval was granted related to Liberty. As such, the manufacturing costs incurred prior to regulatory approval were not recognized as inventory but rather were expensed as incurred as research and development expenses. W. Segment Reporting The Company has a single operating and reportable segment, which is the development of robotic devices for endoluminal surgery. See Note 1A for further details. The Company’s chief operating decision maker (the “CODM”), the Chief Executive Officer (“CEO”), reviews financial information presented on a consolidated basis for purposes of making operating decisions, assessing performance, and allocating resources. For further details, refer to Note 15. X. Recently Adopted accounting pronouncements: In December 2023, FASB issued ASU No. 2023-09, Income Taxes (Topic 740): Improvements to Income Tax Disclosures. This ASU requires disclosure of specific categories in the rate reconciliation and additional information for reconciling items that meet a quantitative threshold. The amendment also includes other changes to improve the effectiveness of income tax disclosures, including further disaggregation of income taxes paid for individually significant jurisdictions. The Company adopted the ASU on its consolidated financial statements and disclosures. For further details, refer to Note 17. Y. Accounting pronouncements not yet effective: In November 2024, FASB issued Accounting Standards Update (ASU) 2024-03, Income Statement—Reporting Comprehensive Income—Expense Disaggregation Disclosures (Subtopic 220-40), Disaggregation of Income Statement Expenses. This update aims to enhance the transparency of financial reporting by requiring public business entities (PBEs) to provide disaggregated disclosure of certain income statement expense captions into specified categories in disclosures within the footnotes to the financial statements. The ASU is effective for fiscal years beginning after December 15, 2026, and interim periods within fiscal years beginning after December 15, 2027. Early adoption is permitted. Adoption of this ASU should be applied on a prospective basis, although retrospective application is permitted. The Company is currently evaluating the impact of adopting this ASU on its consolidated financial statements and disclosures. MICROBOT MEDICAL INC. NOTES TO CONSOLIDATED FINANCIAL STATEMENTS U.S. dollars in thousands (Except share and per share data)

A. Basis of presentation: The financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America (“US GAAP”).

B. Financial statement in U.S. dollars: The functional currency of the Company is the U.S. dollar (“dollar”) since the dollar is the currency of the primary economic environment in which the Company has operated and expects to continue to operate in the foreseeable future. Transactions and balances denominated in dollars are presented at their original amounts. Transactions and balances denominated in foreign currencies have been re-measured to dollars in accordance with the provisions of Accounting Standards Codification (“ASC”) 830-10, “Foreign Currency Translation”. All transaction gains and losses from re-measurement of monetary balance sheet items denominated in non-dollar currencies are reflected in the statements of comprehensive loss as financial income or expenses, as appropriate.

C. Use of estimates: The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions pertaining to transactions and matters whose ultimate effect on the financial statements cannot precisely be determined at the time of financial statements preparation. Although these estimates are based on management’s best judgment, actual results may differ from these estimates. MICROBOT MEDICAL INC. NOTES TO CONSOLIDATED FINANCIAL STATEMENTS U.S. dollars in thousands (Except share and per share data) NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

D. Principles of consolidation: The consolidated financial statements include the accounts of the Company and its wholly owned subsidiary. Inter-company balances and transactions have been eliminated in consolidation.

E. Cash and cash equivalents: Cash and cash equivalents consist of cash and demand deposits in banks, and other short-term liquid investments (primarily interest-bearing time deposits) with original maturities of three months or less at the date of purchase.

F. Restricted cash: Restricted cash serves as collateral for the Company’s lease agreements and are classified as either current or long-term depending on when the anticipated use of these funds will be required.

G. Long-term deposit: Long-term deposit represents cash advances paid to a vendor as security for the performance of the Company’s payment obligations. The Company does not expect these deposits to be utilized in the normal course of business.

H. Fair value of financial instruments: The carrying values of cash and cash equivalents, prepaid expenses and other current assets, accounts payable and accrued liabilities are stated at their carrying value, which approximates fair value due to the short-term maturity of these instruments. The Company measures the fair value of certain of its financial instruments (such as marketable securities) on a recurring basis. The method of determining the fair value of marketable securities is discussed in Note 4 below. A fair value hierarchy is used to rank the quality and reliability of the information used to determine fair values. Financial assets and liabilities carried at fair value will be classified and disclosed in one of the following three categories: Level 1 - Quoted prices (unadjusted) in active markets for identical assets and liabilities. Level 2 - Inputs other than Level 1 that are observable, either directly or indirectly, such as unadjusted quoted prices for similar assets and liabilities, unadjusted quoted prices in the markets that are not active, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities. Level 3 - Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities.

I. Concentrations of credit risk: Financial instruments which potentially subject the Company to credit risk consist primarily of cash and cash equivalents and marketable securities. The Company holds these investments in highly rated financial institutions. These amounts at times may exceed federally insured limits. The Company has not experienced any credit losses in such accounts and does not believe it is exposed to any significant credit risk on these funds. The Company has no off-balance sheet concentrations of credit risk, such as foreign currency exchange contracts, option contracts, or other hedging arrangements. MICROBOT MEDICAL INC. NOTES TO CONSOLIDATED FINANCIAL STATEMENTS U.S. dollars in thousands (Except share and per share data) NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

J. Property and equipment: Property and equipment are presented at cost, less accumulated depreciation. Depreciation is calculated based on the straight-line method over the estimated useful lives of the assets, at the following annual rates: SCHEDULE OF ESTIMATED USEFUL LIVES OF PROPERTY AND EQUIPMENT <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%; margin-left: 0.75in; margin-right: 0.5in"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">%</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="2" style="text-align: center"> </td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Research equipment and software</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_90A_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20251231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--ResearchEquipmentAndSoftwareMember__srt--RangeAxis__srt--MinimumMember_zBbFDxKqVUNj" title="Property, plant and equipment, useful life">25-<span id="xdx_901_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20251231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--ResearchEquipmentAndSoftwareMember__srt--RangeAxis__srt--MaximumMember_zApP10aRKaF8" title="Property, plant and equipment, useful life">33</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="width: 80%; text-align: left">Furniture and office equipment</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 16%; text-align: right"><span id="xdx_904_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20251231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--FurnitureAndOfficeEquipmentMember_z0dFuBS5QzMe" title="Property, plant and equipment, useful life">7</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Leasehold improvements</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_903_eus-gaap--PropertyPlantAndEquipmentUsefulLifeDescriptionOfTermExtensibleEnumeration_iI_dxL_c20251231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--LeaseholdImprovementsMember_zoO7VPM3UrF3" title="::XDX::http%3A%2F%2Ffasb.org%2Fus-gaap%2F2025%23UsefulLifeTermOfLeaseMember">Over the lease period</td><td style="text-align: left"> </td></tr> </table> The Company assesses property and equipment impairment whenever events or changes in circumstances indicate that the carrying amount of the asset may not be recoverable. If such circumstances are determined to exist, an estimate of undiscounted future cash flows produced by the property and equipment assets, or the appropriate grouping of assets, is compared to the carrying value to determine whether impairment exists. If an asset is determined to be impaired, the loss is measured based on the difference between the asset’s estimated fair value and its carrying value. For property and equipment assets, the estimate of fair value is typically based on a discounted cash flow model. As of December 31, 2025 and 2024, no impairment charges were recorded.

Property and equipment are presented at cost, less accumulated depreciation. Depreciation is calculated based on the straight-line method over the estimated useful lives of the assets, at the following annual rates: SCHEDULE OF ESTIMATED USEFUL LIVES OF PROPERTY AND EQUIPMENT <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%; margin-left: 0.75in; margin-right: 0.5in"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">%</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="2" style="text-align: center"> </td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Research equipment and software</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_90A_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20251231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--ResearchEquipmentAndSoftwareMember__srt--RangeAxis__srt--MinimumMember_zBbFDxKqVUNj" title="Property, plant and equipment, useful life">25-<span id="xdx_901_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20251231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--ResearchEquipmentAndSoftwareMember__srt--RangeAxis__srt--MaximumMember_zApP10aRKaF8" title="Property, plant and equipment, useful life">33</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="width: 80%; text-align: left">Furniture and office equipment</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 16%; text-align: right"><span id="xdx_904_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20251231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--FurnitureAndOfficeEquipmentMember_z0dFuBS5QzMe" title="Property, plant and equipment, useful life">7</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Leasehold improvements</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_903_eus-gaap--PropertyPlantAndEquipmentUsefulLifeDescriptionOfTermExtensibleEnumeration_iI_dxL_c20251231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--LeaseholdImprovementsMember_zoO7VPM3UrF3" title="::XDX::http%3A%2F%2Ffasb.org%2Fus-gaap%2F2025%23UsefulLifeTermOfLeaseMember">Over the lease period</td><td style="text-align: left"> </td></tr> </table>

P25Y

P33Y

P7Y

K. Liabilities due to termination of employment agreements: Under Israeli employment laws, employees of Microbot Israel are included under Article 14 of the Severance Compensation Act, 1963 (“Article 14”). According to Article 14, these employees are entitled to monthly deposits made by Microbot Israel on their behalf with insurance companies. Payments in accordance with Article 14 release Microbot Israel from any future severance payments (under the Israeli Severance Compensation Act, 1963) with respect of those employees. The aforementioned deposits are not recorded as an asset in the Company’s balance sheets. As for the U.S. employees, the Company has certain defined contribution plans, including a 401(k)-retirement plan in the U.S., whereby contributions made by eligible employees are matched by the Company with certain limitations.

L. Common stock warrants: The Company accounts for warrants issued to investors as either equity-classified or liability-classified instruments, based on an assessment of the warrant’s specific terms and the applicable authoritative guidance in Financial Accounting Standards Board (“FASB”) ASC 480 and FASB ASC 815, “Derivatives and Hedging” (“ASC 815”). The assessment considers whether the warrants are freestanding financial instruments pursuant to ASC 480, meet the definition of a liability pursuant to ASC 480, or meet all of the requirements for equity classification under FASB ASC 815, including whether the warrants are indexed to the Company’s own shares of common stock and whether the warrant holders could potentially require “net cash settlement” in a circumstance outside of the Company’s control, among other conditions for equity classification. This assessment is conducted at the time of warrant issuance and as of each subsequent quarterly period end date while the warrants are outstanding.

M. Basic and diluted net loss per share: Basic net loss per share is calculated by dividing net loss attributable to common stock shareholders by the weighted average number of shares of common stock outstanding during the year without consideration of potentially dilutive securities. For purposes of the diluted net loss per share attributable to common shareholders calculation, stock options and warrants are considered to be common stock equivalents. All common stock equivalents, as detailed in Notes 2P, 11H and 11I, have been excluded from the calculation of the diluted loss per share for the years ended December 31, 2025 and 2024, as their effect would be anti-dilutive. Therefore, basic and diluted net loss per share were the same for both years presented. In the calculation of the basic and diluted net loss, the Company included warrants that would be exercised for no or little consideration and are exercisable with no contingencies.

N. Research and development expenses, net: Research and development expenses are charged to the statement of comprehensive loss as incurred. Grants for funding of approved research and development projects and others are recognized at the time the Company is entitled to such grants, on the basis of the costs incurred and applied as a deduction from the research and development expenses. See Note 2U below. Reimbursement of expenses for research and development projects is recognized as the costs are incurred and is netted against research and development expenses in the statement of comprehensive loss. Research and development reimbursements of $0, and $83 were offset against research and development costs in the years ended December 31, 2025 and 2024, respectively

O. Sales, general and administrative expenses: Sales, general and administrative expenses are charged to the statement of comprehensive loss as incurred. MICROBOT MEDICAL INC. NOTES TO CONSOLIDATED FINANCIAL STATEMENTS U.S. dollars in thousands (Except share and per share data) NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

P. Share-based compensation: The Company applies ASC 718-10, “Share-Based Payment” (“ASC 718-10”), which requires the measurement and recognition of compensation expenses for all share-based payment awards made to employees and directors including stock options under the Company’s stock plans based on estimated fair values. ASC 718-10 requires companies to estimate the fair value of stock options using an option-pricing model, which is recognized as an expense over the requisite service periods in the Company’s statement of comprehensive loss, based on a straight-line method. The Company recognizes compensation cost for an equity classified award with only service conditions that has a graded vesting schedule on a straight-line basis over the requisite service period for the entire award, provided that the cumulative amount of compensation cost recognized at any date at least equals the portion of the grant date fair value of such award that is vested at that date. The Company recognizes the expense for an equity classified awards subject to performance-based milestone vesting over the remaining service period when management determines that achievement of the milestone is probable. Management evaluates when the achievement of a performance-based milestone is probable based on the expected satisfaction of the performance conditions at each reporting date. If no explicit service period is determined, the Company estimates the implicit service period based on the timing the employee is expected to achieve the related performance condition. When no future services are required to be performed by the grantee in exchange for an award of equity instruments, and if such award does not contain a performance condition, the cost of the award is expensed on the grant date. The Company estimates the fair value of stock options granted as share-based payment awards using a Black-Scholes options pricing model. The option-pricing model requires a number of assumptions, of which the most significant are expected volatility and the expected option term (the time from the grant date until the options are exercised or expire). Expected volatility is estimated based on the standard deviation of the Company’s closing prices according to the expected life (SAB107) for each of the grants. The Company has historically not paid dividends and has no foreseeable plans to issue dividends. The risk-free interest rate is based on the yield from governmental zero-coupon bonds with an equivalent term. For stock options that qualify as “plain-vanilla,” the expected term is calculated using the simplified method. For stock options that do not qualify as “plain-vanilla”, the Company’s management estimated that the expected stock option term is the contractual term of the options. Changes in the determination of each of the inputs can affect the fair value of the stock options granted and the results of operations of the Company.

Q. Income taxes: The Company provides for income taxes using the asset and liability approach. Deferred tax assets and liabilities are recorded based on the differences between the financial statement and tax bases of assets and liabilities and the tax rates in effect when these differences are expected to reverse. Deferred tax assets are reduced by a valuation allowance if, based on the weight of available evidence, it is more likely than not that some or all of the deferred tax assets will not be realized. As of December 31, 2025, and 2024, the Company had a full valuation allowance against deferred tax assets due to the uncertainty as to whether the Company’s deferred tax assets will ever be realized in future periods. MICROBOT MEDICAL INC. NOTES TO CONSOLIDATED FINANCIAL STATEMENTS U.S. dollars in thousands (Except share and per share data) NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

R. Marketable securities: The Company invests in equity securities. Equity securities consist of a mutual fund. The Company records these investments in the consolidated balance sheet at fair value. Unrealized gains or losses for the equity security are reflected in the statements of comprehensive loss as financial income or expenses, as appropriate. The Company classifies its investments as current based on the nature of the investments and their availability for use in current operations.

S. Leases: The Company determines if an arrangement is a lease at inception. Operating lease assets are presented as operating lease long-term right-of-use assets (“ROU”), and corresponding as lease liabilities (current portion), and as operating long-term lease liabilities, on the Company’s consolidated balance sheets. Operating lease ROU assets and operating lease liabilities are recognized based on the present value of the remaining lease payments over the lease term at commencement date. The Company’s leases do not provide an implicit interest rate. The Company calculates the incremental borrowing rate to reflect the interest rate that it would have to pay to borrow on a collateralized basis an amount equal to the lease payments in a similar economic environment over a similar term and considers the Company’s historical borrowing activities and market data in this determination. The operating lease ROU asset also includes any lease payments made and excludes lease incentives and initial direct costs incurred. The Company’s lease terms may include options to extend or terminate the lease when it is reasonably certain that it will exercise that option. Lease expense for minimum lease payments is recognized on a straight-line basis over the lease term. The Company has lease agreements with lease and non-lease components, which it accounts for as a single lease component. The Company has elected not to recognize ROU assets and lease liabilities for short-term leases that have a term of 12 months or less. The Company’s lease agreements do not contain any material residual value guarantees or material restrictive covenants. In addition, the Company does not have any related party leases. MICROBOT MEDICAL INC. NOTES TO CONSOLIDATED FINANCIAL STATEMENTS U.S. dollars in thousands (Except share and per share data) NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

T. Contingencies: Management records and discloses legal contingencies in accordance with ASC Topic 450 Contingencies. A provision is recorded when it is both probable that a liability has been incurred and the amount of the loss can be reasonably estimated. The Company monitors the stage of progress of its litigation matters to determine if any adjustments are required. The Company carries liability insurance to mitigate its exposure to losses, including litigation losses. The Company records the estimated amount of expected insurance proceeds for litigation losses incurred as an asset (typically a receivable from the insurer) and offset to losses up to the amount of the losses incurred when the amount is determinable and approved by the insurance company.

U. Government grants: Government grants which are received from the Israeli Ministry of Economy and Israel Innovation Authority (“IIA”) by way of participation in research and development that is conducted by Microbot Israel, are received in installments as the program progresses based on qualified research spending. Grants received are recognized when the grant becomes receivable, provided there was reasonable assurance that Microbot Israel will comply with the conditions attached to the grant and there was reasonable assurance the grant will be received. The grants are deducted from the research and development expenses as the applicable costs are incurred. Research and development expenses, net, for the years ended December 31, 2025 and 2024, include participation in research and development expenses in the amount of approximately $496 and $149, respectively.

496000 149000

V. Inventory Inventories primarily consist of raw materials, work-in-process and finished goods produced by our third-party contract manufacturer. Inventories are stated at the lower of cost, determined using the first-in, first-out (FIFO) method, or net realizable value. Inventory costs include the purchase price of materials and other manufacturing costs, including overhead and personnel costs for employees involved in production planning. The Company regularly evaluates its inventory for excess and obsolescence. The Company considers the expiration of sterilization dates where applicable. When the carrying value of inventory exceeds its estimated net realizable value, the Company records a write-down. The Company considered regulatory approval of its product candidate to be uncertain and product manufactured prior to regulatory approval could not have been sold unless regulatory approval was obtained. The Company began recognizing inventory related to the manufacture of the Company’s LIBERTY® Endovascular Robotic Surgical System in October 2025, after FDA approval was granted related to Liberty. As such, the manufacturing costs incurred prior to regulatory approval were not recognized as inventory but rather were expensed as incurred as research and development expenses.

W. Segment Reporting The Company has a single operating and reportable segment, which is the development of robotic devices for endoluminal surgery. See Note 1A for further details. The Company’s chief operating decision maker (the “CODM”), the Chief Executive Officer (“CEO”), reviews financial information presented on a consolidated basis for purposes of making operating decisions, assessing performance, and allocating resources. For further details, refer to Note 15.

X. Recently Adopted accounting pronouncements: In December 2023, FASB issued ASU No. 2023-09, Income Taxes (Topic 740): Improvements to Income Tax Disclosures. This ASU requires disclosure of specific categories in the rate reconciliation and additional information for reconciling items that meet a quantitative threshold. The amendment also includes other changes to improve the effectiveness of income tax disclosures, including further disaggregation of income taxes paid for individually significant jurisdictions. The Company adopted the ASU on its consolidated financial statements and disclosures. For further details, refer to Note 17.

Y. Accounting pronouncements not yet effective: In November 2024, FASB issued Accounting Standards Update (ASU) 2024-03, Income Statement—Reporting Comprehensive Income—Expense Disaggregation Disclosures (Subtopic 220-40), Disaggregation of Income Statement Expenses. This update aims to enhance the transparency of financial reporting by requiring public business entities (PBEs) to provide disaggregated disclosure of certain income statement expense captions into specified categories in disclosures within the footnotes to the financial statements. The ASU is effective for fiscal years beginning after December 15, 2026, and interim periods within fiscal years beginning after December 15, 2027. Early adoption is permitted. Adoption of this ASU should be applied on a prospective basis, although retrospective application is permitted. The Company is currently evaluating the impact of adopting this ASU on its consolidated financial statements and disclosures.

NOTE 3 – CASH AND CASH EQUIVALENTS AND MARKETABLE SECURITIES The following table sets forth our cash, cash equivalents and marketable securities as of December 31, 2025 and 2024: SCHEDULE OF CASH AND CASH EQUIVALENTS AND MARKETABLE SECURITIES <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%; margin-left: 0.75in; margin-right: 0.5in"> <tr style="display: none; vertical-align: bottom"> <td style="display: none; text-align: center"> </td><td style="display: none; text-align: center; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_49B_20251231_zO4sq2Hcndcg" style="border-bottom: Black 1pt solid; display: none; font-weight: bold; text-align: center"> </td><td style="display: none; text-align: center; padding-bottom: 1pt; font-weight: bold"> </td><td style="display: none; text-align: center; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_495_20241231_zVBn85MS16dd" style="border-bottom: Black 1pt solid; display: none; font-weight: bold; text-align: center"> </td><td style="display: none; text-align: center; padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: left; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">As of December 31,</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: left"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Cash and cash equivalents:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_40E_eus-gaap--CashEquivalentsAtCarryingValue_iI_pn3n3_hus-gaap--CashAndCashEquivalentsAxis__us-gaap--CashMember_zdkSppnDXSc7" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; width: 60%; padding-bottom: 1pt">Cash</td><td style="width: 2%; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1pt solid; width: 16%; text-align: right">3,912</td><td style="width: 1%; padding-bottom: 1pt; text-align: left"> </td><td style="width: 2%; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1pt solid; width: 16%; text-align: right">3,114</td><td style="width: 1%; padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_400_eus-gaap--CashEquivalentsAtCarryingValue_iI_pn3n3_zHbqdq57F05g" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 2.5pt">Total cash and cash equivalents</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">3,912</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">3,114</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Marketable securities:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_409_eus-gaap--MarketableSecuritiesCurrent_iI_pn3n3_hus-gaap--InvestmentTypeAxis__us-gaap--MoneyMarketFundsMember_zfJcEoclo0Wf" style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1pt; text-align: left">Money market mutual funds</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right">74,680</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right">2,356</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_408_eus-gaap--MarketableSecuritiesCurrent_iI_pn3n3_zZlwICHlYYqc" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 2.5pt">Total marketable securities</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">74,680</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">2,356</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_404_eus-gaap--CashCashEquivalentsAndShortTermInvestments_iI_zBPTO9LyKV5l" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 2.5pt">Total cash, cash equivalents and marketable securities</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">78,592</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">5,470</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> The unrealized gains on our marketable securities were $4 and $0 for the years ended December 31, 2025 and 2024, respectively.

The following table sets forth our cash, cash equivalents and marketable securities as of December 31, 2025 and 2024: SCHEDULE OF CASH AND CASH EQUIVALENTS AND MARKETABLE SECURITIES <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%; margin-left: 0.75in; margin-right: 0.5in"> <tr style="display: none; vertical-align: bottom"> <td style="display: none; text-align: center"> </td><td style="display: none; text-align: center; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_49B_20251231_zO4sq2Hcndcg" style="border-bottom: Black 1pt solid; display: none; font-weight: bold; text-align: center"> </td><td style="display: none; text-align: center; padding-bottom: 1pt; font-weight: bold"> </td><td style="display: none; text-align: center; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_495_20241231_zVBn85MS16dd" style="border-bottom: Black 1pt solid; display: none; font-weight: bold; text-align: center"> </td><td style="display: none; text-align: center; padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: left; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">As of December 31,</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: left"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Cash and cash equivalents:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_40E_eus-gaap--CashEquivalentsAtCarryingValue_iI_pn3n3_hus-gaap--CashAndCashEquivalentsAxis__us-gaap--CashMember_zdkSppnDXSc7" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; width: 60%; padding-bottom: 1pt">Cash</td><td style="width: 2%; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1pt solid; width: 16%; text-align: right">3,912</td><td style="width: 1%; padding-bottom: 1pt; text-align: left"> </td><td style="width: 2%; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1pt solid; width: 16%; text-align: right">3,114</td><td style="width: 1%; padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_400_eus-gaap--CashEquivalentsAtCarryingValue_iI_pn3n3_zHbqdq57F05g" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 2.5pt">Total cash and cash equivalents</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">3,912</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">3,114</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Marketable securities:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_409_eus-gaap--MarketableSecuritiesCurrent_iI_pn3n3_hus-gaap--InvestmentTypeAxis__us-gaap--MoneyMarketFundsMember_zfJcEoclo0Wf" style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1pt; text-align: left">Money market mutual funds</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right">74,680</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right">2,356</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_408_eus-gaap--MarketableSecuritiesCurrent_iI_pn3n3_zZlwICHlYYqc" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 2.5pt">Total marketable securities</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">74,680</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">2,356</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_404_eus-gaap--CashCashEquivalentsAndShortTermInvestments_iI_zBPTO9LyKV5l" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 2.5pt">Total cash, cash equivalents and marketable securities</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">78,592</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">5,470</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table>

3912000

3114000

3912000

3114000

74680000

2356000

74680000

2356000

78592000

5470000

4000

NOTE 4 - FAIR VALUE MEASUREMENTS <p id="xdx_891_eus-gaap--FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_zJFEhWEJhrU4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.75in; text-align: justify">The following table summarizes the Company’s financial assets subject to fair value measurement and the level of inputs used in such measurements as of December 31, 2025 and 2024: SCHEDULE OF FAIR VALUE MEASUREMENT INPUTS AND VALUATION TECHNIQUES <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%; margin-left: 0.75in; margin-right: 0.5in"> <tr style="display: none; vertical-align: bottom"> <td style="display: none; text-align: center"> </td><td style="display: none; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_493_20251231_z4BiM49xPQU" style="border-bottom: Black 1pt solid; display: none; font-weight: bold; text-align: center">Total</td><td style="display: none; padding-bottom: 1pt; font-weight: bold"> </td><td style="display: none; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_497_20251231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zv6M3deTASM3" style="border-bottom: Black 1pt solid; display: none; font-weight: bold; text-align: center">Level 1</td><td style="display: none; padding-bottom: 1pt; font-weight: bold"> </td><td style="display: none; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_49E_20251231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zcRclA2LRw0c" style="border-bottom: Black 1pt solid; display: none; font-weight: bold; text-align: center">Level 2</td><td style="display: none; padding-bottom: 1pt; font-weight: bold"> </td><td style="display: none; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_492_20251231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zzvDrmiy3fTb" style="border-bottom: Black 1pt solid; display: none; font-weight: bold; text-align: center">Level 3</td><td style="display: none; padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="14" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">As of December 31, 2025</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Total</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Level 1</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Level 2</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Level 3</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Marketable securities:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_407_eus-gaap--AssetsFairValueDisclosure_iI_hus-gaap--FairValueByAssetClassAxis__us-gaap--MoneyMarketFundsMember_zr24XuhuNZ3g" style="vertical-align: bottom; background-color: White"> <td style="width: 36%; text-align: left; padding-bottom: 1pt">Money market mutual funds</td><td style="width: 2%; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1pt solid; width: 12%; text-align: right">74,680</td><td style="width: 1%; padding-bottom: 1pt; text-align: left"> </td><td style="width: 2%; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1pt solid; width: 12%; text-align: right">74,680</td><td style="width: 1%; padding-bottom: 1pt; text-align: left"> </td><td style="width: 2%; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1pt solid; width: 12%; text-align: right">-</td><td style="width: 1%; padding-bottom: 1pt; text-align: left"> </td><td style="width: 2%; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1pt solid; width: 12%; text-align: right">-</td><td style="width: 1%; padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_406_eus-gaap--AssetsFairValueDisclosure_iI_zeosSaG4MNDe" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt">Marketable securities </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">74,680</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">74,680</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">-</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">-</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%; margin-left: 0.75in; margin-right: 0.5in"> <tr style="display: none; vertical-align: bottom"> <td style="display: none; text-align: center"> </td><td style="display: none; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_490_20241231_z090KpuucGGc" style="border-bottom: Black 1pt solid; display: none; font-weight: bold; text-align: center">Total</td><td style="display: none; padding-bottom: 1pt; font-weight: bold"> </td><td style="display: none; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_490_20241231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zg5yb8j6P38b" style="border-bottom: Black 1pt solid; display: none; font-weight: bold; text-align: center">Level 1</td><td style="display: none; padding-bottom: 1pt; font-weight: bold"> </td><td style="display: none; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_492_20241231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zUjXga4aelYa" style="border-bottom: Black 1pt solid; display: none; font-weight: bold; text-align: center">Level 2</td><td style="display: none; padding-bottom: 1pt; font-weight: bold"> </td><td style="display: none; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_495_20241231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zvvQWP4ON20b" style="border-bottom: Black 1pt solid; display: none; font-weight: bold; text-align: center">Level 3</td><td style="display: none; padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="14" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">As of December 31, 2024</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Total</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Level 1</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Level 2</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Level 3</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Marketable securities:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_407_eus-gaap--AssetsFairValueDisclosure_iI_hus-gaap--FairValueByAssetClassAxis__us-gaap--MoneyMarketFundsMember_zierAbbXNmB7" style="vertical-align: bottom; background-color: White"> <td style="width: 36%; text-align: left; padding-bottom: 1pt">Money market mutual funds</td><td style="width: 2%; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1pt solid; width: 12%; text-align: right">2,356</td><td style="width: 1%; padding-bottom: 1pt; text-align: left"> </td><td style="width: 2%; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1pt solid; width: 12%; text-align: right">2,356</td><td style="width: 1%; padding-bottom: 1pt; text-align: left"> </td><td style="width: 2%; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1pt solid; width: 12%; text-align: right">-</td><td style="width: 1%; padding-bottom: 1pt; text-align: left"> </td><td style="width: 2%; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1pt solid; width: 12%; text-align: right">-</td><td style="width: 1%; padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_406_eus-gaap--AssetsFairValueDisclosure_iI_zcvNbR7JnuAc" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt">Marketable securities </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">2,356</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">2,356</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">-</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">-</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> The Company’s financial assets are measured at fair value on a recurring basis by level within the fair value hierarchy. The Company’s securities and money market funds are classified as Level 1. Other than that, the Company doesn’t have any other financial assets or financial liabilities marked to market at fair value as of December 31, 2025 and 2024.

<p id="xdx_891_eus-gaap--FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_zJFEhWEJhrU4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.75in; text-align: justify">The following table summarizes the Company’s financial assets subject to fair value measurement and the level of inputs used in such measurements as of December 31, 2025 and 2024: SCHEDULE OF FAIR VALUE MEASUREMENT INPUTS AND VALUATION TECHNIQUES <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%; margin-left: 0.75in; margin-right: 0.5in"> <tr style="display: none; vertical-align: bottom"> <td style="display: none; text-align: center"> </td><td style="display: none; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_493_20251231_z4BiM49xPQU" style="border-bottom: Black 1pt solid; display: none; font-weight: bold; text-align: center">Total</td><td style="display: none; padding-bottom: 1pt; font-weight: bold"> </td><td style="display: none; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_497_20251231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zv6M3deTASM3" style="border-bottom: Black 1pt solid; display: none; font-weight: bold; text-align: center">Level 1</td><td style="display: none; padding-bottom: 1pt; font-weight: bold"> </td><td style="display: none; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_49E_20251231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zcRclA2LRw0c" style="border-bottom: Black 1pt solid; display: none; font-weight: bold; text-align: center">Level 2</td><td style="display: none; padding-bottom: 1pt; font-weight: bold"> </td><td style="display: none; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_492_20251231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zzvDrmiy3fTb" style="border-bottom: Black 1pt solid; display: none; font-weight: bold; text-align: center">Level 3</td><td style="display: none; padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="14" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">As of December 31, 2025</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Total</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Level 1</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Level 2</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Level 3</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Marketable securities:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_407_eus-gaap--AssetsFairValueDisclosure_iI_hus-gaap--FairValueByAssetClassAxis__us-gaap--MoneyMarketFundsMember_zr24XuhuNZ3g" style="vertical-align: bottom; background-color: White"> <td style="width: 36%; text-align: left; padding-bottom: 1pt">Money market mutual funds</td><td style="width: 2%; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1pt solid; width: 12%; text-align: right">74,680</td><td style="width: 1%; padding-bottom: 1pt; text-align: left"> </td><td style="width: 2%; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1pt solid; width: 12%; text-align: right">74,680</td><td style="width: 1%; padding-bottom: 1pt; text-align: left"> </td><td style="width: 2%; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1pt solid; width: 12%; text-align: right">-</td><td style="width: 1%; padding-bottom: 1pt; text-align: left"> </td><td style="width: 2%; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1pt solid; width: 12%; text-align: right">-</td><td style="width: 1%; padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_406_eus-gaap--AssetsFairValueDisclosure_iI_zeosSaG4MNDe" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt">Marketable securities </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">74,680</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">74,680</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">-</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">-</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%; margin-left: 0.75in; margin-right: 0.5in"> <tr style="display: none; vertical-align: bottom"> <td style="display: none; text-align: center"> </td><td style="display: none; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_490_20241231_z090KpuucGGc" style="border-bottom: Black 1pt solid; display: none; font-weight: bold; text-align: center">Total</td><td style="display: none; padding-bottom: 1pt; font-weight: bold"> </td><td style="display: none; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_490_20241231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zg5yb8j6P38b" style="border-bottom: Black 1pt solid; display: none; font-weight: bold; text-align: center">Level 1</td><td style="display: none; padding-bottom: 1pt; font-weight: bold"> </td><td style="display: none; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_492_20241231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zUjXga4aelYa" style="border-bottom: Black 1pt solid; display: none; font-weight: bold; text-align: center">Level 2</td><td style="display: none; padding-bottom: 1pt; font-weight: bold"> </td><td style="display: none; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_495_20241231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zvvQWP4ON20b" style="border-bottom: Black 1pt solid; display: none; font-weight: bold; text-align: center">Level 3</td><td style="display: none; padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="14" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">As of December 31, 2024</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Total</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Level 1</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Level 2</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Level 3</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Marketable securities:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_407_eus-gaap--AssetsFairValueDisclosure_iI_hus-gaap--FairValueByAssetClassAxis__us-gaap--MoneyMarketFundsMember_zierAbbXNmB7" style="vertical-align: bottom; background-color: White"> <td style="width: 36%; text-align: left; padding-bottom: 1pt">Money market mutual funds</td><td style="width: 2%; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1pt solid; width: 12%; text-align: right">2,356</td><td style="width: 1%; padding-bottom: 1pt; text-align: left"> </td><td style="width: 2%; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1pt solid; width: 12%; text-align: right">2,356</td><td style="width: 1%; padding-bottom: 1pt; text-align: left"> </td><td style="width: 2%; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1pt solid; width: 12%; text-align: right">-</td><td style="width: 1%; padding-bottom: 1pt; text-align: left"> </td><td style="width: 2%; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1pt solid; width: 12%; text-align: right">-</td><td style="width: 1%; padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_406_eus-gaap--AssetsFairValueDisclosure_iI_zcvNbR7JnuAc" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt">Marketable securities </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">2,356</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">2,356</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">-</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">-</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table>

74680000

2356000

NOTE 5 – INVENTORY Inventories consisted of the following: SCHEDULE OF INVENTORIES <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%; margin-left: 0.75in; margin-right: 0.5in"> <tr style="display: none; vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_490_20251231_zP7Wo6shDjTe" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_492_20241231_zJWvVN9IIFwc" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">As of December 31,</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td></tr> <tr id="xdx_407_eus-gaap--InventoryRawMaterialsAndSupplies_iI_pn3n3_maINzZ8s_zHSvzOOKourj" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%; text-align: left">Raw materials</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">416</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">-</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_405_eus-gaap--InventoryWorkInProcess_iI_pn3n3_maINzZ8s_z6BLfLwDFwbe" style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1pt">Work-in-process</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">168</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">-</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_404_eus-gaap--InventoryNet_iTI_pn3n3_mtINzZ8s_zaJ8AIGpjW1c" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 2.5pt"> Total inventory</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">584</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">-</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> There have been no write-downs of inventory from the time inventory was first capitalized.

Inventories consisted of the following: SCHEDULE OF INVENTORIES <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%; margin-left: 0.75in; margin-right: 0.5in"> <tr style="display: none; vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_490_20251231_zP7Wo6shDjTe" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_492_20241231_zJWvVN9IIFwc" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">As of December 31,</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td></tr> <tr id="xdx_407_eus-gaap--InventoryRawMaterialsAndSupplies_iI_pn3n3_maINzZ8s_zHSvzOOKourj" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%; text-align: left">Raw materials</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">416</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">-</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_405_eus-gaap--InventoryWorkInProcess_iI_pn3n3_maINzZ8s_z6BLfLwDFwbe" style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1pt">Work-in-process</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">168</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">-</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_404_eus-gaap--InventoryNet_iTI_pn3n3_mtINzZ8s_zaJ8AIGpjW1c" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 2.5pt"> Total inventory</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">584</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">-</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table>

416000

168000

584000

NOTE 6 – PREPAID EXPENSES AND OTHER CURRENT ASSETS SCHEDULE OF PREPAID EXPENSES AND OTHER CURRENT ASSETS <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%; margin-left: 0.75in; margin-right: 0.5in"> <tr style="display: none; vertical-align: bottom"> <td style="display: none; text-align: center"> </td><td style="display: none; text-align: center; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_496_20251231_zBCiMIZMhFjf" style="border-bottom: Black 1pt solid; display: none; font-weight: bold; text-align: center"> </td><td style="display: none; text-align: center; padding-bottom: 1pt; font-weight: bold"> </td><td style="display: none; text-align: center; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_490_20241231_z23W0Ss5dVf6" style="border-bottom: Black 1pt solid; display: none; font-weight: bold; text-align: center"> </td><td style="display: none; text-align: center; padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">As of December 31,</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td></tr> <tr id="xdx_400_eus-gaap--GovernmentContractReceivable_iI_pn3n3_maOACzRgI_zhaBmr2HRh7b" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%; text-align: left">Amounts due from government institutions</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">241</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">89</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_401_eus-gaap--PrepaidExpenseCurrent_iI_pn3n3_maOACzRgI_zjSQsdqQvbv1" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt">Prepaid expenses and other receivables</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">403</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">211</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_407_eus-gaap--PrepaidExpenseAndOtherAssetsCurrent_iTI_pn3n3_mtOACzRgI_znlQ43NMzC2i" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt">Total prepaid expenses and other current assets</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">644</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">300</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> MICROBOT MEDICAL INC. NOTES TO CONSOLIDATED FINANCIAL STATEMENTS U.S. dollars in thousands (Except share and per share data)

SCHEDULE OF PREPAID EXPENSES AND OTHER CURRENT ASSETS <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%; margin-left: 0.75in; margin-right: 0.5in"> <tr style="display: none; vertical-align: bottom"> <td style="display: none; text-align: center"> </td><td style="display: none; text-align: center; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_496_20251231_zBCiMIZMhFjf" style="border-bottom: Black 1pt solid; display: none; font-weight: bold; text-align: center"> </td><td style="display: none; text-align: center; padding-bottom: 1pt; font-weight: bold"> </td><td style="display: none; text-align: center; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_490_20241231_z23W0Ss5dVf6" style="border-bottom: Black 1pt solid; display: none; font-weight: bold; text-align: center"> </td><td style="display: none; text-align: center; padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">As of December 31,</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td></tr> <tr id="xdx_400_eus-gaap--GovernmentContractReceivable_iI_pn3n3_maOACzRgI_zhaBmr2HRh7b" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%; text-align: left">Amounts due from government institutions</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">241</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">89</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_401_eus-gaap--PrepaidExpenseCurrent_iI_pn3n3_maOACzRgI_zjSQsdqQvbv1" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt">Prepaid expenses and other receivables</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">403</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">211</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_407_eus-gaap--PrepaidExpenseAndOtherAssetsCurrent_iTI_pn3n3_mtOACzRgI_znlQ43NMzC2i" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt">Total prepaid expenses and other current assets</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">644</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">300</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table>

241000

89000

403000

211000

644000

300000

NOTE 7 - LEASES In March 2025, the Company entered into a lease agreement for its US office for the period from March 2025 until February 2027. The monthly lease payments are approximately $2. In July 2025, the Subsidiary entered into a lease agreement for its Israel office for the period from July 2025 until October 2029. The monthly lease payments are approximately $20. To secure the lease payments, the Company issued a bank guarantee of $56 in favor of the facility’s lessor. Additionally, the Company has several agreements for car leases. For the years ended December 31, 2025 and 2024, operating lease cost, which is classified as a component of research and development in the consolidated statement of comprehensive loss for all periods presented, was $256 and $215, respectively. Also for the years ended December 31, 2025 and 2024, cash paid under operating lease agreements were $212 and $219, respectively. Undiscounted maturities of future operating lease payments as of December 31, 2025 are summarized as follows: SCHEDULE OF MATURITIES OF LEASE LIABILITIES <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%; margin-left: 0.75in; margin-right: 0.5in"> <tr style="vertical-align: bottom"> <td style="text-align: left"> </td><td style="font-weight: bold"> </td> <td colspan="2" id="xdx_491_20251231_zfIVG13qiXl9" style="font-weight: bold; text-align: center">As of December 31,</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: left"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr id="xdx_40C_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_iI_pn3n3_maLOLLPzDag_z9ytBHPucLLi" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 80%; text-align: left">2026</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">308</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_405_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_iI_pn3n3_maLOLLPzDag_zP4byIMnHIYa" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">2027</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">256</td><td style="text-align: left"> </td></tr> <tr id="xdx_400_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearThree_iI_pn3n3_maLOLLPzDag_zrDvcpX5CTWi" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">2028</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">238</td><td style="text-align: left"> </td></tr> <tr id="xdx_405_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearFour_iI_pn3n3_maLOLLPzDag_z7qQz9WrDD6l" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt">2029</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">196</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_407_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDue_iTI_pn3n3_mtLOLLPzDag_zBjYxIY2h8de" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Total future lease payments</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">998</td><td style="text-align: left"> </td></tr> <tr id="xdx_40D_eus-gaap--LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_iNI_pn3n3_di_zalFBgEwNoV9" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt">Less imputed interest</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(133</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr> <tr id="xdx_403_eus-gaap--OperatingLeaseLiability_iTI_pn3n3_zrWrQeGGmSA9" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 2.5pt">Total lease liabilities</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">865</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> The following table includes the weighted-average lease terms and discount rates for operating leases as of December 31, 2025 and 2024: SCHEDULE OF SUPPLEMENTAL INFORMATION RELATED TO LEASES <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%; margin-left: 0.75in; margin-right: 0.5in"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">As of December 31,</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%; text-align: left">Operating leases weighted-average remaining lease term (in years)</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 16%; text-align: right">3.6</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 16%; text-align: right">1.6</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Operating leases weighted-average discount rate</td><td> </td> <td style="text-align: left"> </td><td id="xdx_981_eus-gaap--OperatingLeaseWeightedAverageDiscountRatePercent_iI_pid_dp_uPure_c20251231_znxokb34ObT" style="text-align: right" title="Operating leases weighted average discount rate">8.2</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td id="xdx_985_eus-gaap--OperatingLeaseWeightedAverageDiscountRatePercent_iI_pid_dp_uPure_c20241231_zfn8VATxpXEf" style="text-align: right" title="Operating leases weighted average discount rate">6.7</td><td style="text-align: left">%</td></tr> </table> MICROBOT MEDICAL INC. NOTES TO CONSOLIDATED FINANCIAL STATEMENTS U.S. dollars in thousands (Except share and per share data)

2000

20000

56000

256000

215000

212000

219000

Undiscounted maturities of future operating lease payments as of December 31, 2025 are summarized as follows: SCHEDULE OF MATURITIES OF LEASE LIABILITIES <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%; margin-left: 0.75in; margin-right: 0.5in"> <tr style="vertical-align: bottom"> <td style="text-align: left"> </td><td style="font-weight: bold"> </td> <td colspan="2" id="xdx_491_20251231_zfIVG13qiXl9" style="font-weight: bold; text-align: center">As of December 31,</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: left"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr id="xdx_40C_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_iI_pn3n3_maLOLLPzDag_z9ytBHPucLLi" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 80%; text-align: left">2026</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">308</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_405_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_iI_pn3n3_maLOLLPzDag_zP4byIMnHIYa" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">2027</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">256</td><td style="text-align: left"> </td></tr> <tr id="xdx_400_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearThree_iI_pn3n3_maLOLLPzDag_zrDvcpX5CTWi" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">2028</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">238</td><td style="text-align: left"> </td></tr> <tr id="xdx_405_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearFour_iI_pn3n3_maLOLLPzDag_z7qQz9WrDD6l" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt">2029</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">196</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_407_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDue_iTI_pn3n3_mtLOLLPzDag_zBjYxIY2h8de" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Total future lease payments</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">998</td><td style="text-align: left"> </td></tr> <tr id="xdx_40D_eus-gaap--LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_iNI_pn3n3_di_zalFBgEwNoV9" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt">Less imputed interest</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(133</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr> <tr id="xdx_403_eus-gaap--OperatingLeaseLiability_iTI_pn3n3_zrWrQeGGmSA9" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 2.5pt">Total lease liabilities</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">865</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table>

308000

256000

238000

196000

998000

133000

865000

The following table includes the weighted-average lease terms and discount rates for operating leases as of December 31, 2025 and 2024: SCHEDULE OF SUPPLEMENTAL INFORMATION RELATED TO LEASES <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%; margin-left: 0.75in; margin-right: 0.5in"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">As of December 31,</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%; text-align: left">Operating leases weighted-average remaining lease term (in years)</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 16%; text-align: right">3.6</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 16%; text-align: right">1.6</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Operating leases weighted-average discount rate</td><td> </td> <td style="text-align: left"> </td><td id="xdx_981_eus-gaap--OperatingLeaseWeightedAverageDiscountRatePercent_iI_pid_dp_uPure_c20251231_znxokb34ObT" style="text-align: right" title="Operating leases weighted average discount rate">8.2</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td id="xdx_985_eus-gaap--OperatingLeaseWeightedAverageDiscountRatePercent_iI_pid_dp_uPure_c20241231_zfn8VATxpXEf" style="text-align: right" title="Operating leases weighted average discount rate">6.7</td><td style="text-align: left">%</td></tr> </table>

P3Y7M6D

P1Y7M6D

0.082

0.067

NOTE 8 - PROPERTY AND EQUIPMENT, NET SCHEDULE OF PROPERTY AND EQUIPMENT <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%; margin-left: 0.75in; margin-right: 0.5in"> <tr style="display: none; vertical-align: bottom"> <td style="display: none; text-align: center"> </td><td style="display: none; text-align: center; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_497_20251231_zW5aGSrH9JT6" style="border-bottom: Black 1pt solid; display: none; font-weight: bold; text-align: center"> </td><td style="display: none; text-align: center; padding-bottom: 1pt; font-weight: bold"> </td><td style="display: none; text-align: center; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_49B_20241231_z0KpQNIdg1B3" style="border-bottom: Black 1pt solid; display: none; font-weight: bold; text-align: center"> </td><td style="display: none; text-align: center; padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: left"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">As of December 31,</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: left"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold; text-align: left">Cost:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_40F_eus-gaap--PropertyPlantAndEquipmentGross_iI_pn3n3_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--ResearchEquipmentAndSoftwareMember_zK7Q1Tevk7f" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; width: 60%; text-align: left">Research equipment and software</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">241</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">193</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_40B_eus-gaap--PropertyPlantAndEquipmentGross_iI_pn3n3_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--LeaseholdImprovementsMember_zrTHUyHyYuOe" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: left">Leasehold improvement</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">229</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">229</td><td style="text-align: left"> </td></tr> <tr id="xdx_409_eus-gaap--PropertyPlantAndEquipmentGross_iI_pn3n3_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--FurnitureAndOfficeEquipmentMember_zNMFlBSD65th" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; text-align: left; padding-bottom: 1pt">Furniture and office equipment</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">254</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">242</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_404_eus-gaap--PropertyPlantAndEquipmentGross_iI_pn3n3_zfvw1jzrZpfb" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1pt">Cost</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">724</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">664</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-weight: bold; text-align: left">Accumulated Depreciation:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_400_eus-gaap--AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_iI_pn3n3_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--ResearchEquipmentAndSoftwareMember_zAuSW7LL0FXc" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: left">Research equipment and software</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">152</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">138</td><td style="text-align: left"> </td></tr> <tr id="xdx_401_eus-gaap--AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_iI_pn3n3_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--LeaseholdImprovementsMember_z8Wn3dKziEwe" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; text-align: left">Leasehold improvement</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">214</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">210</td><td style="text-align: left"> </td></tr> <tr id="xdx_40A_eus-gaap--AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_iI_pn3n3_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--FurnitureAndOfficeEquipmentMember_z70g0pgaRW06" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: left; padding-bottom: 1pt">Furniture and office equipment</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">265</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">236</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_409_eus-gaap--AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_iI_pn3n3_zhBCkNZMvLCk" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt">Accumulated Depreciation</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">631</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">584</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_407_eus-gaap--PropertyPlantAndEquipmentNet_iI_pn3n3_zIUrafvSEJX7" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 2.5pt">Net book value</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">93</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">80</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table>

SCHEDULE OF PROPERTY AND EQUIPMENT <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%; margin-left: 0.75in; margin-right: 0.5in"> <tr style="display: none; vertical-align: bottom"> <td style="display: none; text-align: center"> </td><td style="display: none; text-align: center; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_497_20251231_zW5aGSrH9JT6" style="border-bottom: Black 1pt solid; display: none; font-weight: bold; text-align: center"> </td><td style="display: none; text-align: center; padding-bottom: 1pt; font-weight: bold"> </td><td style="display: none; text-align: center; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_49B_20241231_z0KpQNIdg1B3" style="border-bottom: Black 1pt solid; display: none; font-weight: bold; text-align: center"> </td><td style="display: none; text-align: center; padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: left"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">As of December 31,</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: left"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold; text-align: left">Cost:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_40F_eus-gaap--PropertyPlantAndEquipmentGross_iI_pn3n3_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--ResearchEquipmentAndSoftwareMember_zK7Q1Tevk7f" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; width: 60%; text-align: left">Research equipment and software</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">241</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">193</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_40B_eus-gaap--PropertyPlantAndEquipmentGross_iI_pn3n3_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--LeaseholdImprovementsMember_zrTHUyHyYuOe" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: left">Leasehold improvement</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">229</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">229</td><td style="text-align: left"> </td></tr> <tr id="xdx_409_eus-gaap--PropertyPlantAndEquipmentGross_iI_pn3n3_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--FurnitureAndOfficeEquipmentMember_zNMFlBSD65th" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; text-align: left; padding-bottom: 1pt">Furniture and office equipment</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">254</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">242</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_404_eus-gaap--PropertyPlantAndEquipmentGross_iI_pn3n3_zfvw1jzrZpfb" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1pt">Cost</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">724</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">664</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-weight: bold; text-align: left">Accumulated Depreciation:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_400_eus-gaap--AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_iI_pn3n3_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--ResearchEquipmentAndSoftwareMember_zAuSW7LL0FXc" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: left">Research equipment and software</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">152</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">138</td><td style="text-align: left"> </td></tr> <tr id="xdx_401_eus-gaap--AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_iI_pn3n3_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--LeaseholdImprovementsMember_z8Wn3dKziEwe" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; text-align: left">Leasehold improvement</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">214</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">210</td><td style="text-align: left"> </td></tr> <tr id="xdx_40A_eus-gaap--AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_iI_pn3n3_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--FurnitureAndOfficeEquipmentMember_z70g0pgaRW06" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: left; padding-bottom: 1pt">Furniture and office equipment</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">265</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">236</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_409_eus-gaap--AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_iI_pn3n3_zhBCkNZMvLCk" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt">Accumulated Depreciation</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">631</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">584</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_407_eus-gaap--PropertyPlantAndEquipmentNet_iI_pn3n3_zIUrafvSEJX7" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 2.5pt">Net book value</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">93</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">80</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table>

241000

193000

229000

254000

242000

724000

664000

152000

138000

214000

210000

265000

236000

631000

584000

93000

80000

NOTE 9 - ACCRUED LIABILITIES SCHEDULE OF ACCRUED LIABILITIES <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%; margin-left: 0.75in; margin-right: 0.5in"> <tr style="display: none; vertical-align: bottom"> <td style="display: none; text-align: center"> </td><td style="display: none; text-align: center; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_491_20251231_zI5P7Jdx2JUc" style="border-bottom: Black 1pt solid; display: none; font-weight: bold; text-align: center"> </td><td style="display: none; text-align: center; padding-bottom: 1pt; font-weight: bold"> </td><td style="display: none; text-align: center; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_498_20241231_zFGr5ecpuS08" style="border-bottom: Black 1pt solid; display: none; font-weight: bold; text-align: center"> </td><td style="display: none; text-align: center; padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: left"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">As of December 31,</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: left"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: left"> </td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td></tr> <tr id="xdx_400_eus-gaap--EmployeeRelatedLiabilitiesCurrent_iI_pn3n3_maALCz4CP_ztWSyDbBuQl8" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%; text-align: left">Employee-related liabilities</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">1,979</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">1,409</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_402_eus-gaap--OtherAccruedLiabilitiesCurrent_iI_pn3n3_maALCz4CP_zvEAUwg9DeEd" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Accrued expenses</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">537</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">811</td><td style="text-align: left"> </td></tr> <tr id="xdx_403_eus-gaap--DeferredIncome_iI_pn3n3_maALCz4CP_zGRqTifOLWo5" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Deferred income grants</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">93</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td></tr> <tr id="xdx_403_eus-gaap--OtherLiabilitiesCurrent_iI_pn3n3_maALCz4CP_zy7wUyDOWAT3" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt">Other current liabilities</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">5</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">5</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_400_eus-gaap--AccruedLiabilitiesCurrent_iTI_pn3n3_mtALCz4CP_ziawXbUs4jU9" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 2.5pt">Total Accrued Liabilities</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">2,614</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">2,225</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> MICROBOT MEDICAL INC. NOTES TO CONSOLIDATED FINANCIAL STATEMENTS U.S. dollars in thousands (Except share and per share data)

SCHEDULE OF ACCRUED LIABILITIES <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%; margin-left: 0.75in; margin-right: 0.5in"> <tr style="display: none; vertical-align: bottom"> <td style="display: none; text-align: center"> </td><td style="display: none; text-align: center; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_491_20251231_zI5P7Jdx2JUc" style="border-bottom: Black 1pt solid; display: none; font-weight: bold; text-align: center"> </td><td style="display: none; text-align: center; padding-bottom: 1pt; font-weight: bold"> </td><td style="display: none; text-align: center; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_498_20241231_zFGr5ecpuS08" style="border-bottom: Black 1pt solid; display: none; font-weight: bold; text-align: center"> </td><td style="display: none; text-align: center; padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: left"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">As of December 31,</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: left"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: left"> </td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td></tr> <tr id="xdx_400_eus-gaap--EmployeeRelatedLiabilitiesCurrent_iI_pn3n3_maALCz4CP_ztWSyDbBuQl8" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%; text-align: left">Employee-related liabilities</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">1,979</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">1,409</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_402_eus-gaap--OtherAccruedLiabilitiesCurrent_iI_pn3n3_maALCz4CP_zvEAUwg9DeEd" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Accrued expenses</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">537</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">811</td><td style="text-align: left"> </td></tr> <tr id="xdx_403_eus-gaap--DeferredIncome_iI_pn3n3_maALCz4CP_zGRqTifOLWo5" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Deferred income grants</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">93</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td></tr> <tr id="xdx_403_eus-gaap--OtherLiabilitiesCurrent_iI_pn3n3_maALCz4CP_zy7wUyDOWAT3" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt">Other current liabilities</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">5</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">5</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_400_eus-gaap--AccruedLiabilitiesCurrent_iTI_pn3n3_mtALCz4CP_ziawXbUs4jU9" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 2.5pt">Total Accrued Liabilities</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">2,614</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">2,225</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table>

1979000

1409000

537000

811000

93000

5000

2614000

2225000

<p id="xdx_804_eus-gaap--CommitmentsAndContingenciesDisclosureTextBlock_zhIXVqD2hqF9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 49.65pt; text-align: justify; text-indent: -49.65pt">NOTE 10 - COMMITMENTS AND CONTINGENCIES A. Government grants: Microbot Israel has received grants from the IIA for participation in research and development since 2013 through December 31, 2025 totaling approximately $<span id="xdx_90D_eus-gaap--RevenueFromContractWithCustomerIncludingAssessedTax_pn3n3_c20250101__20251231__us-gaap--AwardDateAxis__custom--TwoThousandThirteenToJuneThirtyTwoThousandTwentyTwoMember__dei--LegalEntityAxis__custom--IsraeliInnovationAuthorityMember_zsz02mcqzQUd" title="Revenues">2,468. This includes amounts received of approximately $518, in 2025 which is a portion of an additional grant from the IIA in the amount of approximately NIS 2,153 (approximately $673) approved by the IIA on July 15, 2025, to further finance the development of the manufacturing process of the LIBERTY® Endovascular Robotic Surgical System. In addition, as a result of the agreement with Nitiloop, on October 6, 2022, Microbot Israel took over the liability to repay Nitiloop’s IIA grants in the aggregate amount of approximately $<span id="xdx_906_ecustom--RepaymentOfGovernmentGrants_pn3n3_c20231006__20231006__dei--LegalEntityAxis__custom--IsraeliInnovationAuthorityMember__us-gaap--BusinessAcquisitionAxis__custom--CardioSertLtdMember_zRJkmCmPHmZ2" title="Repayment of government grants">925. In relation to the IIA grants described above, the Company is obligated to pay royalties amounting to <span id="xdx_90A_ecustom--NetSalesRoyaltyPercentage_pid_dp_uPure_c20250101__20251231__dei--LegalEntityAxis__custom--IsraeliInnovationAuthorityMember__srt--RangeAxis__srt--MinimumMember_zN8gBQffsFrh" title="Net sales royalty percenatge">3%-<span id="xdx_90A_ecustom--NetSalesRoyaltyPercentage_pid_dp_uPure_c20250101__20251231__dei--LegalEntityAxis__custom--IsraeliInnovationAuthorityMember__srt--RangeAxis__srt--MaximumMember_zsx7MmZvrDAi" title="Net sales royalty percenatge">5% of its future sales of the products relating to such grants. The grants are linked to the exchange rate of the dollar to the New Israeli Shekel and bears interest of SOFR per year (SOFR is a benchmark interest rate which replaced LIBOR). The repayment of the grants is contingent upon the successful completion of the Company’s research and development programs and generating sales. The Company has no obligation to repay these grants, if the project fails, is unsuccessful or aborted or if no sales are generated. The financial risk is assumed completely by the Government of Israel. The grants are received from the Government on a project-by-project basis. As of December 31, 2025, the Company received grants from the Ministry of Economy of the State of Israel in the amount of approximately $50, to further finance the marketing activities of the LIBERTY® Endovascular Robotic Surgical System in the U.S. market. In relation to the Ministry of Economy grant, the Company is obligated to pay royalties amounting to 3% of future sales of the LIBERTY® Endovascular Robotic Surgical System up to the grant amount plus interest. B. TRDF agreement: Microbot Israel signed an agreement with the Technion Research and Development Foundation (“TRDF”) in June 2012 by which TRDF transferred to Microbot Israel a global, exclusive, royalty-bearing license (as amended, the “License Agreement”) with respect to the Company’s Self-Cleaning Shunt (SCS) project and its TipCat assets in addition to certain technology relating to the Company’s LIBERTY® Endovascular Robotic Surgical System. As partial consideration for the license, Microbot Israel shall pay TRDF royalties on net sales (between <span id="xdx_90F_ecustom--NetSalesRoyaltyPercentage_pid_dp_uPure_c20120601__20120630__dei--LegalEntityAxis__custom--TechnionResearchAndDevelopmentFoundationLimitedMember__srt--RangeAxis__srt--MinimumMember_zSsfikEx0Tp4" title="Net sales">1.5%-<span id="xdx_90F_ecustom--NetSalesRoyaltyPercentage_pid_dp_uPure_c20120601__20120630__dei--LegalEntityAxis__custom--TechnionResearchAndDevelopmentFoundationLimitedMember__srt--RangeAxis__srt--MaximumMember_zRH7fX2jBVG4" title="Net sales royalty percenatge">3.0%) and on sublicense income as detailed in the License Agreement. In October 2022 the Company suspended the SCS project and as a result of the Company’s May 2023 implementation of its core-business focus program and cost reduction plan, the Company returned the licensed intellectual property for the TipCat back to TRDF in June 2023 and returned the licensed intellectual property for the SCS (ViRob) back to TRDF in July 2023. As a result, as of the date of these financial statements, the License Agreement is limited to the certain technology relating to the Company’s LIBERTY® Endovascular Robotic Surgical System. MICROBOT MEDICAL INC. NOTES TO CONSOLIDATED FINANCIAL STATEMENTS U.S. dollars in thousands (Except share and per share data) NOTE 10 - COMMITMENTS AND CONTINGENCIES C. ATM agreement: On June 10, 2021, the Company entered into an At-the-Market Offering Agreement (the “ATM Agreement”) with H.C. Wainwright & Co. LLC (“Wainwright”), as sales agent, in connection with an “at the market offering” under which the Company may offer and sell, from time to time in its sole discretion, shares of its common stock having an aggregate offering price of up to $<span id="xdx_90E_ecustom--OfferingCosts_iI_pn3n3_c20210610__us-gaap--TypeOfArrangementAxis__custom--AtTheMarketOfferingAgreementMember__dei--LegalEntityAxis__custom--HCWainwrightAndCoLLCMember_zkU8Z2LRDIl1" title="Offering costs">10,000 at market prices or as otherwise agreed with Wainwright. The Company entered into an amendment, dated July 1, 2024, to the ATM Agreement with Wainwright dated June 10, 2021, relating to the offer and sale of shares of the Company’s common stock having an aggregate offering price of up to approximately $<span id="xdx_90C_eus-gaap--SaleOfStockConsiderationReceivedOnTransaction_pn3n3_c20240701__20240701__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--TypeOfArrangementAxis__custom--AtTheMarketOfferingAgreementMember_zKGLJ4kWWLG1" title="Aggregate offering">4,820 from time to time through Wainwright, acting as sales agent. The compensation to Wainwright for sales of the shares is a placement fee of <span id="xdx_902_ecustom--PlacementFeePercent_pid_dp_c20240701__20240701__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--TypeOfArrangementAxis__custom--AtTheMarketOfferingAgreementMember_zBXGANe36Kof" title="Percentage of placement fee">3.0% of the gross sales price of the shares of common stock sold pursuant to this ATM Agreement. See also Notes 11D. D. Engagement letters with H.C. Wainwright: In connection with registered direct and private placement offerings, the Company entered into engagement letters (the “Engagement Letters”) with Wainwright on October 3, 2022, on May 16, 2023, on October 24, 2023 and on May 29, 2024 (which was amended most recently on February 9, 2025), pursuant to which Wainwright agreed to serve as the exclusive placement agent for the issuance and sale of securities of the Company. As compensation for such placement agent services, the Company has agreed to pay Wainwright an aggregate cash fee equal to 7.0% of the gross proceeds received by the Company from offerings contemplated by the Engagement Letters, plus in certain circumstances a management fee equal to 1.0% of the gross proceeds received by the Company from such offerings as well as other reimbursable expenses. The Company has also agreed to issue to Wainwright or its designees preferred investment options upon the closing of such offerings, equal to five (5.0%) percent of the aggregate number of such shares of common stock in such offerings, including upon exercise for cash of any warrants issued to investors in such offering. See also Note 11E below. E. Acquisition of Nitiloop’s assets: On October 6, 2022, Microbot Israel purchased substantially all of the assets, including intellectual property, devices, components and product related materials (the “Assets”), of Nitiloop Ltd., an Israeli limited liability company (“Nitiloop”). The Assets include intellectual property and technology in the field of intraluminal revascularization devices with anchoring mechanism and integrated microcatheter (the “Technology”) and the products or potential products incorporating the Technology owned by Nitiloop and designated by Nitiloop as “NovaCross”, “NovaCross Xtreme” and “NovaCross BTK” and any enhancements, modifications and improvements thereof (“Devices”). Microbot Israel did not assume any material liabilities of Nitiloop other than obligations Nitiloop has to the IIA and relating to certain renewal/maintenance fees for a European patent application. In consideration for the acquisition of the Assets, Microbot Israel shall pay royalties to Nitiloop, which shall not, in the aggregate, exceed $<span id="xdx_904_eus-gaap--StockIssuedDuringPeriodValueNewIssues_pn3n3_c20221006__20221006__us-gaap--TypeOfArrangementAxis__custom--AtTheMarketOfferingAgreementMember__dei--LegalEntityAxis__custom--HCWainwrightAndCoLLCMember_zZpujpsmOWn3" title="Stock issued during period, value, new issues">8,000, as follows: Royalties at a rate of <span id="xdx_904_ecustom--RoyaltiesPercentage1_pid_dp_uPure_c20221006__20221006__srt--ProductOrServiceAxis__custom--DeviceMember__srt--RangeAxis__srt--MinimumMember_zRbtuIxeU2r6" title="Royalties percentage">3%-<span id="xdx_903_ecustom--RoyaltiesPercentage1_pid_dp_uPure_c20221006__20221006__srt--ProductOrServiceAxis__custom--DeviceMember__srt--RangeAxis__srt--MaximumMember_znLUuq4TpnNd" title="Royalties percentage">5% of net revenue generated as a result of sales, license or other exploitation of the Devices; and Royalties at a rate of 1.5% of net revenue generated from the sale, license or other exploitation of commercialization of the technology as part of an integrated product. Based on the Company’s analysis, the Company concluded that the acquisition of the assets does not meet the definition of a business for the purpose of applying SEC Rules (S-X Rules of 3-05, 8-04 and 11-01). MICROBOT MEDICAL INC. NOTES TO CONSOLIDATED FINANCIAL STATEMENTS U.S. dollars in thousands (Except share and per share data) NOTE 10 - COMMITMENTS AND CONTINGENCIES F. Litigation resulting from the 2017 financing: The Company was named as the defendant in a lawsuit captioned Empery Asset Master Ltd., Empery Tax Efficient, LP, Empery Tax Efficient II, LP, Hudson Bay Master Fund Ltd., (the “Plaintiffs”), against Microbot Medical Inc., Defendant, in the Supreme Court of the State of New York, County of New York (Index No. 651182/2020) (the “Lawsuit”). The complaint alleged, among other things, that the Company breached multiple representations and warranties contained in the Securities Purchase Agreement (the “SPA”) related to the Company’s June 8, 2017 equity financing (the “2017 Financing”), of which the Plaintiffs participated, and fraudulently induced Plaintiffs into signing the SPA. The complaint sought rescission of the SPA and return of the Plaintiffs’ $<span id="xdx_901_eus-gaap--LossContingencyDamagesSoughtValue_pn3n3_c20250101__20251231__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember_zL08OQ7ffoLl" title="Purchase price of plaintiffs">6,750 purchase price with respect to the 2017 Financing. On January 26, 2024 (the “Effective Date”), the Company entered into a settlement agreement and release with the Plaintiffs (the “Settlement Agreement”), effectively resolving the Lawsuit. Pursuant to the Settlement Agreement, the Company paid $2,154 consisting of a cash payment of $1,100, covered by the Company’s insurance company, and <span id="xdx_901_eus-gaap--StockIssuedDuringPeriodSharesRestrictedStockAwardGross_pid_c20240126__20240126__us-gaap--TypeOfArrangementAxis__custom--LitigationSettlementMember_z9TaY5mxkot2" title="Restricted common shares issued for legal settlement">1,005,965 shares of restricted common stock which were subsequently registered for resale. Furthermore, the Company’s insurance company is responsible for covering legal expenses incurred by the Company in relation to the legal proceedings of the Lawsuit. In February 2024, the Plaintiffs filed a stipulation discontinuing the Lawsuit with prejudice. The Company concluded the Settlement Agreement gave rise to loss contingencies in the scope of ASC Subtopic 450-20, Contingencies – Loss Contingencies, and as of December 31, 2023, the Company recorded a contingent liability, as the Company deemed it both probable and reasonably estimable. The Company determined that the loss contingency should be recognized as non-operating losses, offset by loss recoveries received from the Company’s insurance company. As a result of the Settlement Agreement and the insurance recovery received from the insurance company, as of December 31, 2023, the Company recorded a current liability and a current asset on its consolidated balance sheet totaling $2,211 and $1,335, respectively. Within this asset, $1,100 represents the recovery of the cash payment of the settlement amount, and $235 represents recovery of legal expenses. A net non-operating loss of $1,111 from legal settlement was reflected in the Company’s consolidated statement of comprehensive loss for the year ended December 31, 2023. In the first quarter of 2024, the Company received $1,335 from the insurance company. Additionally, during the first quarter of 2024, the Company paid the settlement amount by transferring $1,100 in cash to the Plaintiffs and issuing <span id="xdx_909_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20240101__20240331__us-gaap--TypeOfArrangementAxis__custom--LitigationSettlementMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zsmjAawqCSA" title="Number of share issued">1,005,965 shares of the Company’s common stock, thereby settling the liability recorded as of December 31, 2023. G. Mona litigation: In March 2025, an appellate court held in favor of the Company with respect to a 2019 action against Alliance Investment Management, Ltd. (“Alliance”), later amended to add Joseph Mona (“Mona”) as a defendant, in the Southern District of New York under Section 16(b) of the Securities Exchange Act of 1934 (the “Exchange Act”), to compel Alliance and/or Mona to disgorge short swing profits realized from purchases and sales of the Company’s securities within a period of less than six months. As a result, the Company received a judgment in the amount of approximately $316, net of legal fees and expenses. The amount received was recorded as other income in the Company’s audited consolidated statements of comprehensive loss. H. Employment-Related Matter On June 17, 2025, the Company received a demand letter from legal counsel representing a former employee in connection with an employment-related matter. On December 3, 2025, the Company received a charge filed by the former employee with the Massachusetts Commission Against Discrimination and Equal Employment Opportunity Commission, alleging discrimination and retaliation. On January 16, 2026, the Company filed a position statement responding to same and challenging the merits of the charge in total. Based on its initial assessment, the Company believes the allegations lack merit. I. Accrued bonuses As of December 31, 2025, the Company recorded accrued bonuses to the CEO, executives and certain employees in the amount of $<span id="xdx_90B_eus-gaap--AccruedBonusesCurrentAndNoncurrent_iI_pn3n3_c20251231__srt--TitleOfIndividualAxis__custom--ChiefExecutiveOfficerAndExecutivesAndCertainEmployeesMember_zVy9SEq9yE7c" title="Accrued bonuses current and non current">1,089, related to fiscal year 2025 (refer also to Note 18A). MICROBOT MEDICAL INC. NOTES TO CONSOLIDATED FINANCIAL STATEMENTS U.S. dollars in thousands (Except share and per share data)

2468000

518000

2153 673000 925000 0.03 0.05

50000

0.03 0.015 0.030 10000000

4820000

0.030 0.070 0.010

The Company has also agreed to issue to Wainwright or its designees preferred investment options upon the closing of such offerings, equal to five (5.0%) percent of the aggregate number of such shares of common stock in such offerings, including upon exercise for cash of any warrants issued to investors in such offering. See also Note 11E below.

8000000

0.03 0.05 0.015

6750000

2154000

1100000

1005965

2211000

1335000

1100000

235000

-1111000

1335000

1100000

1005965

316000

1089000

NOTE 11 - SHARE CAPITAL A. Preferred investment options inducement On December 29, 2023, the Company entered into a preferred investment option exercise inducement offer letter with certain holders of existing (i) Series A preferred investment options to purchase <span id="xdx_90C_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20221025__20221025__us-gaap--SubsidiarySaleOfStockAxis__custom--SeriesAPreferredInvestmentOptionsMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z5nZqFES2QFj">1,022,495 shares of the Company’s common stock at an exercise price of $<span id="xdx_902_eus-gaap--SharesIssuedPricePerShare_iI_pid_c20221025__us-gaap--SubsidiarySaleOfStockAxis__custom--SeriesAPreferredInvestmentOptionsMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zWSdAUPhg627">2.20 per share, issued on October 25, 2022, as amended on May 24, 2023, (ii) Series C preferred investment options to purchase 350,878 shares of the Company’s common stock at an exercise price of $<span id="xdx_902_eus-gaap--SharesIssuedPricePerShare_iI_pid_c20230606__us-gaap--SubsidiarySaleOfStockAxis__custom--SeriesCPreferredInvestmentOptionsMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zP6sO3ruyGY4">2.075 per share, issued on June 6, 2023, and (iii) Series D preferred investment options to purchase <span id="xdx_907_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20230626__20230626__us-gaap--SubsidiarySaleOfStockAxis__custom--SeriesDPreferredInvestmentOptionsMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zpB5L5fvXaDi">312,309 shares of the Company’s common stock at an exercise price of $<span id="xdx_902_eus-gaap--SharesIssuedPricePerShare_iI_pid_c20230626__us-gaap--SubsidiarySaleOfStockAxis__custom--SeriesDPreferredInvestmentOptionsMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zBHOeB8xwCxk">3.19 per share issued on June 26, 2023, pursuant to which the holders agreed to exercise for cash such preferred investment options to purchase an aggregate of <span id="xdx_904_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20231229__20231229__us-gaap--SubsidiarySaleOfStockAxis__custom--ExistingPreferredInvestmentOptionsMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zpZoUz9kIzZj">1,685,682 shares of the Company’s common stock, at a reduced exercised price of $<span id="xdx_902_eus-gaap--SharesIssuedPricePerShare_iI_pid_c20231229__us-gaap--SubsidiarySaleOfStockAxis__custom--ExistingPreferredInvestmentOptionsMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zEOfREE59bXk">1.62 per share, in consideration for the Company’s agreement to issue new series E preferred investment options having terms to purchase up to <span id="xdx_904_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20231229__20231229__us-gaap--SubsidiarySaleOfStockAxis__custom--InducementInvestmentOptionsMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zV3RuSirxZM2">1,685,682 shares of the Company’s common stock (the “Inducement Investment Options”). Each Inducement Investment Option has an exercise price equal to $<span id="xdx_909_eus-gaap--SharesIssuedPricePerShare_iI_pid_c20231229__us-gaap--SubsidiarySaleOfStockAxis__custom--InducementInvestmentOptionsMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zLytKDftzrb7">1.50 per share, and is exercisable from the date of the issuance until five and one-half (5.5) years following the date of the issuance. The estimated fair value of the Inducement Investment Options using a Black-Scholes options pricing model is approximately $<span id="xdx_902_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_pn3n3_c20231229__20231229__us-gaap--SubsidiarySaleOfStockAxis__custom--InducementInvestmentOptionsMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zaZbkRU15bp2">1,853. At the closing on January 3, 2024, the Company received aggregate gross proceeds of approximately $2,730 from the exercise of such preferred investment options by the holders and the sale of the Inducement Investment Options, before deducting placement agent fees and other offering expenses of approximately $333. The Company also issued to Wainwright or its designees preferred investment options to purchase up to <span id="xdx_902_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20231229__20231229__us-gaap--SubsidiarySaleOfStockAxis__custom--PreferredInvestmentOptionExerciseInducementOffersLetterMember__dei--LegalEntityAxis__custom--HCWainwrightAndCoLLCMember_z1I2AL3k3Ach">84,284 shares of common stock which have the same terms as the Inducement Investment Options except for an exercise price equal to $<span id="xdx_90C_eus-gaap--SharesIssuedPricePerShare_iI_pid_c20231229__us-gaap--SubsidiarySaleOfStockAxis__custom--PreferredInvestmentOptionExerciseInducementOffersLetterMember__dei--LegalEntityAxis__custom--HCWainwrightAndCoLLCMember_zIly67G26ir7">2.025 per share. The estimated fair value of the preferred investment options using a Black-Scholes options pricing model is approximately $<span id="xdx_903_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_pn3n3_c20231229__20231229__us-gaap--SubsidiarySaleOfStockAxis__custom--PreferredInvestmentOptionExerciseInducementOffersLetterMember__dei--LegalEntityAxis__custom--HCWainwrightAndCoLLCMember_zQdFv621ubwf">89. B. Registered direct and private placement offerings: On June 3, 2024, the Company entered into Securities Purchase Agreements with institutional investors, pursuant to which the Company agreed to issue and sell, in a registered direct offering priced at-the-market under the rules of The Nasdaq Stock Market, an aggregate of <span id="xdx_905_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20240603__20240603__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zrbSv4Y1eR5c">1,566,669 shares of the Company’s common stock, par value $<span id="xdx_90A_eus-gaap--CommonStockParOrStatedValuePerShare_iI_pid_c20240603__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember_zSsAOQFkeqKh">0.01 per share, at an offering price of $<span id="xdx_903_eus-gaap--SharesIssuedPricePerShare_iI_pid_c20240603__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember_zBxoXCMuXZF5">1.50 per share, for aggregate gross proceeds of approximately $<span id="xdx_905_eus-gaap--ProceedsFromIssuanceOfPrivatePlacement_pn3n3_c20240603__20240603__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z7cO50RDa9ob">2,350 before deducting the placement agent fee and related offering expenses of approximately $<span id="xdx_90B_eus-gaap--DeferredOfferingCosts_iI_pn3n3_c20240603__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zonQzy7BrVtf">328. In a concurrent private placement, the Company agreed to issue to the investors series F preferred investment options to purchase up to <span id="xdx_90B_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20240603__20240603__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--SubsidiarySaleOfStockAxis__custom--SeriesFPreferredInvestmentOptionsMember_zIDavBuvVQh3">3,133,338 shares of common stock at an exercise price of $<span id="xdx_90C_eus-gaap--SharesIssuedPricePerShare_iI_pid_c20240603__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--SubsidiarySaleOfStockAxis__custom--SeriesFPreferredInvestmentOptionsMember_zfTxAy0b2Ue">1.50 per share. Each Series F preferred investment option is exercisable immediately and will expire two years from the initial exercise date. The Company also issued to Wainwright or its designees preferred investment options to purchase up to <span id="xdx_90E_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20240603__20240603__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--TypeOfArrangementAxis__custom--HCWainwrightAndCoLLCMember_zBBR5paRcZU4">78,333 shares of common stock which have the same terms as investors’ preferred investment options except for an exercise price equal to $<span id="xdx_900_eus-gaap--SharesIssuedPricePerShare_iI_pid_c20240603__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--TypeOfArrangementAxis__custom--HCWainwrightAndCoLLCMember_z1JXJeZK8Rhb">1.875 per share. On January 6, 2025, the Company entered into Securities Purchase Agreements with institutional investors, pursuant to which the Company agreed to issue and sell, in a registered direct offering priced at-the-market under the rules of the Nasdaq Stock Market, an aggregate of <span id="xdx_90E_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20250106__20250106__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zdKmfKAUotq6" title="Shares issued">4,000,001 shares of the Company’s common stock, par value $<span id="xdx_905_eus-gaap--CommonStockParOrStatedValuePerShare_iI_pid_c20250106__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z8u8i3T8OiI6" title="Common stock, par value">0.01 per share, at an offering price of $<span id="xdx_90D_eus-gaap--SharesIssuedPricePerShare_iI_pid_c20250106__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zLCLSHNXlobc">1.75 per share, for aggregate gross proceeds from the offerings of approximately $<span id="xdx_90E_eus-gaap--ProceedsFromIssuanceOfPrivatePlacement_pn3n3_c20250106__20250106__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zIEpzC3d7Yo" title="Placement agent fee">7,000 before deducting the placement agent fee and related offering expenses of approximately $<span id="xdx_901_eus-gaap--DeferredOfferingCosts_iI_pn3n3_c20250106__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z8fNKyS7v7p7" title="Offering expense">690. In a concurrent private placement, the Company agreed to issue to the investors series G preferred investment options to purchase up to <span id="xdx_90A_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20250106__20250106__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--SubsidiarySaleOfStockAxis__custom--SeriesGPreferredInvestmentOptionsMember_zQxTGcT5mVB6" title="Shares issued">8,000,002 shares of common stock at an exercise price of $<span id="xdx_908_eus-gaap--SharesIssuedPricePerShare_iI_pid_c20250106__us-gaap--SubsidiarySaleOfStockAxis__custom--SeriesGPreferredInvestmentOptionsMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_ztoOgzbi0G8h" title="Exercise price">1.75 per share. Each Series G preferred investment option is exercisable immediately and will expire two years from the initial exercise date. The Company also issued to Wainwright or its designees preferred investment options to purchase up to <span id="xdx_907_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20250106__20250106__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--TypeOfArrangementAxis__custom--HCWainwrightAndCoLLCMember_zK0BrosuX2z6" title="Options purchased">200,000 shares of common stock which have the same terms as investors’ preferred investment options except for an exercise price equal to $<span id="xdx_908_eus-gaap--SharesIssuedPricePerShare_iI_pid_c20250106__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--TypeOfArrangementAxis__custom--HCWainwrightAndCoLLCMember_zvFZUA5zvWv2" title="Share price">2.1875 per share. MICROBOT MEDICAL INC. NOTES TO CONSOLIDATED FINANCIAL STATEMENTS U.S. dollars in thousands (Except share and per share data) NOTE 11 - SHARE CAPITAL On January 7, 2025, the Company entered into Securities Purchase Agreements with institutional investors, pursuant to which the Company agreed to issue and sell, in a registered direct offering priced at-the-market under the rules of the Nasdaq Stock Market, an aggregate of <span id="xdx_902_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20250107__20250107__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zoUt8G4F4sLk" title="Shares issued">3,788,550 shares of the Company’s common stock, par value $<span id="xdx_900_eus-gaap--CommonStockParOrStatedValuePerShare_iI_pid_c20250107__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zDf28B6RIKd2" title="Common stock, par value">0.01 per share, at an offering price of $<span id="xdx_908_eus-gaap--SharesIssuedPricePerShare_iI_pid_c20250107__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zcWc6rgl4v8d">2.27 per share, for aggregate gross proceeds from the offerings of approximately $<span id="xdx_90D_eus-gaap--ProceedsFromIssuanceOfPrivatePlacement_pn3n3_c20250107__20250107__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zlYi65Suqlug">8,600 before deducting the placement agent fee and related offering expenses of approximately $<span id="xdx_904_eus-gaap--DeferredOfferingCosts_iI_pn3n3_c20250107__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z3AUkHOGxeOa" title="Offering expense">818. In a concurrent private placement, the Company agreed to issue to the investors series H preferred investment options to purchase up to <span id="xdx_906_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20250107__20250107__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--SubsidiarySaleOfStockAxis__custom--SeriesHPreferredInvestmentOptionsMember_zQqEHWeR9Wjh" title="Shares issued">7,577,100 shares of common stock at an exercise price of $<span id="xdx_90D_eus-gaap--SharesIssuedPricePerShare_iI_pid_c20250107__us-gaap--SubsidiarySaleOfStockAxis__custom--SeriesHPreferredInvestmentOptionsMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zM4mOJxqjysb" title="Exercise price">2.10 per share. Each Series H preferred investment option is exercisable immediately and will expire two years from the initial exercise date. The Company also issued to Wainwright or its designees preferred investment options to purchase up to <span id="xdx_907_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20250107__20250107__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--TypeOfArrangementAxis__custom--HCWainwrightAndCoLLCMember_zcBOYAzErms4" title="Options purchased">189,428 shares of common stock which have the same terms as investors’ preferred investment options except for an exercise price equal to $<span id="xdx_901_eus-gaap--SharesIssuedPricePerShare_iI_pid_c20250107__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--TypeOfArrangementAxis__custom--HCWainwrightAndCoLLCMember_zifoK8CmlKEg" title="Share price">2.8375 per share. On February 9, 2025, the Company entered into Securities Purchase Agreements with institutional investors, pursuant to which the Company agreed to issue and sell, in a registered direct offering priced at-the-market under the rules of the Nasdaq Stock Market, an aggregate of <span id="xdx_900_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20250209__20250209__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zXVUv9dMkpNc" title="Shares issued">6,103,289 shares of the Company’s common stock, par value $<span id="xdx_90A_eus-gaap--CommonStockParOrStatedValuePerShare_iI_pid_c20250209__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zCqrT0AI2wTf" title="Common stock, par value">0.01 per share, at an offering price of $<span id="xdx_90E_eus-gaap--SharesIssuedPricePerShare_iI_pid_c20250209__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zVPoKEvZFcJc">2.13 per share, for aggregate gross proceeds from the offerings of approximately $<span id="xdx_901_eus-gaap--ProceedsFromIssuanceOfPrivatePlacement_pn3n3_c20250209__20250209__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zVbMGoj6rhZh">13,000 before deducting the placement agent fee and related offering expenses of approximately $<span id="xdx_90C_eus-gaap--DeferredOfferingCosts_iI_pn3n3_c20250209__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zh43zRKttGcl" title="Offering expense">1,175. In a concurrent private placement, the Company agreed to issue to the investors series I preferred investment options to purchase up to <span id="xdx_903_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20250209__20250209__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--SubsidiarySaleOfStockAxis__custom--SeriesIPreferredInvestmentOptionsMember_z4kLzWCFdnX3" title="Shares issued">12,206,578 shares of common stock at an exercise price of $<span id="xdx_905_eus-gaap--SharesIssuedPricePerShare_iI_pid_c20250209__us-gaap--SubsidiarySaleOfStockAxis__custom--SeriesIPreferredInvestmentOptionsMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zeiNVp0JvXP7" title="Exercise price">2.13 per share. Each Series I preferred investment option is exercisable on the later of (i) the date on which the amendment to the Company’s articles of incorporation that increases the number of authorized shares of common stock to an amount of shares of common stock sufficient for the exercise in full of the series I preferred investment options is filed and accepted with the State of Delaware law (such date, the “Authorized Share Increase Date”) and (ii) the date on which approval as may be required by the applicable rules and regulations of the Nasdaq Stock Market (or any successor entity) from the stockholders of the Company with respect to the issuance of all the series I preferred investment options and the shares of common stock issuable upon the exercise thereof, is received and deemed effective under Delaware law (the “Initial exercise date”), and will expire two years from the initial exercise date. Net cash settlements are not permitted under any event under the Securities Purchase Agreements. The Company also issued to Wainwright or its designees preferred investment options to purchase up to <span id="xdx_900_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20250209__20250209__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--TypeOfArrangementAxis__custom--HCWainwrightAndCoLLCMember_z4mCNvVUHlu2">305,164 shares of common stock which have the same terms as investors’ preferred investment options except for an exercise price equal to $<span id="xdx_904_eus-gaap--SharesIssuedPricePerShare_iI_pid_c20250209__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--TypeOfArrangementAxis__custom--HCWainwrightAndCoLLCMember_z8jkhdLsTihi" title="Share price">2.6625 per share. On June 10, 2025, at the Company’s annual meeting of stockholders, an amendment to the Company’s articles of incorporation was approved, increasing the number of authorized shares of common stock to 120,000,000. The amendment was subsequently filed with and accepted by the State of Delaware law and became effective on that date. Refer to Note 11F. As a result, the Series I preferred investment options to purchase up to <span id="xdx_906_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20250610__20250610__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--SubsidiarySaleOfStockAxis__custom--SeriesIPreferredInvestmentOptionsMember_z3J4b67dUeJ5">12,206,578 shares of common stock at an exercise price of $<span id="xdx_904_eus-gaap--SharesIssuedPricePerShare_iI_pid_c20250610__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--SubsidiarySaleOfStockAxis__custom--SeriesIPreferredInvestmentOptionsMember_zeJFyUvwXI2a" title="Share price">2.13 per share, and the placement agent preferred investment options to purchase up to <span id="xdx_901_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20250610__20250610__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--SubsidiarySaleOfStockAxis__custom--PlacementAgentPreferredInvestmentOptionsMember_za1g9DGOwJD1">305,164 shares of common stock at an exercise price of $<span id="xdx_90E_eus-gaap--SharesIssuedPricePerShare_iI_pid_c20250610__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--SubsidiarySaleOfStockAxis__custom--PlacementAgentPreferredInvestmentOptionsMember_zU4ne9qGMb0e" title="Share price">2.6625 per share, each of which was issued on February 11, 2025, became immediately exercisable until their two year anniversary. C. Equity Classification: The common stock of the Company is classified as equity under the requirements of ASC Topic 505 Equity. MICROBOT MEDICAL INC. NOTES TO CONSOLIDATED FINANCIAL STATEMENTS U.S. dollars in thousands (Except share and per share data) NOTE 11 - SHARE CAPITAL Pursuant to the guidance of ASC 480 and ASC 815 the warrants were classified as equity instruments. The Company analyzed the accounting treatment for all of the outstanding preferred investment options issued to Wainwright and all such preferred investment options are equity-classified awards. D. At-the-market offerings: On July 1, 2024, the Company filed with the SEC a prospectus supplement relating to the offer, issuance and sale of up to $<span id="xdx_90F_eus-gaap--SaleOfStockConsiderationReceivedOnTransaction_pn3n3_c20240701__20240701__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--TypeOfArrangementAxis__custom--AtTheMarketOfferingAgreementMember_zkRETCG6Eu4c">4,820 of the Company’s shares of common stock pursuant to the ATM Agreement. During the fiscal year ended December 31, 2024, the Company issued <span id="xdx_903_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--TypeOfArrangementAxis__custom--AtTheMarketOfferingAgreementMember_zxz0ALpDXcwf">3,433,880 shares of the Company’s common stock pursuant to the ATM Agreement, for total gross proceeds of approximately $<span id="xdx_908_eus-gaap--ProceedsFromIssuanceOfCommonStock_pn3n3_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--TypeOfArrangementAxis__custom--AtTheMarketOfferingAgreementMember_z4dfAEb5aIuc" title="Total gross proceeds">3,756 before deducting sales agent commissions and other offering expenses of $239. In January 2025, the Company issued <span id="xdx_90A_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20250101__20250131__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--TypeOfArrangementAxis__custom--AtTheMarketOfferingAgreementMember_z2Z5yyuVLIs4" title="Shares issued">842,606 shares of the Company’s common stock pursuant to the ATM Agreement, for total gross proceeds of approximately $<span id="xdx_909_eus-gaap--ProceedsFromIssuanceOfCommonStock_pn3n3_c20250101__20250131__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--TypeOfArrangementAxis__custom--AtTheMarketOfferingAgreementMember_zjnKC7RkucO1" title="Total gross proceeds">1,062 before deducting sales agent commissions and other offering expenses of $65. The Company is no longer selling its securities pursuant to the ATM Agreement and has not as of the filing of these financial statements entered into a new or replacement ATM agreement. E. Exercise of Investment Options During the year ended December 31, 2025, the Company raised approximately $33,855 in gross proceeds from the exercise of an aggregate of <span id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_pid_c20251231__us-gaap--StatementClassOfStockAxis__custom--SeriesEGHIAndSeriesFPreferredInvestmentOptionsMember_z8WsDRgLAfid">18,613,585 outstanding Series E, Series F, Series G, Series H and Series I preferred investment options. As a result of these exercises, and in accordance with the Company’s engagement letters with its placement agent, as mentioned in Note 10D, the Company incurred placement agent cash fees of approximately $2,370. Additionally, the Company issued an aggregate of <span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_c20250101__20251231__us-gaap--StatementClassOfStockAxis__us-gaap--PrivatePlacementMember_z8v7bZ6S4QT7">930,680 placement agent options in accordance with such engagement letter. Additionally, during the year ended December 31, 2025, the Company received gross proceeds of approximately $<span id="xdx_900_eus-gaap--ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions_pn3n3_c20250701__20250930__us-gaap--StatementClassOfStockAxis__us-gaap--PrivatePlacementMember_z6wcELVjNgo8" title="Proceeds from options">895 from the exercise of an aggregate of <span id="xdx_90C_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_c20250701__20250930__us-gaap--StatementClassOfStockAxis__us-gaap--PrivatePlacementMember_zWfszqzxOO5" title="Number of shares issued">374,167 outstanding placement agent options. F. Increase in Authorized Share Following the 2025 annual meeting of stockholders of the Company held on June 10, 2025, the Company filed with the State of Delaware a certificate of amendment to the Company’s restated certificate of incorporation, as amended, which increased the total number of shares of common stock authorized for issuance to 120,000,000 shares, with a corresponding increase in the total authorized shares from 61,000,000 to 121,000,000. Immediately thereafter, the Company had 121,000,000 shares of authorized stock, consisting of (i) 120,000,000 shares of common stock, and (ii) 1,000,000 shares of undesignated preferred stock. G. Investment Inducement Transaction On September 14, 2025, the Company entered into an inducement agreement (the “Letter Agreement”) with certain holders (the “Holders”) of existing (i) series F preferred investment options to purchase <span id="xdx_900_eus-gaap--StockIssuedDuringPeriodSharesOther_c20250914__20250914__us-gaap--TypeOfArrangementAxis__custom--TheLetterAgreementMember__us-gaap--StatementClassOfStockAxis__custom--SeriesFPreferredInvestmentOptionsMember_zdgFiUqzLFxb">207,224 shares of Company’s common stock at an exercise price of $<span id="xdx_905_eus-gaap--SharePrice_iI_c20250914__us-gaap--TypeOfArrangementAxis__custom--TheLetterAgreementMember__us-gaap--StatementClassOfStockAxis__custom--SeriesFPreferredInvestmentOptionsMember_zEwkupOLleAf">1.50 per share, (ii) series G preferred investment options to purchase <span id="xdx_90E_eus-gaap--StockIssuedDuringPeriodSharesOther_c20250914__20250914__us-gaap--TypeOfArrangementAxis__custom--TheLetterAgreementMember__us-gaap--StatementClassOfStockAxis__custom--SeriesGPreferredInvestmentOptionsMember_zk4srSN1JZih">628,571 shares of Company’s common stock at an exercise price of $<span id="xdx_90A_eus-gaap--SharePrice_iI_c20250914__us-gaap--TypeOfArrangementAxis__custom--TheLetterAgreementMember__us-gaap--StatementClassOfStockAxis__custom--SeriesGPreferredInvestmentOptionsMember_z3w0vQzuxrb7">1.75 per share, (iii) series H preferred investment options to purchase <span id="xdx_90D_eus-gaap--StockIssuedDuringPeriodSharesOther_c20250914__20250914__us-gaap--TypeOfArrangementAxis__custom--TheLetterAgreementMember__us-gaap--StatementClassOfStockAxis__custom--SeriesHPreferredInvestmentOptionsMember_zNrS2hrpOkhj">4,702,612 shares of Company’s common stock at an exercise price of $<span id="xdx_908_eus-gaap--SharePrice_iI_c20250914__us-gaap--TypeOfArrangementAxis__custom--TheLetterAgreementMember__us-gaap--StatementClassOfStockAxis__custom--SeriesHPreferredInvestmentOptionsMember_z1mx3QzYYMo4">2.10 per share, and (iv) series I preferred investment options to purchase <span id="xdx_903_eus-gaap--StockIssuedDuringPeriodSharesOther_c20250914__20250914__us-gaap--TypeOfArrangementAxis__custom--TheLetterAgreementMember__us-gaap--StatementClassOfStockAxis__custom--SeriesIPreferredInvestmentOptionsMember_znwsA7aYVjG8">8,450,708 shares of Company’s common stock at an exercise price of $<span id="xdx_900_eus-gaap--SharePrice_iI_c20250914__us-gaap--TypeOfArrangementAxis__custom--TheLetterAgreementMember__us-gaap--StatementClassOfStockAxis__custom--SeriesIPreferredInvestmentOptionsMember_zc76W4GPIIY8">2.13 per share (collectively, the “Existing Preferred Investment Options”). Pursuant to the Letter Agreement, the Holders exercised for cash their Existing Preferred Investment Options to purchase an aggregate of <span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_c20250914__20250914__us-gaap--TypeOfArrangementAxis__custom--TheLetterAgreementMember_zPTW1GzQRhx5">13,989,115 shares of Company’s common stock, at exercise prices ranging from $1.50 to $2.13 per share, in consideration for the Company’s agreement to issue new series J preferred investment options (the “New Preferred Investment Options”) to purchase up to an aggregate of <span id="xdx_907_eus-gaap--StockIssuedDuringPeriodSharesOther_c20250914__20250914__us-gaap--TypeOfArrangementAxis__custom--TheLetterAgreementMember__us-gaap--StatementClassOfStockAxis__custom--SeriesJPreferredInvestmentOptionsMember_zNISEFdH5ox8">13,989,115 shares of Company’s common stock at an exercise price of $<span id="xdx_907_eus-gaap--SharePrice_iI_c20250914__us-gaap--TypeOfArrangementAxis__custom--TheLetterAgreementMember__us-gaap--StatementClassOfStockAxis__custom--SeriesJPreferredInvestmentOptionsMember_zts9hNrW7Rva">4.50 per share (collectively, the “Inducement Transaction”). The New Preferred Investment Options are exercisable beginning six months after issuance and will expire two years thereafter. At the first closing of the Inducement Transaction, which occurred on September 16, 2025, certain Holders exercised Existing Preferred Investment Options to purchase up to an aggregate of <span id="xdx_90D_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20250916__20250916__us-gaap--TypeOfArrangementAxis__custom--TheLetterAgreementMember__us-gaap--AwardTypeAxis__custom--PreferredInvestmentOptionsMember_z6pk7F1hlMTk">12,064,627 shares of Company’s common stock for cash and received New Preferred Investment Options to purchase up to an aggregate of <span id="xdx_900_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20250916__20250916__us-gaap--TypeOfArrangementAxis__custom--TheLetterAgreementMember__us-gaap--AwardTypeAxis__custom--PreferredInvestmentOptionsMember_zvjuVUM29dXf">12,064,627 shares of Company’s common stock. At the second closing of the Inducement Transaction on September 29, 2025, a certain Holder exercised Existing Preferred Investment Options to purchase <span id="xdx_90B_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20250929__20250929__us-gaap--TypeOfArrangementAxis__custom--TheLetterAgreementMember__us-gaap--DerivativeInstrumentRiskAxis__custom--SecondClosingMember__us-gaap--AwardTypeAxis__custom--PreferredInvestmentOptionsMember_zI1LA0u8g1Kj">600,000 shares of Company’s common stock for cash and received New Preferred Investment Options to purchase up to <span id="xdx_904_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20250929__20250929__us-gaap--TypeOfArrangementAxis__custom--TheLetterAgreementMember__us-gaap--DerivativeInstrumentRiskAxis__custom--SecondClosingMember__us-gaap--AwardTypeAxis__custom--PreferredInvestmentOptionsMember_zSAINUvgC3g">600,000 shares of Company’s common stock. At the third closing of the Inducement Transaction, which occurred on October 6, 2025, certain Holders exercised Existing Preferred Investment Options to purchase up to an aggregate of <span id="xdx_900_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20251006__20251006__us-gaap--TypeOfArrangementAxis__custom--TheLetterAgreementMember__us-gaap--DerivativeInstrumentRiskAxis__custom--ThirdClosingMember__us-gaap--AwardTypeAxis__custom--PreferredInvestmentOptionsMember_z8z50gtd9Z32">1,324,488 shares of Company’s common stock for cash and received New Preferred Investment Options to purchase up to an aggregate of <span id="xdx_905_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20251006__20251006__us-gaap--TypeOfArrangementAxis__custom--TheLetterAgreementMember__us-gaap--DerivativeInstrumentRiskAxis__custom--ThirdClosingMember__us-gaap--AwardTypeAxis__custom--PreferredInvestmentOptionsMember_zc74mXpm24ee">1,324,488 shares of Company’s common stock. The Company received aggregate gross proceeds of approximately $29,286 from the exercise of the Existing Preferred Investment Options at the closings, before deducting placement agent fees and other offering expenses of approximately $2,472, of which $101 had not been paid as of December 31, 2025. Additionally, as a result of the Inducement Transaction, and in accordance with the Company’s engagement letters with its placement agent, as mentioned in Note 10D, the Company issued an aggregate of 699,456 placement agent options. The inducement occurred concurrently with a fund raising. Pursuant to the guidance of ASC 480 and ASC 815 the warrants were classified as equity instruments before and after the warrant modification. In accordance with ASC Topic 815 guidance on equity classified warrant modifications, the incremental change in fair value of the warrants was accounted as an equity issuance cost, which was recorded to additional paid-in capital. MICROBOT MEDICAL INC. NOTES TO CONSOLIDATED FINANCIAL STATEMENTS U.S. dollars in thousands (Except share and per share data) NOTE 11 - SHARE CAPITAL H. Employee Stock Option Grants and Exercises: During the year ended December 31, 2024: <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 1in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">●</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">The Company granted the CEO, its executives and management, fully vested options to purchase an aggregate of <span id="xdx_907_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__srt--TitleOfIndividualAxis__srt--ChiefExecutiveOfficerMember_zl2maiSzjK29" title="Agggregate number of options granted">80,000 and <span id="xdx_905_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__srt--TitleOfIndividualAxis__srt--ManagementMember_zhhMOuG73Jw7" title="Agggregate number of options granted">50,000 shares of the Company’s common stock, respectively, at an exercise price per share of $<span id="xdx_905_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pid_uUSDPShares_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__srt--TitleOfIndividualAxis__srt--ManagementMember_z5FfmMKYemK3" title="Weighted-average exercise price per share, granted">1.2684.</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 1in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">●</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">The Company granted the CEO and certain executives, options to purchase an aggregate of <span id="xdx_90D_ecustom--AdditionalShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__srt--TitleOfIndividualAxis__srt--ChiefExecutiveOfficerMember_zBqq1M6kS06h" title="Additional number of stock options granted">80,000 and <span id="xdx_902_ecustom--AdditionalShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__srt--TitleOfIndividualAxis__srt--ManagementMember_zqAOFYD8sW8j" title="Additional number of stock options granted">52,500 shares of the Company’s common stock, respectively, at an exercise price per share of $1.25. The vesting of these options is subject to the achievement of specified performance conditions. For the year ended December 31, 2024, the Company recorded an expense of $<span id="xdx_90A_eus-gaap--AllocatedShareBasedCompensationExpense_pn3n3_c20240101__20241231__srt--TitleOfIndividualAxis__custom--ChiefExecutiveOfficerAndOtherExecutivesMember_zVRKV7s9KM5k" title="Compensation expenses">38, reflecting management’s assessment that the specified performance milestones for <span id="xdx_90C_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20240101__20241231__srt--TitleOfIndividualAxis__custom--ChiefExecutiveOfficerAndOtherExecutivesMember_zzTs3U3uYv24" title="Issued shares">35,625 of the <span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_c20240101__20241231__srt--TitleOfIndividualAxis__custom--ChiefExecutiveOfficerAndOtherExecutivesMember_z8kZAaYRwbGk" title="Agggregate number of options granted">132,500 options were achieved by their due date.</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 1in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">●</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">The Company granted the CEO, its executives, and certain employees, options to purchase an aggregate of <span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_c20240101__20241231__srt--TitleOfIndividualAxis__custom--ChiefExecutiveOfficerAndExecutivesMember_zlVkIP0lkNp6" title="Agggregate number of options granted">80,000 and <span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_c20240101__20241231__srt--TitleOfIndividualAxis__custom--CertainEmployeesMember_zTuJVAFectW1" title="Agggregate number of options granted">115,000 shares of the Company’s common stock, respectively, at an exercise price per share of $1.2684, with a vesting period of three years.</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 1in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">●</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">The Company granted an advisor options to purchase an aggregate of <span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_c20240101__20241231__srt--TitleOfIndividualAxis__custom--AdvisorsMember_zMmTxriKqnfk" title="Agggregate number of options granted">25,000 shares of the Company’s common stock, at an exercise price per share of $0.881, with a vesting period of three years.</td></tr></table> With respect to the CEO’s 2023 annual bonus, during February 2024, the Company paid <span id="xdx_90F_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_dp_c20240201__20240229__srt--TitleOfIndividualAxis__srt--ChiefExecutiveOfficerMember_zy5yxamQ8fWa" title="Compensation percentage">25% of the CEO’s total 2023 bonus – amounting to approximately $99, through the grant of fully vested options to purchase an aggregate of <span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_c20240201__20240229__srt--TitleOfIndividualAxis__srt--ChiefExecutiveOfficerMember_ziZwEPvJUOW8" title="Agggregate number of options granted">79,567 shares of the Company’s common stock with an exercise price per share of $1.25. In February 2025, the Company determined that 35,625 out of 132,500 performance-based options granted in February 2024 had met their milestones and been vested, while the remainder <span id="xdx_90A_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares_pid_c20250201__20250228__srt--TitleOfIndividualAxis__custom--BoardMember_zYcGgPbymUI8">96,875 options which did not meet their milestones had been forfeited. On June 10, 2025, at the Company’s annual meeting of stockholders, an amendment to the Company’s 2020 Omnibus Performance Award Plan (as amended) was approved. This amendment increased the number of shares of common stock authorized and reserved for issuance under the plan by <span id="xdx_904_eus-gaap--CommonStockCapitalSharesReservedForFutureIssuance_iI_pid_c20250610__us-gaap--PlanNameAxis__custom--TwentyTwentyOmnibusPerformanceAwardPlanMember_zYJ5jmISPww5" title="Common stock capital shares reserved for future issuance">2,591,019 shares. During the year ended December 31, 2025, the Company granted the CEO, other executives and certain employees, and certain board members <span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_c20250101__20251231__srt--TitleOfIndividualAxis__srt--ChiefExecutiveOfficerMember_zrRGRUp1Jgzi">228,000, 483,875 and <span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_c20250101__20251231__srt--TitleOfIndividualAxis__custom--CertainEmployeesAndCertainBoardMembersMember_z0EhUNo1LLCj">70,000 options, respectively. In August 2025, a former advisor of the Company exercised 47,218 vested options at an exercise price of NIS 0.01 per option. As a result of this exercise, the Company received total consideration of approximately $1. The stock options vest over a period of three years as outlined in the option agreements evidencing such grants. A summary of the Company’s option activity related to options to employees and directors, and related information is as follows: MICROBOT MEDICAL INC. NOTES TO CONSOLIDATED FINANCIAL STATEMENTS U.S. dollars in thousands (Except share and per share data) NOTE 11 - SHARE CAPITAL H. Employee Stock Option Grants and Exercises: SUMMARY OF STOCK OPTION ACTIVITY <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%; margin-left: 0.75in; margin-right: 0.5in"> <tr style="vertical-align: bottom"> <td style="text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; text-align: center">For the Year Ended December 31, 2025</td><td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: left"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Number of stock options</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Weighted average exercise price</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: left"> </td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; width: 60%">Outstanding as of December 31, 2024</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_pid_c20250101__20251231__srt--TitleOfIndividualAxis__custom--EmployeesAndDirectorsMember_z1yuOSaFLu5i" style="width: 16%; text-align: right" title="Number of stock options outstanding, Outstanding at beginning of period">2,497,366</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pid_c20250101__20251231__srt--TitleOfIndividualAxis__custom--EmployeesAndDirectorsMember_z8RiRF42JGud" style="width: 16%; text-align: right" title="Weighted average exercise price, Outstanding at beginning of period">4.70</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Granted</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_c20250101__20251231__srt--TitleOfIndividualAxis__custom--EmployeesAndDirectorsMember_zMbQXKFHWxG4" style="text-align: right" title="Number of stock options outstanding, Granted">781,875</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pid_c20250101__20251231__srt--TitleOfIndividualAxis__custom--EmployeesAndDirectorsMember_zDnzmqFLX7Qj" style="text-align: right" title="Weighted average exercise price, Granted">2.12</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Exercised</td><td> </td> <td style="text-align: left"> </td><td id="xdx_982_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_iN_pid_di_c20250101__20251231__srt--TitleOfIndividualAxis__custom--EmployeesAndDirectorsMember_zipg0tFv4yQ4" style="text-align: right" title="Number of stock options outstanding, exercised">(47,218</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_pid_c20250101__20251231__srt--TitleOfIndividualAxis__custom--EmployeesAndDirectorsMember_z9qp1gdpiDN8" style="text-align: right" title="Weighted average exercise price, exercised">0.01</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt">Forfeitures</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_iN_pid_di_c20250101__20251231__srt--TitleOfIndividualAxis__custom--EmployeesAndDirectorsMember_zTymUU1gj9c4" style="border-bottom: Black 1pt solid; text-align: right" title="Number of stock options outstanding, forfeitures">(126,408</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt; text-align: left"> </td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_pid_c20250101__20251231__srt--TitleOfIndividualAxis__custom--EmployeesAndDirectorsMember_zgzplxmaz7Dd" style="padding-bottom: 1pt; text-align: right" title="Weighted average exercise price, forfeitures">3.30</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 2.5pt">Outstanding as of December 31, 2025</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_pid_c20250101__20251231__srt--TitleOfIndividualAxis__custom--EmployeesAndDirectorsMember_zS4XAlaMCWCg" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of stock options outstanding, Outstanding at end of period">3,105,615</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; text-align: left">$</td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_pid_c20250101__20251231__srt--TitleOfIndividualAxis__custom--EmployeesAndDirectorsMember_zj00W7GbbkUc" style="padding-bottom: 2.5pt; text-align: right" title="Weighted average exercise price, Outstanding at end of period">4.18</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 2.5pt">Exercisable as of December 31, 2025</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_iE_pid_c20250101__20251231__srt--TitleOfIndividualAxis__custom--EmployeesAndDirectorsMember_zQvJBHrDr0M" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of stock options outstanding, Exercisable at end of period">2,342,707</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; text-align: left">$</td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_iE_pid_c20250101__20251231__srt--TitleOfIndividualAxis__custom--EmployeesAndDirectorsMember_zPgzJZAQghkh" style="padding-bottom: 2.5pt; text-align: right" title="Weighted average exercise price, Exercisable at end of period">4.91</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%; margin-left: 0.75in; margin-right: 0.5in"> <tr style="vertical-align: bottom"> <td style="text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; text-align: center">For the Year Ended December 31, 2024</td><td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: left"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Number of stock options</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Weighted average exercise price</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: left"> </td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; width: 60%">Outstanding as of December 31, 2023</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_pid_c20240101__20241231__srt--TitleOfIndividualAxis__custom--EmployeesAndDirectorsMember_zayG5S2CuXg3" style="width: 16%; text-align: right" title="Number of stock options outstanding, Outstanding at beginning of period">2,095,362</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pid_c20240101__20241231__srt--TitleOfIndividualAxis__custom--EmployeesAndDirectorsMember_z12YoHxDB3gg" style="width: 16%; text-align: right" title="Weighted average exercise price, Outstanding at beginning of period">5.51</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Granted</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_c20240101__20241231__srt--TitleOfIndividualAxis__custom--EmployeesAndDirectorsMember_zlDYGevE3ry" style="text-align: right" title="Number of stock options outstanding, Granted">562,067</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pid_c20240101__20241231__srt--TitleOfIndividualAxis__custom--EmployeesAndDirectorsMember_z4pvA3iQFwU1" style="text-align: right" title="Weighted average exercise price, Granted">1.24</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1pt">Forfeitures</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_iN_pid_di_c20240101__20241231__srt--TitleOfIndividualAxis__custom--EmployeesAndDirectorsMember_zMCvtHYzmKlk" style="border-bottom: Black 1pt solid; text-align: right" title="Number of stock options outstanding, forfeitures">(160,063</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt; text-align: left"> </td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_pid_c20240101__20241231__srt--TitleOfIndividualAxis__custom--EmployeesAndDirectorsMember_z4QJnZzW3yN2" style="padding-bottom: 1pt; text-align: right" title="Weighted average exercise price, forfeitures">3.23</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 2.5pt">Outstanding as of December 31, 2024</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_pid_c20240101__20241231__srt--TitleOfIndividualAxis__custom--EmployeesAndDirectorsMember_zI9m7GpephU8" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of stock options outstanding, Outstanding at end of period">2,497,366</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; text-align: left">$</td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_pid_c20240101__20241231__srt--TitleOfIndividualAxis__custom--EmployeesAndDirectorsMember_zzDRf5IdeWb2" style="padding-bottom: 2.5pt; text-align: right" title="Weighted average exercise price, Outstanding at end of period">4.70</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 2.5pt">Exercisable as of December 31, 2024</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_iE_pid_c20240101__20241231__srt--TitleOfIndividualAxis__custom--EmployeesAndDirectorsMember_zVETznieIQW3" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of stock options outstanding, Exercisable at end of period">1,866,523</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; text-align: left">$</td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_iE_pid_c20240101__20241231__srt--TitleOfIndividualAxis__custom--EmployeesAndDirectorsMember_zpv2bhIriErh" style="padding-bottom: 2.5pt; text-align: right" title="Weighted average exercise price, Exercisable at end of period">5.63</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> The Company recognizes forfeitures of outstanding options as they occur. The intrinsic value is calculated as the difference between the fair market value of the common stock and the exercise price, multiplied by the number of in-the-money stock options on those dates that would have been received by the stock option holders had all stock option holders exercised their stock options on those dates as of December 31, 2025 and 2024, respectively. As of December 31, 2025, and 2024, the aggregate intrinsic value of the outstanding options is $<span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iI_pn3n3_c20251231_z0DBGvwcfswa" title="Aggregate intrinsic value of outstanding options">726 and $<span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iI_pn3n3_c20241231_ztCoprCy3TBk" title="Aggregate intrinsic value of outstanding options">75, respectively, and the aggregate intrinsic value of the exercisable options is $<span id="xdx_900_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_iI_pn3n3_c20251231_zOLFEJ1pxI8d" title="Aggregate intrinsic value of exercisable options">558 and $<span id="xdx_903_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_iI_pn3n3_c20241231_zZBpTzXaPjO6" title="Aggregate intrinsic value of exercisable options">69, respectively. The weighted average grant date fair value of options granted during the years ended December 31, 2025 and 2024 was $<span id="xdx_900_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_iI_pid_c20251231_zM5YlAFSdC72" title="Weighted average grant date fair value of options granted">1.65 and $<span id="xdx_90D_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_iI_pid_c20241231_zhOXX7fkjJzl" title="Weighted average grant date fair value of options granted">0.99, respectively. MICROBOT MEDICAL INC. NOTES TO CONSOLIDATED FINANCIAL STATEMENTS U.S. dollars in thousands (Except share and per share data) NOTE 11 - SHARE CAPITAL H. Employee Stock Option Grants and Exercises: As of December 31, 2025, there were approximately $<span id="xdx_90A_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_iI_pn3n3_c20251231_zrdcIFi9ISP3" title="Unrecognized compensation costs, net of expected forfeitures">1,109 of total unrecognized compensation costs related to unvested share-based compensation awards granted under the Share Incentive Plan. The costs are expected to be recognized over a weighted average period of <span id="xdx_908_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_dtY_c20250101__20251231_zeBPnkchX6w4" title="Unrecognized compensation weighted average period">2 years. <p id="xdx_89B_eus-gaap--ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock_zmBqOXQqh5gj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.75in; text-align: justify">The stock options outstanding as of December 31, 2025 and 2024, summarized by exercise prices, are as follows: SCHEDULE OF STOCK OPTIONS OUTSTANDING <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Exercise price $</td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Stock options outstanding as of December 31, 2025</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Stock options outstanding as of December 31, 2024</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Weighted average remaining contractual life – years as of December 31, 2025</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Weighted average remaining contractual life – years as of December 31, 2024</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Stock options exercisable as of December 31, 2025</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Stock options exercisable as of December 31, 2024</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 28%; text-align: center"><span id="xdx_902_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_pid_c20250101__20251231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceOneMember__srt--RangeAxis__srt--MinimumMember_zy7eKQByZ7T5" title="Exercise price"><span id="xdx_90A_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_pid_c20240101__20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceOneMember__srt--RangeAxis__srt--MinimumMember_z1GfoS6epeYh" title="Exercise price">0.00-<span id="xdx_902_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_pid_c20250101__20251231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceOneMember__srt--RangeAxis__srt--MaximumMember_zICcQ9nSO2m6" title="Exercise price"><span id="xdx_90A_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_pid_c20240101__20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceOneMember__srt--RangeAxis__srt--MaximumMember_zAQj2Z81pPO2" title="Exercise price">0.99</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_98A_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_pid_c20251231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceOneMember_zgyLYzal45p3" style="width: 8%; text-align: right" title="Stock options outstanding">39,359</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_980_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_pid_c20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceOneMember_zbYLHhkgm3B6" style="width: 8%; text-align: right" title="Stock options outstanding">86,577</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 8%; text-align: right"><span id="xdx_905_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_dtY_c20250101__20251231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceOneMember_zyEhLjAETBA4" title="Weighted average remaining contractual life">5.66</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 8%; text-align: right"><span id="xdx_90A_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_dtY_c20240101__20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceOneMember_zXQIVuQHQ401" title="Weighted average remaining contractual life">3.8</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_98F_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_pid_c20251231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceOneMember_zRxnuzHQfXzi" style="width: 8%; text-align: right" title="Stock options exercisable">26,234</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_985_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_pid_c20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceOneMember_zjqXCQFUZ3ec" style="width: 8%; text-align: right" title="Stock options exercisable">61,577</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: center"><span id="xdx_901_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_pid_c20250101__20251231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTwoMember__srt--RangeAxis__srt--MinimumMember_zcqsJUhPKhNf" title="Exercise price"><span id="xdx_90A_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_pid_c20240101__20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTwoMember__srt--RangeAxis__srt--MinimumMember_zFgU0LWyIcmj" title="Exercise price">1.00-<span id="xdx_90A_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_pid_c20250101__20251231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTwoMember__srt--RangeAxis__srt--MaximumMember_zGS5n5RDe0b9" title="Exercise price"><span id="xdx_906_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_pid_c20240101__20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTwoMember__srt--RangeAxis__srt--MaximumMember_zaoOtA0WMRG2" title="Exercise price">3.73</td><td> </td> <td style="text-align: left"> </td><td id="xdx_987_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_pid_c20251231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTwoMember_zd91GB2RGFhi" style="text-align: right" title="Stock options outstanding">2,032,875</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98B_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_pid_c20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTwoMember_z2lpujUFqdZk" style="text-align: right" title="Stock options outstanding">1,299,562</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_906_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_dtY_c20250101__20251231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTwoMember_znG0JO6dv57h" title="Weighted average remaining contractual life">8.31</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_908_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_dtY_c20240101__20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTwoMember_zdAmIPzZutN" title="Weighted average remaining contractual life">8.7</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_986_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_pid_c20251231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTwoMember_zLR2fqvq2Lgh" style="text-align: right" title="Stock options exercisable">1,283,092</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_982_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_pid_c20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTwoMember_zSW5140zZ4ac" style="text-align: right" title="Stock options exercisable">731,559</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: center"><span id="xdx_903_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_pid_c20250101__20251231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceThreeMember__srt--RangeAxis__srt--MinimumMember_zJe1TE5cSJE4" title="Exercise price"><span id="xdx_904_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_pid_c20240101__20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceThreeMember__srt--RangeAxis__srt--MinimumMember_zvkHhpUpSas5" title="Exercise price">4.2-<span id="xdx_90A_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_pid_c20250101__20251231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceThreeMember__srt--RangeAxis__srt--MaximumMember_zU0b5KY2jtBk" title="Exercise price"><span id="xdx_908_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_pid_c20240101__20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceThreeMember__srt--RangeAxis__srt--MaximumMember_zI7J5BcsuxN2" title="Exercise price">7.26</td><td> </td> <td style="text-align: left"> </td><td id="xdx_980_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_pid_c20251231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceThreeMember_zhD2aMZr8O11" style="text-align: right" title="Stock options outstanding">499,636</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_988_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_pid_c20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceThreeMember_zMX9lcOqDZPk" style="text-align: right" title="Stock options outstanding">577,482</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_909_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_dtY_c20250101__20251231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceThreeMember_zMpXNSvOpKx4" title="Weighted average remaining contractual life">5.82</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_902_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_dtY_c20240101__20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceThreeMember_zxiYjwm2w1i2">5.9</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_987_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_pid_c20251231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceThreeMember_zW7qs1oVrx7b" style="text-align: right" title="Stock options exercisable">499,636</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_988_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_pid_c20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceThreeMember_zBbQqGzgFGU" style="text-align: right" title="Stock options exercisable">539,642</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: center"><span id="xdx_90C_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_pid_c20250101__20251231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFourMember__srt--RangeAxis__srt--MinimumMember_zx3J1Zk7I50c" title="Exercise price"><span id="xdx_903_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_pid_c20240101__20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFourMember__srt--RangeAxis__srt--MinimumMember_zNNvnaLpQIsa" title="Exercise price">8.16-<span id="xdx_902_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_pid_c20250101__20251231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFourMember__srt--RangeAxis__srt--MaximumMember_zwPLGnzBp4v6" title="Exercise price"><span id="xdx_90D_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_pid_c20240101__20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFourMember__srt--RangeAxis__srt--MaximumMember_zMxmwCRxB0Nh" title="Exercise price">9.64</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98B_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_pid_c20251231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFourMember_zicp119nTubc" style="text-align: right" title="Stock options outstanding">380,872</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98C_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_pid_c20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFourMember_z9I8BDSHSqhj" style="text-align: right" title="Stock options outstanding">380,872</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_90F_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_dtY_c20250101__20251231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFourMember_zkGLVB96CuGc" title="Weighted average remaining contractual life">4.56</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_901_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_dtY_c20240101__20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFourMember_z5lpdPalW2n6" title="Weighted average remaining contractual life">5.6</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98E_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_pid_c20251231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFourMember_zmbjakY4Ign8" style="text-align: right" title="Stock options exercisable">380,872</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98C_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_pid_c20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFourMember_zUaEFazC8n4b" style="text-align: right" title="Stock options exercisable">380,872</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: center; padding-bottom: 1pt"><span id="xdx_90B_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_pid_c20250101__20251231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFiveMember__srt--RangeAxis__srt--MinimumMember_z7SpxjlIJ5Q3" title="Exercise price"><span id="xdx_90A_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_pid_c20240101__20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFiveMember__srt--RangeAxis__srt--MinimumMember_zKwZ9YqsX154" title="Exercise price">15.3-<span id="xdx_906_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_pid_c20250101__20251231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFiveMember__srt--RangeAxis__srt--MaximumMember_ztUTUQuG4FL1" title="Exercise price"><span id="xdx_907_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_pid_c20240101__20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFiveMember__srt--RangeAxis__srt--MaximumMember_zdzL8vP6Pic7" title="Exercise price">15.75</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_98B_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_pid_c20251231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFiveMember_zQ6TVzcxuJw5" style="border-bottom: Black 1pt solid; text-align: right" title="Stock options outstanding">152,873</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_982_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_pid_c20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFiveMember_zPISDilIdWWd" style="border-bottom: Black 1pt solid; text-align: right" title="Stock options outstanding">152,873</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt; text-align: right"><span id="xdx_900_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_dtY_c20250101__20251231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFiveMember_zSrjI1NLSRT4" title="Weighted average remaining contractual life">1.76</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt; text-align: right"><span id="xdx_90A_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_dtY_c20240101__20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFiveMember_zLyHGUeUKmBj" title="Weighted average remaining contractual life">2.7</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_982_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_pid_c20251231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFiveMember_zuyGnM7Myfj4" style="border-bottom: Black 1pt solid; text-align: right" title="Stock options exercisable">152,873</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_988_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_pid_c20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFiveMember_zEP8FBbAyA6g" style="border-bottom: Black 1pt solid; text-align: right" title="Stock options exercisable">152,873</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: center; padding-bottom: 2.5pt"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_985_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_pid_c20251231_z6eaAg29yGij" style="border-bottom: Black 2.5pt double; text-align: right" title="Stock options outstanding">3,105,615</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_98E_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_pid_c20241231_zdQetLVNOZ78" style="border-bottom: Black 2.5pt double; text-align: right" title="Stock options outstanding">2,497,366</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt; text-align: right"> </td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt; text-align: right"> </td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_985_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_pid_c20251231_zCyJttspU2J1" style="border-bottom: Black 2.5pt double; text-align: right" title="Stock options exercisable">2,342,707</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_98B_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_pid_c20241231_zJNkzUzhwXVk" style="border-bottom: Black 2.5pt double; text-align: right" title="Stock options exercisable">1,866,523</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> MICROBOT MEDICAL INC. NOTES TO CONSOLIDATED FINANCIAL STATEMENTS U.S. dollars in thousands (Except share and per share data) NOTE 11 - SHARE CAPITAL H. Employee Stock Option Grants and Exercises: <p id="xdx_895_eus-gaap--ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_zeXslNJm6A1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.75in; text-align: justify">The grant date fair values of employee stock options granted in the years ended December 31, 2025 and 2024 were estimated using the Black-Scholes valuation model with the following: SCHEDULE OF STOCK OPTIONS VALUATION ASSUMPTIONS <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%; margin-left: 0.75in; margin-right: 0.5in"> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td colspan="5" style="border-bottom: Black 1pt solid; text-align: right">For the Years Ended December 31, </td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1pt"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</td><td style="padding-bottom: 1pt; font-weight: bold; text-align: left"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%; text-align: left">Expected volatility</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 16%; text-align: right"><span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_pid_dp_uPure_c20250101__20251231_zzDojm6zCBQ7" title="Expected volatility, minimum">94.0%-<span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_pid_dp_uPure_c20250101__20251231_zJbXMV5K3ysk" title="Expected volatility, maximum">102.3%</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 16%; text-align: right"><span id="xdx_909_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_pid_dp_uPure_c20240101__20241231_z2GXYbqeqmYl" title="Expected volatility, minimum">90.4%-<span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_pid_dp_uPure_c20240101__20241231_zDA7iC64zMf2" title="Expected volatility, maximum">100.7%</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Risk-free interest</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_pid_dp_uPure_c20250101__20251231_zZsQ5iMCqWaf" title="Risk-free interest, minimum">3.7%-<span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_pid_dp_uPure_c20250101__20251231_zyYmLSwFUCc8" title="Risk-free interest, maximum">4.4%</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_909_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_pid_dp_uPure_c20240101__20241231_zIq0DhTxhwI8" title="Risk-free interest, minimum">3.5%-<span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_pid_dp_uPure_c20240101__20241231_zjvBg1a6zFVe" title="Risk-free interest, maximum"> 4.3%</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Dividend yield</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Expected terms (years)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_904_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20250101__20251231__srt--RangeAxis__srt--MinimumMember_z5AImLztMX5f" title="Expected terms (years)">5.5-<span id="xdx_90B_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20250101__20251231__srt--RangeAxis__srt--MaximumMember_z0yMcCpQIjk6" title="Expected terms (years)">5.8</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_90A_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20240101__20241231__srt--RangeAxis__srt--MinimumMember_zB08Gub5AMhe" title="Expected terms (years)">5-<span id="xdx_903_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20240101__20241231__srt--RangeAxis__srt--MaximumMember_zZd2kPgvdZh8" title="Expected terms (years)">10</td><td style="text-align: left"> </td></tr> </table> I. Warrants: The remaining outstanding warrants and terms as of December 31, 2025 and 2024 are as follows: SCHEDULE OF WARRANTS OUTSTANDING <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Issuance date</td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Outstanding and exercisable as of December 31, 2025</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Outstanding and exercisable as of December 31, 2024</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Exercise Price</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: center">Exercisable Through</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 22%; text-align: left">Warrant to underwriters October 2022</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_98C_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20251231__us-gaap--StatementEquityComponentsAxis__custom--WarrantToUnderwritersOctoberTwoThousandTwentyTwoMember_z4Ug6MUoYNn3" style="width: 14%; text-align: right" title="Number of outstanding warrants">51,125</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_98A_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20241231__us-gaap--StatementEquityComponentsAxis__custom--WarrantToUnderwritersOctoberTwoThousandTwentyTwoMember_zGSqSZcflnIl" style="width: 14%; text-align: right" title="Number of outstanding warrants">51,125</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_989_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20251231__us-gaap--StatementEquityComponentsAxis__custom--WarrantToUnderwritersOctoberTwoThousandTwentyTwoMember_zXJoIenITnMh" style="width: 14%; text-align: right" title="Exercise price">6.11</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 22%; text-align: center"><span id="xdx_904_ecustom--ClassOfWarrantOrRighstMonthYearFromWhichWarrantsOrRightsExercisable_c20250101__20251231__us-gaap--StatementEquityComponentsAxis__custom--WarrantToUnderwritersOctoberTwoThousandTwentyTwoMember_zTJhRrW1Om0g" title="Exercisable Through">October 21, 2027</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Warrant to underwriters May 2023</td><td> </td> <td style="text-align: left"> </td><td id="xdx_983_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20251231__us-gaap--StatementEquityComponentsAxis__custom--WarrantToUnderwritersMayTwoThousandTwentyThreeMember_zKpVUZt0OsI6" style="text-align: right" title="Number of outstanding warrants">32,778</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_988_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20241231__us-gaap--StatementEquityComponentsAxis__custom--WarrantToUnderwritersMayTwoThousandTwentyThreeMember_zpdbSwEExF35" style="text-align: right" title="Number of outstanding warrants">32,778</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_98E_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20251231__us-gaap--StatementEquityComponentsAxis__custom--WarrantToUnderwritersMayTwoThousandTwentyThreeMember_zeAo5A0Rt3G1" style="text-align: right" title="Exercise price">2.75</td><td style="text-align: left"> </td><td> </td> <td style="text-align: center"><span id="xdx_908_ecustom--ClassOfWarrantOrRighstMonthYearFromWhichWarrantsOrRightsExercisable_c20250101__20251231__us-gaap--StatementEquityComponentsAxis__custom--WarrantToUnderwritersMayTwoThousandTwentyThreeMember_zjcm5FVWwBL9" title="Exercisable Through">November 23, 2026</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Warrant to underwriters May 2023</td><td> </td> <td style="text-align: left"> </td><td id="xdx_984_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20251231__us-gaap--StatementEquityComponentsAxis__custom--WarrantToUnderwritersMayTwoThousandTwentyThreeOneMember_zcqavep0Bx8h" style="text-align: right" title="Number of outstanding warrants">60,476</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_984_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20241231__us-gaap--StatementEquityComponentsAxis__custom--WarrantToUnderwritersMayTwoThousandTwentyThreeOneMember_zMmGhiULMkx" style="text-align: right" title="Number of outstanding warrants">60,476</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_984_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20251231__us-gaap--StatementEquityComponentsAxis__custom--WarrantToUnderwritersMayTwoThousandTwentyThreeOneMember_zk6qVSmDawa4" style="text-align: right" title="Exercise price">2.75</td><td style="text-align: left"> </td><td> </td> <td style="text-align: center"><span id="xdx_900_ecustom--ClassOfWarrantOrRighstMonthYearFromWhichWarrantsOrRightsExercisable_c20250101__20251231__us-gaap--StatementEquityComponentsAxis__custom--WarrantToUnderwritersMayTwoThousandTwentyThreeOneMember_zV6IExvr3zl5" title="Exercisable Through">November 24, 2026</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Warrant to underwriters June 2023</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98C_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20251231__us-gaap--StatementEquityComponentsAxis__custom--WarrantToUnderwritersJuneTwoThousandTwentyThreeMember_zn6pmh7Yo984" style="text-align: right" title="Number of outstanding warrants">35,088</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_987_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20241231__us-gaap--StatementEquityComponentsAxis__custom--WarrantToUnderwritersJuneTwoThousandTwentyThreeMember_zBijD2A82oX5" style="text-align: right" title="Number of outstanding warrants">35,088</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_98E_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20251231__us-gaap--StatementEquityComponentsAxis__custom--WarrantToUnderwritersJuneTwoThousandTwentyThreeMember_z2mLCjm68VE7" style="text-align: right" title="Exercise price">2.67</td><td style="text-align: left"> </td><td> </td> <td style="text-align: center"><span id="xdx_90D_ecustom--ClassOfWarrantOrRighstMonthYearFromWhichWarrantsOrRightsExercisable_c20250101__20251231__us-gaap--StatementEquityComponentsAxis__custom--WarrantToUnderwritersJuneTwoThousandTwentyThreeMember_zdL6PLs41Bjl" title="Exercisable Through">June 2, 2028</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: center"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Warrant to underwriters June 2023</td><td> </td> <td style="text-align: left"> </td><td id="xdx_983_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20251231__us-gaap--StatementEquityComponentsAxis__custom--WarrantToUnderwritersJuneTwoThousandTwentyThreeOneMember_zWOj2rjxEjQf" style="text-align: right" title="Number of outstanding warrants">31,231</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98C_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20241231__us-gaap--StatementEquityComponentsAxis__custom--WarrantToUnderwritersJuneTwoThousandTwentyThreeOneMember_zpdhqSRRmIsa" style="text-align: right" title="Number of outstanding warrants">31,231</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_985_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20251231__us-gaap--StatementEquityComponentsAxis__custom--WarrantToUnderwritersJuneTwoThousandTwentyThreeOneMember_z6BH6J7IZgrl" style="text-align: right" title="Exercise price">4.06</td><td style="text-align: left"> </td><td> </td> <td style="text-align: center"><span id="xdx_90E_ecustom--ClassOfWarrantOrRighstMonthYearFromWhichWarrantsOrRightsExercisable_c20250101__20251231__us-gaap--StatementEquityComponentsAxis__custom--WarrantToUnderwritersJuneTwoThousandTwentyThreeOneMember_zhCthBTXMeld" title="Exercisable Through">June 28, 2028</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: center"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Warrant series E January 2024</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98A_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20251231__us-gaap--StatementEquityComponentsAxis__custom--WarrantSeriesEJanuary2024Member_zf55Ovs0Hkp" style="text-align: right" title="Number of outstanding warrants">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_983_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20241231__us-gaap--StatementEquityComponentsAxis__custom--WarrantSeriesEJanuary2024Member_z9ICJxQ77QA5" style="text-align: right" title="Number of outstanding warrants">1,685,682</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_98A_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20251231__us-gaap--StatementEquityComponentsAxis__custom--WarrantSeriesEJanuary2024Member_zN434DOLjaX9" style="text-align: right" title="Exercise price">1.50</td><td style="text-align: left"> </td><td> </td> <td style="text-align: center"><span id="xdx_905_ecustom--ClassOfWarrantOrRighstMonthYearFromWhichWarrantsOrRightsExercisable_c20250101__20251231__us-gaap--StatementEquityComponentsAxis__custom--WarrantSeriesEJanuary2024Member_zE2844rRw8V6" title="Exercisable Through">July 3, 2029</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Warrant to underwriters January 2024</td><td> </td> <td style="text-align: left"> </td><td id="xdx_989_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20251231__us-gaap--StatementEquityComponentsAxis__custom--WarrantToUnderwritersJanuaryTwoThousandTwentyFourMember_zGuC1kJH4Tf8" style="text-align: right" title="Number of outstanding warrants">84,284</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_984_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20241231__us-gaap--StatementEquityComponentsAxis__custom--WarrantToUnderwritersJanuaryTwoThousandTwentyFourMember_zErIgmLUnLha" style="text-align: right" title="Number of outstanding warrants">84,284</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_98E_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20251231__us-gaap--StatementEquityComponentsAxis__custom--WarrantToUnderwritersJanuaryTwoThousandTwentyFourMember_zLczQ0ZUhAV5" style="text-align: right" title="Exercise price">2.03</td><td style="text-align: left"> </td><td> </td> <td style="text-align: center"><span id="xdx_90C_ecustom--ClassOfWarrantOrRighstMonthYearFromWhichWarrantsOrRightsExercisable_c20250101__20251231__us-gaap--StatementEquityComponentsAxis__custom--WarrantToUnderwritersJanuaryTwoThousandTwentyFourMember_z7aDDZDToVp8" title="Exercisable Through">July 3, 2029</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Warrant series F June 2024</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98D_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20251231__us-gaap--StatementEquityComponentsAxis__custom--WarrantSeriesFJune2024Member_z4tQ3HmaVFE1" style="text-align: right" title="Number of outstanding warrants">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98D_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20241231__us-gaap--StatementEquityComponentsAxis__custom--WarrantSeriesFJune2024Member_zB8FqbWM4uZ4" style="text-align: right" title="Number of outstanding warrants">3,133,338</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_981_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20251231__us-gaap--StatementEquityComponentsAxis__custom--WarrantSeriesFJune2024Member_zPqsFTklohwk" style="text-align: right" title="Exercise price">1.50</td><td style="text-align: left"> </td><td> </td> <td style="text-align: center"><span id="xdx_905_ecustom--ClassOfWarrantOrRighstMonthYearFromWhichWarrantsOrRightsExercisable_c20250101__20251231__us-gaap--StatementEquityComponentsAxis__custom--WarrantSeriesFJune2024Member_zlRlwpoE1Dfb" title="Exercisable Through">June 3, 2026</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Warrant to underwriters June 2024</td><td> </td> <td style="text-align: left"> </td><td id="xdx_981_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20251231__us-gaap--StatementEquityComponentsAxis__custom--WarrantToUnderwritersJuneTwoThousandTwentyFourMember_zIm5qP6hb5Fj" style="text-align: right" title="Number of outstanding warrants">28,102</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_981_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20241231__us-gaap--StatementEquityComponentsAxis__custom--WarrantToUnderwritersJuneTwoThousandTwentyFourMember_zrdgmgCSCqT6" style="text-align: right" title="Number of outstanding warrants">78,333</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_984_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20251231__us-gaap--StatementEquityComponentsAxis__custom--WarrantToUnderwritersJuneTwoThousandTwentyFourMember_zsT7DKy7l5n3" style="text-align: right" title="Exercise price">1.88</td><td style="text-align: left"> </td><td> </td> <td style="text-align: center"><span id="xdx_906_ecustom--ClassOfWarrantOrRighstMonthYearFromWhichWarrantsOrRightsExercisable_c20250101__20251231__us-gaap--StatementEquityComponentsAxis__custom--WarrantToUnderwritersJuneTwoThousandTwentyFourMember_z4liUsqQeotc" title="Exercisable Through">June 3, 2026</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Warrant to underwriters January 2025</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98F_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20251231__us-gaap--StatementEquityComponentsAxis__custom--WarrantToUnderwritersJanuaryTwoThousandTwentyFiveMember_zUthmwdDNBnb" style="text-align: right" title="Number of outstanding warrants">71,750</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_980_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20241231__us-gaap--StatementEquityComponentsAxis__custom--WarrantToUnderwritersJanuaryTwoThousandTwentyFiveMember_z16HcqjbCgr1" style="text-align: right" title="Number of outstanding warrants">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_98F_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20251231__us-gaap--StatementEquityComponentsAxis__custom--WarrantToUnderwritersJanuaryTwoThousandTwentyFiveMember_zR555qGDUas6" style="text-align: right" title="Exercise price">2.19</td><td style="text-align: left"> </td><td> </td> <td style="text-align: center"><span id="xdx_90E_ecustom--ClassOfWarrantOrRighstMonthYearFromWhichWarrantsOrRightsExercisable_c20250101__20251231__us-gaap--StatementEquityComponentsAxis__custom--WarrantToUnderwritersJanuaryTwoThousandTwentyFiveMember_zJG5ThDHGTG7" title="Exercisable Through">January 7, 2027</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Warrant to underwriters January 2025</td><td> </td> <td style="text-align: left"> </td><td id="xdx_988_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20251231__us-gaap--StatementEquityComponentsAxis__custom--WarrantToUnderwritersJanuaryTwoThousandTwentyFiveOneMember_zjRvP9GWXla5" style="text-align: right" title="Number of outstanding warrants">189,428</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98C_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20241231__us-gaap--StatementEquityComponentsAxis__custom--WarrantToUnderwritersJanuaryTwoThousandTwentyFiveOneMember_zLPaZ9xbQdwh" style="text-align: right" title="Number of outstanding warrants">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_987_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20251231__us-gaap--StatementEquityComponentsAxis__custom--WarrantToUnderwritersJanuaryTwoThousandTwentyFiveOneMember_z7REMEYrx6u6" style="text-align: right" title="Exercise price">2.84</td><td style="text-align: left"> </td><td> </td> <td style="text-align: center"><span id="xdx_906_ecustom--ClassOfWarrantOrRighstMonthYearFromWhichWarrantsOrRightsExercisable_c20250101__20251231__us-gaap--StatementEquityComponentsAxis__custom--WarrantToUnderwritersJanuaryTwoThousandTwentyFiveOneMember_zoVvzhS2er86" title="Exercisable Through">January 10, 2027</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Warrant to underwriters January 2025</td><td> </td> <td style="text-align: left"> </td><td id="xdx_980_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20251231__us-gaap--StatementEquityComponentsAxis__custom--WarrantToUnderwritersJanuaryTwoThousandTwentyFiveTwoMember_zovUiuaI9pwh" style="text-align: right" title="Number of outstanding warrants">30,526</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98B_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20241231__us-gaap--StatementEquityComponentsAxis__custom--WarrantToUnderwritersJanuaryTwoThousandTwentyFiveTwoMember_zJKPeh26Wy8h" style="text-align: right" title="Number of outstanding warrants">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_98B_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20251231__us-gaap--StatementEquityComponentsAxis__custom--WarrantToUnderwritersJanuaryTwoThousandTwentyFiveTwoMember_znwsYghAvo3d" style="text-align: right" title="Exercise price">1.88</td><td style="text-align: left"> </td><td> </td> <td style="text-align: center"><span id="xdx_902_ecustom--ClassOfWarrantOrRighstMonthYearFromWhichWarrantsOrRightsExercisable_c20250101__20251231__us-gaap--StatementEquityComponentsAxis__custom--WarrantToUnderwritersJanuaryTwoThousandTwentyFiveTwoMember_zE8KUlCvHNOa" title="Exercisable Through">July 8, 2030</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Warrant to underwriters February 2025</td><td> </td> <td style="text-align: left"> </td><td id="xdx_986_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20251231__us-gaap--StatementEquityComponentsAxis__custom--WarrantToUnderwritersFebruaryTwoThousandTwentyFiveTwoMember_zYDOI8xcLd3b" style="text-align: right" title="Number of outstanding warrants">109,478</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_989_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20241231__us-gaap--StatementEquityComponentsAxis__custom--WarrantToUnderwritersFebruaryTwoThousandTwentyFiveTwoMember_z2mbtLPNY9Ol" style="text-align: right" title="Number of outstanding warrants">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_988_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20251231__us-gaap--StatementEquityComponentsAxis__custom--WarrantToUnderwritersFebruaryTwoThousandTwentyFiveTwoMember_zLMWd19IsAgd" style="text-align: right" title="Exercise price">2.66</td><td style="text-align: left"> </td><td> </td> <td style="text-align: center"><span id="xdx_90E_ecustom--ClassOfWarrantOrRighstMonthYearFromWhichWarrantsOrRightsExercisable_c20250101__20251231__us-gaap--StatementEquityComponentsAxis__custom--WarrantToUnderwritersFebruaryTwoThousandTwentyFiveTwoMember_z9zm23NXLOYc" title="Exercisable Through">June 10, 2027</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Warrant to underwriters September 2025</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98D_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20251231__us-gaap--StatementEquityComponentsAxis__custom--WarrantToUnderwritersSeptemberTwoThousandTwentyFiveMember_zcTA8DkRb3o6" style="text-align: right" title="Number of outstanding warrants">10,362</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98B_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20241231__us-gaap--StatementEquityComponentsAxis__custom--WarrantToUnderwritersSeptemberTwoThousandTwentyFiveMember_zwcKhdLATRf7" style="text-align: right" title="Number of outstanding warrants">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_984_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20251231__us-gaap--StatementEquityComponentsAxis__custom--WarrantToUnderwritersSeptemberTwoThousandTwentyFiveMember_z5TeP6b81ena" style="text-align: right" title="Exercise price">1.88</td><td style="text-align: left"> </td><td> </td> <td style="text-align: center"><span id="xdx_90A_ecustom--ClassOfWarrantOrRighstMonthYearFromWhichWarrantsOrRightsExercisable_c20250101__20251231__us-gaap--StatementEquityComponentsAxis__custom--WarrantToUnderwritersSeptemberTwoThousandTwentyFiveMember_z70YKcYeu16k" title="Exercisable Through">March 16, 2028</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Warrant to underwriters September 2025</td><td> </td> <td style="text-align: left"> </td><td id="xdx_985_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20251231__us-gaap--StatementEquityComponentsAxis__custom--WarrantToUnderwritersSeptemberTwoThousandTwentyFiveOneMember_zhArCiAvPRU7" style="text-align: right" title="Number of outstanding warrants">31,429</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98D_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20241231__us-gaap--StatementEquityComponentsAxis__custom--WarrantToUnderwritersSeptemberTwoThousandTwentyFiveOneMember_z5P3JvbE41ki" style="text-align: right" title="Number of outstanding warrants">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_98A_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20251231__us-gaap--StatementEquityComponentsAxis__custom--WarrantToUnderwritersSeptemberTwoThousandTwentyFiveOneMember_zF2FnAaXM9ma" style="text-align: right" title="Exercise price">2.12</td><td style="text-align: left"> </td><td> </td> <td style="text-align: center"><span id="xdx_907_ecustom--ClassOfWarrantOrRighstMonthYearFromWhichWarrantsOrRightsExercisable_c20250101__20251231__us-gaap--StatementEquityComponentsAxis__custom--WarrantToUnderwritersSeptemberTwoThousandTwentyFiveOneMember_zKg74X9b9qxd" title="Exercisable Through">March 16, 2028</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Warrant to underwriters September 2025</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98E_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20251231__us-gaap--StatementEquityComponentsAxis__custom--WarrantToUnderwritersSeptemberTwoThousandTwentyFiveTwoMember_zw9vQiAzS474" style="text-align: right" title="Number of outstanding warrants">138,906</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_982_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20241231__us-gaap--StatementEquityComponentsAxis__custom--WarrantToUnderwritersSeptemberTwoThousandTwentyFiveTwoMember_zUmDe7RKTp5g" style="text-align: right" title="Number of outstanding warrants">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_980_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20251231__us-gaap--StatementEquityComponentsAxis__custom--WarrantToUnderwritersSeptemberTwoThousandTwentyFiveTwoMember_zHHIGLgdatX4" style="text-align: right" title="Exercise price">2.62</td><td style="text-align: left"> </td><td> </td> <td style="text-align: center"><span id="xdx_907_ecustom--ClassOfWarrantOrRighstMonthYearFromWhichWarrantsOrRightsExercisable_c20250101__20251231__us-gaap--StatementEquityComponentsAxis__custom--WarrantToUnderwritersSeptemberTwoThousandTwentyFiveTwoMember_zy7gKk1ZVQN9" title="Exercisable Through">March 16, 2028</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Warrant to underwriters September 2025</td><td> </td> <td style="text-align: left"> </td><td id="xdx_980_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20251231__us-gaap--StatementEquityComponentsAxis__custom--WarrantToUnderwritersSeptemberTwoThousandTwentyFiveThreeMember_zBLFDW4xLSLf" style="text-align: right" title="Number of outstanding warrants">422,535</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_980_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20241231__us-gaap--StatementEquityComponentsAxis__custom--WarrantToUnderwritersSeptemberTwoThousandTwentyFiveThreeMember_zCOLiEHgPqVe" style="text-align: right" title="Number of outstanding warrants">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_982_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20251231__us-gaap--StatementEquityComponentsAxis__custom--WarrantToUnderwritersSeptemberTwoThousandTwentyFiveThreeMember_zpODHdVn7Lwk" style="text-align: right" title="Exercise price">2.66</td><td style="text-align: left"> </td><td> </td> <td style="text-align: center"><span id="xdx_905_ecustom--ClassOfWarrantOrRighstMonthYearFromWhichWarrantsOrRightsExercisable_c20250101__20251231__us-gaap--StatementEquityComponentsAxis__custom--WarrantToUnderwritersSeptemberTwoThousandTwentyFiveThreeMember_zN885O7SjQe8" title="Exercisable Through">March 16, 2028</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Warrant to underwriters September 2025</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98D_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20251231__us-gaap--StatementEquityComponentsAxis__custom--WarrantToUnderwritersSeptemberTwoThousandTwentyFiveFourMember_zox7alya8Cq4" style="text-align: right" title="Number of outstanding warrants">30,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_985_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20241231__us-gaap--StatementEquityComponentsAxis__custom--WarrantToUnderwritersSeptemberTwoThousandTwentyFiveFourMember_zPujEtkJjYm1" style="text-align: right" title="Number of outstanding warrants">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_982_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20251231__us-gaap--StatementEquityComponentsAxis__custom--WarrantToUnderwritersSeptemberTwoThousandTwentyFiveFourMember_zgjwOxFm4I5i" style="text-align: right" title="Exercise price">2.62</td><td style="text-align: left"> </td><td> </td> <td style="text-align: center"><span id="xdx_908_ecustom--ClassOfWarrantOrRighstMonthYearFromWhichWarrantsOrRightsExercisable_c20250101__20251231__us-gaap--StatementEquityComponentsAxis__custom--WarrantToUnderwritersSeptemberTwoThousandTwentyFiveFourMember_ziHlqgoZYqM1" title="Exercisable Through">March 29, 2028</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Warrant to underwriters September 2025</td><td> </td> <td style="text-align: left"> </td><td id="xdx_984_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20251231__us-gaap--StatementEquityComponentsAxis__custom--WarrantToUnderwritersSeptemberTwoThousandTwentyFiveFiveMember_ztio3Zo0Hnq4" style="text-align: right" title="Number of outstanding warrants">53,758</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_985_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20241231__us-gaap--StatementEquityComponentsAxis__custom--WarrantToUnderwritersSeptemberTwoThousandTwentyFiveFiveMember_z2Oyh8lokeo6" style="text-align: right" title="Number of outstanding warrants">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_986_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20251231__us-gaap--StatementEquityComponentsAxis__custom--WarrantToUnderwritersSeptemberTwoThousandTwentyFiveFiveMember_ztpSMXWRwdDh" style="text-align: right" title="Exercise price">1,88</td><td style="text-align: left"> </td><td> </td> <td style="text-align: center"><span id="xdx_901_ecustom--ClassOfWarrantOrRighstMonthYearFromWhichWarrantsOrRightsExercisable_c20250101__20251231__us-gaap--StatementEquityComponentsAxis__custom--WarrantToUnderwritersSeptemberTwoThousandTwentyFiveFiveMember_zyWPUSd6U1y" title="Exercisable Through">March 16, 2031</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Warrant to underwriters September 2025</td><td> </td> <td style="text-align: left"> </td><td id="xdx_988_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20251231__us-gaap--StatementEquityComponentsAxis__custom--WarrantToUnderwritersSeptemberTwoThousandTwentyFiveSixMember_z9GsrcuUJQj4" style="text-align: right" title="Number of outstanding warrants">146,306</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_983_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20241231__us-gaap--StatementEquityComponentsAxis__custom--WarrantToUnderwritersSeptemberTwoThousandTwentyFiveSixMember_znbSMSQyd97f" style="text-align: right" title="Number of outstanding warrants">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_983_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20251231__us-gaap--StatementEquityComponentsAxis__custom--WarrantToUnderwritersSeptemberTwoThousandTwentyFiveSixMember_zq6mxkZGlRdi" style="text-align: right" title="Exercise price">1.88</td><td style="text-align: left"> </td><td> </td> <td style="text-align: center"><span id="xdx_906_ecustom--ClassOfWarrantOrRighstMonthYearFromWhichWarrantsOrRightsExercisable_c20250101__20251231__us-gaap--StatementEquityComponentsAxis__custom--WarrantToUnderwritersSeptemberTwoThousandTwentyFiveSixMember_ztm91kz5Xfh4" title="Exercisable Through">September 16, 2027</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Warrant to underwriters September 2025</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98E_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20251231__us-gaap--StatementEquityComponentsAxis__custom--WarrantToUnderwritersSeptemberTwoThousandTwentyFiveSevenMember_z4MHSik3OvIh" style="text-align: right" title="Number of outstanding warrants">368,572</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_987_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20241231__us-gaap--StatementEquityComponentsAxis__custom--WarrantToUnderwritersSeptemberTwoThousandTwentyFiveSevenMember_zRlAbU0tyiye" style="text-align: right" title="Number of outstanding warrants">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_985_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20251231__us-gaap--StatementEquityComponentsAxis__custom--WarrantToUnderwritersSeptemberTwoThousandTwentyFiveSevenMember_z4jHEDWQHzCg" style="text-align: right" title="Exercise price">2.12</td><td style="text-align: left"> </td><td> </td> <td style="text-align: center"><span id="xdx_90E_ecustom--ClassOfWarrantOrRighstMonthYearFromWhichWarrantsOrRightsExercisable_c20250101__20251231__us-gaap--StatementEquityComponentsAxis__custom--WarrantToUnderwritersSeptemberTwoThousandTwentyFiveSevenMember_zgHBB2zmcTx1" title="Exercisable Through">September 16, 2027</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Warrant to underwriters September 2025</td><td> </td> <td style="text-align: left"> </td><td id="xdx_988_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20251231__us-gaap--StatementEquityComponentsAxis__custom--WarrantToUnderwritersSeptemberTwoThousandTwentyFiveEightMember_zTN1jdVh00a8" style="text-align: right" title="Number of outstanding warrants">143,723</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_981_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20241231__us-gaap--StatementEquityComponentsAxis__custom--WarrantToUnderwritersSeptemberTwoThousandTwentyFiveEightMember_zvF9qF6r5or8" style="text-align: right" title="Number of outstanding warrants">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_987_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20251231__us-gaap--StatementEquityComponentsAxis__custom--WarrantToUnderwritersSeptemberTwoThousandTwentyFiveEightMember_zm5oe5CKZiC6" style="text-align: right" title="Exercise price">2.63</td><td style="text-align: left"> </td><td> </td> <td style="text-align: center"><span id="xdx_902_ecustom--ClassOfWarrantOrRighstMonthYearFromWhichWarrantsOrRightsExercisable_c20250101__20251231__us-gaap--StatementEquityComponentsAxis__custom--WarrantToUnderwritersSeptemberTwoThousandTwentyFiveEightMember_z3WQBqoGLWOh" title="Exercisable Through">September 16, 2027</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Warrant to underwriters September 2025</td><td> </td> <td style="text-align: left"> </td><td id="xdx_985_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20251231__us-gaap--StatementEquityComponentsAxis__custom--WarrantToUnderwritersSeptemberTwoThousandTwentyFiveNineMember_zNTlBfF8lQ3e" style="text-align: right" title="Number of outstanding warrants">187,794</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98C_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20241231__us-gaap--StatementEquityComponentsAxis__custom--WarrantToUnderwritersSeptemberTwoThousandTwentyFiveNineMember_zAOMOVbNIp5e" style="text-align: right" title="Number of outstanding warrants">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_985_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20251231__us-gaap--StatementEquityComponentsAxis__custom--WarrantToUnderwritersSeptemberTwoThousandTwentyFiveNineMember_ziTHLaNdeMb4" style="text-align: right" title="Exercise price">2.66</td><td style="text-align: left"> </td><td> </td> <td style="text-align: center"><span id="xdx_905_ecustom--ClassOfWarrantOrRighstMonthYearFromWhichWarrantsOrRightsExercisable_c20250101__20251231__us-gaap--StatementEquityComponentsAxis__custom--WarrantToUnderwritersSeptemberTwoThousandTwentyFiveNineMember_zUKmb6k6kXWg" title="Exercisable Through">September 16, 2027</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Warrant series J September 2025</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98C_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20251231__us-gaap--StatementEquityComponentsAxis__custom--WarrantSeriesJSeptemberTwoThousandTwentyFiveMember_zGDPDNPAldql" style="text-align: right" title="Number of outstanding warrants">12,064,627</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_984_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20241231__us-gaap--StatementEquityComponentsAxis__custom--WarrantSeriesJSeptemberTwoThousandTwentyFiveMember_zn6TGRpO80m1" style="text-align: right" title="Number of outstanding warrants">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_983_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20251231__us-gaap--StatementEquityComponentsAxis__custom--WarrantSeriesJSeptemberTwoThousandTwentyFiveMember_zXA3np5OxOAd" style="text-align: right" title="Exercise price">4.50</td><td style="text-align: left"> </td><td> </td> <td style="text-align: center"><span id="xdx_900_ecustom--ClassOfWarrantOrRighstMonthYearFromWhichWarrantsOrRightsExercisable_c20250101__20251231__us-gaap--StatementEquityComponentsAxis__custom--WarrantSeriesJSeptemberTwoThousandTwentyFiveMember_zp1RAop3lgkj" title="Exercisable Through">March 16, 2028</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Warrant series J September 2025</td><td> </td> <td style="text-align: left"> </td><td id="xdx_989_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20251231__us-gaap--StatementEquityComponentsAxis__custom--WarrantSeriesJOneSeptemberTwoThousandTwentyFiveMember_z9YRqWNu8QJ" style="text-align: right" title="Number of outstanding warrants">600,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98D_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20241231__us-gaap--StatementEquityComponentsAxis__custom--WarrantSeriesJOneSeptemberTwoThousandTwentyFiveMember_znCAsPcAsuDd" style="text-align: right" title="Number of outstanding warrants">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_983_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20251231__us-gaap--StatementEquityComponentsAxis__custom--WarrantSeriesJOneSeptemberTwoThousandTwentyFiveMember_zJtFvMqTf2Lc" style="text-align: right" title="Exercise price">4.50</td><td style="text-align: left"> </td><td> </td> <td style="text-align: center"><span id="xdx_906_ecustom--ClassOfWarrantOrRighstMonthYearFromWhichWarrantsOrRightsExercisable_c20250101__20251231__us-gaap--StatementEquityComponentsAxis__custom--WarrantSeriesJOneSeptemberTwoThousandTwentyFiveMember_zUwl2Wfl5aD" title="Exercisable Through">March 29, 2028</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Warrant series J October 2025</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98F_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20251231__us-gaap--StatementEquityComponentsAxis__custom--WarrantSeriesJOctoberTwoThousandTwentyFiveOneMember_znwX9XqCCir8" style="text-align: right" title="Number of outstanding warrants">1,324,488</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_982_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20241231__us-gaap--StatementEquityComponentsAxis__custom--WarrantSeriesJOctoberTwoThousandTwentyFiveOneMember_zgT2ZHSBr13d" style="text-align: right" title="Number of outstanding warrants">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_981_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20251231__us-gaap--StatementEquityComponentsAxis__custom--WarrantSeriesJOctoberTwoThousandTwentyFiveOneMember_z2OGx54bWud5" style="text-align: right" title="Exercise price">4.50</td><td style="text-align: left"> </td><td> </td> <td style="text-align: center"><span id="xdx_905_ecustom--ClassOfWarrantOrRighstMonthYearFromWhichWarrantsOrRightsExercisable_c20250101__20251231__us-gaap--StatementEquityComponentsAxis__custom--WarrantSeriesJOctoberTwoThousandTwentyFiveOneMember_zSwQTLspHRnh" title="Exercisable Through">April 6, 2028</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1pt; text-align: left">Warrant series J October 2025</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: right"> </td><td style="border-bottom: Black 1pt solid; text-align: right" title="Number of outstanding warrants"><p id="xdx_98B_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20251231__us-gaap--StatementEquityComponentsAxis__custom--WarrantSeriesJOctoberTwoThousandTwentyFiveTwoMember_z8cj8kf4Zcg8" style="margin: 0" title="Number of outstanding warrants">66,224</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: right"> </td><td style="border-bottom: Black 1pt solid; text-align: right" title="Number of outstanding warrants"><p id="xdx_989_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20241231__us-gaap--StatementEquityComponentsAxis__custom--WarrantSeriesJOctoberTwoThousandTwentyFiveTwoMember_zdbjXFhsONQi" style="margin: 0" title="Number of outstanding warrants">-</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt; text-align: left">$</td><td style="padding-bottom: 1pt; text-align: right" title="Exercise price"><p id="xdx_985_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20251231__us-gaap--StatementEquityComponentsAxis__custom--WarrantSeriesJOctoberTwoThousandTwentyFiveTwoMember_zB6iVjgA02jh" style="margin: 0" title="Exercise price">2.66</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt; text-align: center"><span id="xdx_901_ecustom--ClassOfWarrantOrRighstMonthYearFromWhichWarrantsOrRightsExercisable_c20250101__20251231__us-gaap--StatementEquityComponentsAxis__custom--WarrantSeriesJOctoberTwoThousandTwentyFiveTwoMember_zIie8aZCfFsh" title="Exercisable Through">April 6, 2028</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: right"> </td><td style="border-bottom: Black 2.5pt double; text-align: right" title="Number of outstanding warrants">16,312,990</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: right"> </td><td id="xdx_982_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20241231_zJKpqHx0fB46" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of outstanding warrants">5,192,335</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt; text-align: right" title="Exercise price"> </td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; text-align: center"> </td></tr> </table> MICROBOT MEDICAL INC. NOTES TO CONSOLIDATED FINANCIAL STATEMENTS U.S. dollars in thousands (Except share and per share data)

1022495

2.20

2.075

312309

3.19

1685682

1.62

1685682

1.50

1853000

2730000

333000

84284

2.025

89000

1566669

0.01

1.50

2350000

328000

3133338

1.50

78333

1.875

4000001

0.01

1.75

7000000

690000

8000002

1.75

200000

2.1875

3788550

0.01

2.27

8600000

818000

7577100

2.10

189428

2.8375

6103289

0.01

2.13

13000000

1175000

12206578

2.13

305164

2.6625

120000000

12206578

2.13

305164

2.6625

4820000

3433880

3756000

239000

842606

1062000

65000

33855000

18613585

2370000

930680

895000

374167

120000000

61000000

121000000

120000000

1000000

207224

1.50

628571

1.75

4702612

2.10

8450708

2.13

13989115

1.50

2.13

13989115

4.50

12064627

600000

1324488

29286000000

2472 101

699456

80000

50000

1.2684

80000 52500

1.25

38000

35625

132500

80000

115000

1.2684

25000

0.881

0.25

99000

79567

1.25

35625

132500

96875

2591019

228000

483875

70000

SUMMARY OF STOCK OPTION ACTIVITY <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%; margin-left: 0.75in; margin-right: 0.5in"> <tr style="vertical-align: bottom"> <td style="text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; text-align: center">For the Year Ended December 31, 2025</td><td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: left"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Number of stock options</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Weighted average exercise price</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: left"> </td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; width: 60%">Outstanding as of December 31, 2024</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_pid_c20250101__20251231__srt--TitleOfIndividualAxis__custom--EmployeesAndDirectorsMember_z1yuOSaFLu5i" style="width: 16%; text-align: right" title="Number of stock options outstanding, Outstanding at beginning of period">2,497,366</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pid_c20250101__20251231__srt--TitleOfIndividualAxis__custom--EmployeesAndDirectorsMember_z8RiRF42JGud" style="width: 16%; text-align: right" title="Weighted average exercise price, Outstanding at beginning of period">4.70</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Granted</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_c20250101__20251231__srt--TitleOfIndividualAxis__custom--EmployeesAndDirectorsMember_zMbQXKFHWxG4" style="text-align: right" title="Number of stock options outstanding, Granted">781,875</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pid_c20250101__20251231__srt--TitleOfIndividualAxis__custom--EmployeesAndDirectorsMember_zDnzmqFLX7Qj" style="text-align: right" title="Weighted average exercise price, Granted">2.12</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Exercised</td><td> </td> <td style="text-align: left"> </td><td id="xdx_982_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_iN_pid_di_c20250101__20251231__srt--TitleOfIndividualAxis__custom--EmployeesAndDirectorsMember_zipg0tFv4yQ4" style="text-align: right" title="Number of stock options outstanding, exercised">(47,218</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_pid_c20250101__20251231__srt--TitleOfIndividualAxis__custom--EmployeesAndDirectorsMember_z9qp1gdpiDN8" style="text-align: right" title="Weighted average exercise price, exercised">0.01</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt">Forfeitures</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_iN_pid_di_c20250101__20251231__srt--TitleOfIndividualAxis__custom--EmployeesAndDirectorsMember_zTymUU1gj9c4" style="border-bottom: Black 1pt solid; text-align: right" title="Number of stock options outstanding, forfeitures">(126,408</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt; text-align: left"> </td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_pid_c20250101__20251231__srt--TitleOfIndividualAxis__custom--EmployeesAndDirectorsMember_zgzplxmaz7Dd" style="padding-bottom: 1pt; text-align: right" title="Weighted average exercise price, forfeitures">3.30</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 2.5pt">Outstanding as of December 31, 2025</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_pid_c20250101__20251231__srt--TitleOfIndividualAxis__custom--EmployeesAndDirectorsMember_zS4XAlaMCWCg" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of stock options outstanding, Outstanding at end of period">3,105,615</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; text-align: left">$</td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_pid_c20250101__20251231__srt--TitleOfIndividualAxis__custom--EmployeesAndDirectorsMember_zj00W7GbbkUc" style="padding-bottom: 2.5pt; text-align: right" title="Weighted average exercise price, Outstanding at end of period">4.18</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 2.5pt">Exercisable as of December 31, 2025</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_iE_pid_c20250101__20251231__srt--TitleOfIndividualAxis__custom--EmployeesAndDirectorsMember_zQvJBHrDr0M" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of stock options outstanding, Exercisable at end of period">2,342,707</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; text-align: left">$</td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_iE_pid_c20250101__20251231__srt--TitleOfIndividualAxis__custom--EmployeesAndDirectorsMember_zPgzJZAQghkh" style="padding-bottom: 2.5pt; text-align: right" title="Weighted average exercise price, Exercisable at end of period">4.91</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%; margin-left: 0.75in; margin-right: 0.5in"> <tr style="vertical-align: bottom"> <td style="text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; text-align: center">For the Year Ended December 31, 2024</td><td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: left"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Number of stock options</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Weighted average exercise price</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: left"> </td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; width: 60%">Outstanding as of December 31, 2023</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_pid_c20240101__20241231__srt--TitleOfIndividualAxis__custom--EmployeesAndDirectorsMember_zayG5S2CuXg3" style="width: 16%; text-align: right" title="Number of stock options outstanding, Outstanding at beginning of period">2,095,362</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pid_c20240101__20241231__srt--TitleOfIndividualAxis__custom--EmployeesAndDirectorsMember_z12YoHxDB3gg" style="width: 16%; text-align: right" title="Weighted average exercise price, Outstanding at beginning of period">5.51</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Granted</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_c20240101__20241231__srt--TitleOfIndividualAxis__custom--EmployeesAndDirectorsMember_zlDYGevE3ry" style="text-align: right" title="Number of stock options outstanding, Granted">562,067</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pid_c20240101__20241231__srt--TitleOfIndividualAxis__custom--EmployeesAndDirectorsMember_z4pvA3iQFwU1" style="text-align: right" title="Weighted average exercise price, Granted">1.24</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1pt">Forfeitures</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_iN_pid_di_c20240101__20241231__srt--TitleOfIndividualAxis__custom--EmployeesAndDirectorsMember_zMCvtHYzmKlk" style="border-bottom: Black 1pt solid; text-align: right" title="Number of stock options outstanding, forfeitures">(160,063</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt; text-align: left"> </td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_pid_c20240101__20241231__srt--TitleOfIndividualAxis__custom--EmployeesAndDirectorsMember_z4QJnZzW3yN2" style="padding-bottom: 1pt; text-align: right" title="Weighted average exercise price, forfeitures">3.23</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 2.5pt">Outstanding as of December 31, 2024</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_pid_c20240101__20241231__srt--TitleOfIndividualAxis__custom--EmployeesAndDirectorsMember_zI9m7GpephU8" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of stock options outstanding, Outstanding at end of period">2,497,366</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; text-align: left">$</td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_pid_c20240101__20241231__srt--TitleOfIndividualAxis__custom--EmployeesAndDirectorsMember_zzDRf5IdeWb2" style="padding-bottom: 2.5pt; text-align: right" title="Weighted average exercise price, Outstanding at end of period">4.70</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 2.5pt">Exercisable as of December 31, 2024</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_iE_pid_c20240101__20241231__srt--TitleOfIndividualAxis__custom--EmployeesAndDirectorsMember_zVETznieIQW3" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of stock options outstanding, Exercisable at end of period">1,866,523</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; text-align: left">$</td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_iE_pid_c20240101__20241231__srt--TitleOfIndividualAxis__custom--EmployeesAndDirectorsMember_zpv2bhIriErh" style="padding-bottom: 2.5pt; text-align: right" title="Weighted average exercise price, Exercisable at end of period">5.63</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table>

2497366

4.70

781875

2.12

47218

0.01

126408

3.30

3105615

4.18

2342707

4.91

2095362

5.51

562067

1.24

160063

3.23

2497366

4.70

1866523

5.63

726000

75000

558000

69000

1.65

0.99

1109000

P2Y

<p id="xdx_89B_eus-gaap--ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock_zmBqOXQqh5gj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.75in; text-align: justify">The stock options outstanding as of December 31, 2025 and 2024, summarized by exercise prices, are as follows: SCHEDULE OF STOCK OPTIONS OUTSTANDING <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Exercise price $</td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Stock options outstanding as of December 31, 2025</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Stock options outstanding as of December 31, 2024</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Weighted average remaining contractual life – years as of December 31, 2025</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Weighted average remaining contractual life – years as of December 31, 2024</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Stock options exercisable as of December 31, 2025</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Stock options exercisable as of December 31, 2024</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 28%; text-align: center"><span id="xdx_902_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_pid_c20250101__20251231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceOneMember__srt--RangeAxis__srt--MinimumMember_zy7eKQByZ7T5" title="Exercise price"><span id="xdx_90A_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_pid_c20240101__20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceOneMember__srt--RangeAxis__srt--MinimumMember_z1GfoS6epeYh" title="Exercise price">0.00-<span id="xdx_902_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_pid_c20250101__20251231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceOneMember__srt--RangeAxis__srt--MaximumMember_zICcQ9nSO2m6" title="Exercise price"><span id="xdx_90A_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_pid_c20240101__20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceOneMember__srt--RangeAxis__srt--MaximumMember_zAQj2Z81pPO2" title="Exercise price">0.99</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_98A_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_pid_c20251231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceOneMember_zgyLYzal45p3" style="width: 8%; text-align: right" title="Stock options outstanding">39,359</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_980_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_pid_c20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceOneMember_zbYLHhkgm3B6" style="width: 8%; text-align: right" title="Stock options outstanding">86,577</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 8%; text-align: right"><span id="xdx_905_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_dtY_c20250101__20251231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceOneMember_zyEhLjAETBA4" title="Weighted average remaining contractual life">5.66</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 8%; text-align: right"><span id="xdx_90A_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_dtY_c20240101__20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceOneMember_zXQIVuQHQ401" title="Weighted average remaining contractual life">3.8</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_98F_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_pid_c20251231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceOneMember_zRxnuzHQfXzi" style="width: 8%; text-align: right" title="Stock options exercisable">26,234</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_985_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_pid_c20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceOneMember_zjqXCQFUZ3ec" style="width: 8%; text-align: right" title="Stock options exercisable">61,577</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: center"><span id="xdx_901_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_pid_c20250101__20251231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTwoMember__srt--RangeAxis__srt--MinimumMember_zcqsJUhPKhNf" title="Exercise price"><span id="xdx_90A_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_pid_c20240101__20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTwoMember__srt--RangeAxis__srt--MinimumMember_zFgU0LWyIcmj" title="Exercise price">1.00-<span id="xdx_90A_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_pid_c20250101__20251231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTwoMember__srt--RangeAxis__srt--MaximumMember_zGS5n5RDe0b9" title="Exercise price"><span id="xdx_906_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_pid_c20240101__20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTwoMember__srt--RangeAxis__srt--MaximumMember_zaoOtA0WMRG2" title="Exercise price">3.73</td><td> </td> <td style="text-align: left"> </td><td id="xdx_987_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_pid_c20251231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTwoMember_zd91GB2RGFhi" style="text-align: right" title="Stock options outstanding">2,032,875</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98B_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_pid_c20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTwoMember_z2lpujUFqdZk" style="text-align: right" title="Stock options outstanding">1,299,562</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_906_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_dtY_c20250101__20251231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTwoMember_znG0JO6dv57h" title="Weighted average remaining contractual life">8.31</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_908_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_dtY_c20240101__20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTwoMember_zdAmIPzZutN" title="Weighted average remaining contractual life">8.7</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_986_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_pid_c20251231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTwoMember_zLR2fqvq2Lgh" style="text-align: right" title="Stock options exercisable">1,283,092</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_982_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_pid_c20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTwoMember_zSW5140zZ4ac" style="text-align: right" title="Stock options exercisable">731,559</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: center"><span id="xdx_903_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_pid_c20250101__20251231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceThreeMember__srt--RangeAxis__srt--MinimumMember_zJe1TE5cSJE4" title="Exercise price"><span id="xdx_904_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_pid_c20240101__20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceThreeMember__srt--RangeAxis__srt--MinimumMember_zvkHhpUpSas5" title="Exercise price">4.2-<span id="xdx_90A_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_pid_c20250101__20251231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceThreeMember__srt--RangeAxis__srt--MaximumMember_zU0b5KY2jtBk" title="Exercise price"><span id="xdx_908_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_pid_c20240101__20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceThreeMember__srt--RangeAxis__srt--MaximumMember_zI7J5BcsuxN2" title="Exercise price">7.26</td><td> </td> <td style="text-align: left"> </td><td id="xdx_980_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_pid_c20251231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceThreeMember_zhD2aMZr8O11" style="text-align: right" title="Stock options outstanding">499,636</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_988_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_pid_c20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceThreeMember_zMX9lcOqDZPk" style="text-align: right" title="Stock options outstanding">577,482</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_909_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_dtY_c20250101__20251231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceThreeMember_zMpXNSvOpKx4" title="Weighted average remaining contractual life">5.82</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_902_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_dtY_c20240101__20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceThreeMember_zxiYjwm2w1i2">5.9</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_987_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_pid_c20251231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceThreeMember_zW7qs1oVrx7b" style="text-align: right" title="Stock options exercisable">499,636</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_988_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_pid_c20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceThreeMember_zBbQqGzgFGU" style="text-align: right" title="Stock options exercisable">539,642</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: center"><span id="xdx_90C_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_pid_c20250101__20251231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFourMember__srt--RangeAxis__srt--MinimumMember_zx3J1Zk7I50c" title="Exercise price"><span id="xdx_903_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_pid_c20240101__20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFourMember__srt--RangeAxis__srt--MinimumMember_zNNvnaLpQIsa" title="Exercise price">8.16-<span id="xdx_902_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_pid_c20250101__20251231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFourMember__srt--RangeAxis__srt--MaximumMember_zwPLGnzBp4v6" title="Exercise price"><span id="xdx_90D_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_pid_c20240101__20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFourMember__srt--RangeAxis__srt--MaximumMember_zMxmwCRxB0Nh" title="Exercise price">9.64</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98B_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_pid_c20251231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFourMember_zicp119nTubc" style="text-align: right" title="Stock options outstanding">380,872</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98C_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_pid_c20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFourMember_z9I8BDSHSqhj" style="text-align: right" title="Stock options outstanding">380,872</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_90F_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_dtY_c20250101__20251231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFourMember_zkGLVB96CuGc" title="Weighted average remaining contractual life">4.56</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_901_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_dtY_c20240101__20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFourMember_z5lpdPalW2n6" title="Weighted average remaining contractual life">5.6</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98E_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_pid_c20251231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFourMember_zmbjakY4Ign8" style="text-align: right" title="Stock options exercisable">380,872</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98C_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_pid_c20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFourMember_zUaEFazC8n4b" style="text-align: right" title="Stock options exercisable">380,872</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: center; padding-bottom: 1pt"><span id="xdx_90B_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_pid_c20250101__20251231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFiveMember__srt--RangeAxis__srt--MinimumMember_z7SpxjlIJ5Q3" title="Exercise price"><span id="xdx_90A_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_pid_c20240101__20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFiveMember__srt--RangeAxis__srt--MinimumMember_zKwZ9YqsX154" title="Exercise price">15.3-<span id="xdx_906_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_pid_c20250101__20251231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFiveMember__srt--RangeAxis__srt--MaximumMember_ztUTUQuG4FL1" title="Exercise price"><span id="xdx_907_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_pid_c20240101__20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFiveMember__srt--RangeAxis__srt--MaximumMember_zdzL8vP6Pic7" title="Exercise price">15.75</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_98B_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_pid_c20251231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFiveMember_zQ6TVzcxuJw5" style="border-bottom: Black 1pt solid; text-align: right" title="Stock options outstanding">152,873</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_982_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_pid_c20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFiveMember_zPISDilIdWWd" style="border-bottom: Black 1pt solid; text-align: right" title="Stock options outstanding">152,873</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt; text-align: right"><span id="xdx_900_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_dtY_c20250101__20251231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFiveMember_zSrjI1NLSRT4" title="Weighted average remaining contractual life">1.76</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt; text-align: right"><span id="xdx_90A_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_dtY_c20240101__20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFiveMember_zLyHGUeUKmBj" title="Weighted average remaining contractual life">2.7</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_982_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_pid_c20251231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFiveMember_zuyGnM7Myfj4" style="border-bottom: Black 1pt solid; text-align: right" title="Stock options exercisable">152,873</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_988_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_pid_c20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFiveMember_zEP8FBbAyA6g" style="border-bottom: Black 1pt solid; text-align: right" title="Stock options exercisable">152,873</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: center; padding-bottom: 2.5pt"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_985_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_pid_c20251231_z6eaAg29yGij" style="border-bottom: Black 2.5pt double; text-align: right" title="Stock options outstanding">3,105,615</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_98E_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_pid_c20241231_zdQetLVNOZ78" style="border-bottom: Black 2.5pt double; text-align: right" title="Stock options outstanding">2,497,366</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt; text-align: right"> </td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt; text-align: right"> </td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_985_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_pid_c20251231_zCyJttspU2J1" style="border-bottom: Black 2.5pt double; text-align: right" title="Stock options exercisable">2,342,707</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_98B_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_pid_c20241231_zJNkzUzhwXVk" style="border-bottom: Black 2.5pt double; text-align: right" title="Stock options exercisable">1,866,523</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table>

0.00

0.99

39359

86577

P5Y7M28D

P3Y9M18D

26234

61577

1.00

3.73

2032875

1299562

P8Y3M21D

P8Y8M12D

1283092

731559

4.2

7.26

499636

577482

P5Y9M25D

P5Y10M24D

499636

539642

8.16

9.64

380872

P4Y6M21D

P5Y7M6D

380872

15.3

15.75

152873

P1Y9M3D

P2Y8M12D

152873

3105615

2497366

2342707

1866523

<p id="xdx_895_eus-gaap--ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_zeXslNJm6A1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.75in; text-align: justify">The grant date fair values of employee stock options granted in the years ended December 31, 2025 and 2024 were estimated using the Black-Scholes valuation model with the following: SCHEDULE OF STOCK OPTIONS VALUATION ASSUMPTIONS <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%; margin-left: 0.75in; margin-right: 0.5in"> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td colspan="5" style="border-bottom: Black 1pt solid; text-align: right">For the Years Ended December 31, </td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1pt"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</td><td style="padding-bottom: 1pt; font-weight: bold; text-align: left"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%; text-align: left">Expected volatility</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 16%; text-align: right"><span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_pid_dp_uPure_c20250101__20251231_zzDojm6zCBQ7" title="Expected volatility, minimum">94.0%-<span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_pid_dp_uPure_c20250101__20251231_zJbXMV5K3ysk" title="Expected volatility, maximum">102.3%</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 16%; text-align: right"><span id="xdx_909_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_pid_dp_uPure_c20240101__20241231_z2GXYbqeqmYl" title="Expected volatility, minimum">90.4%-<span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_pid_dp_uPure_c20240101__20241231_zDA7iC64zMf2" title="Expected volatility, maximum">100.7%</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Risk-free interest</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_pid_dp_uPure_c20250101__20251231_zZsQ5iMCqWaf" title="Risk-free interest, minimum">3.7%-<span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_pid_dp_uPure_c20250101__20251231_zyYmLSwFUCc8" title="Risk-free interest, maximum">4.4%</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_909_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_pid_dp_uPure_c20240101__20241231_zIq0DhTxhwI8" title="Risk-free interest, minimum">3.5%-<span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_pid_dp_uPure_c20240101__20241231_zjvBg1a6zFVe" title="Risk-free interest, maximum"> 4.3%</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Dividend yield</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Expected terms (years)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_904_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20250101__20251231__srt--RangeAxis__srt--MinimumMember_z5AImLztMX5f" title="Expected terms (years)">5.5-<span id="xdx_90B_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20250101__20251231__srt--RangeAxis__srt--MaximumMember_z0yMcCpQIjk6" title="Expected terms (years)">5.8</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_90A_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20240101__20241231__srt--RangeAxis__srt--MinimumMember_zB08Gub5AMhe" title="Expected terms (years)">5-<span id="xdx_903_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20240101__20241231__srt--RangeAxis__srt--MaximumMember_zZd2kPgvdZh8" title="Expected terms (years)">10</td><td style="text-align: left"> </td></tr> </table>

0.940

1.023

0.904

1.007

0.037

0.044

0.035

0.043

P5Y6M

P5Y9M18D

P5Y

P10Y

The remaining outstanding warrants and terms as of December 31, 2025 and 2024 are as follows: SCHEDULE OF WARRANTS OUTSTANDING <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Issuance date</td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Outstanding and exercisable as of December 31, 2025</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Outstanding and exercisable as of December 31, 2024</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Exercise Price</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: center">Exercisable Through</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 22%; text-align: left">Warrant to underwriters October 2022</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_98C_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20251231__us-gaap--StatementEquityComponentsAxis__custom--WarrantToUnderwritersOctoberTwoThousandTwentyTwoMember_z4Ug6MUoYNn3" style="width: 14%; text-align: right" title="Number of outstanding warrants">51,125</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_98A_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20241231__us-gaap--StatementEquityComponentsAxis__custom--WarrantToUnderwritersOctoberTwoThousandTwentyTwoMember_zGSqSZcflnIl" style="width: 14%; text-align: right" title="Number of outstanding warrants">51,125</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_989_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20251231__us-gaap--StatementEquityComponentsAxis__custom--WarrantToUnderwritersOctoberTwoThousandTwentyTwoMember_zXJoIenITnMh" style="width: 14%; text-align: right" title="Exercise price">6.11</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 22%; text-align: center"><span id="xdx_904_ecustom--ClassOfWarrantOrRighstMonthYearFromWhichWarrantsOrRightsExercisable_c20250101__20251231__us-gaap--StatementEquityComponentsAxis__custom--WarrantToUnderwritersOctoberTwoThousandTwentyTwoMember_zTJhRrW1Om0g" title="Exercisable Through">October 21, 2027</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Warrant to underwriters May 2023</td><td> </td> <td style="text-align: left"> </td><td id="xdx_983_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20251231__us-gaap--StatementEquityComponentsAxis__custom--WarrantToUnderwritersMayTwoThousandTwentyThreeMember_zKpVUZt0OsI6" style="text-align: right" title="Number of outstanding warrants">32,778</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_988_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20241231__us-gaap--StatementEquityComponentsAxis__custom--WarrantToUnderwritersMayTwoThousandTwentyThreeMember_zpdbSwEExF35" style="text-align: right" title="Number of outstanding warrants">32,778</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_98E_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20251231__us-gaap--StatementEquityComponentsAxis__custom--WarrantToUnderwritersMayTwoThousandTwentyThreeMember_zeAo5A0Rt3G1" style="text-align: right" title="Exercise price">2.75</td><td style="text-align: left"> </td><td> </td> <td style="text-align: center"><span id="xdx_908_ecustom--ClassOfWarrantOrRighstMonthYearFromWhichWarrantsOrRightsExercisable_c20250101__20251231__us-gaap--StatementEquityComponentsAxis__custom--WarrantToUnderwritersMayTwoThousandTwentyThreeMember_zjcm5FVWwBL9" title="Exercisable Through">November 23, 2026</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Warrant to underwriters May 2023</td><td> </td> <td style="text-align: left"> </td><td id="xdx_984_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20251231__us-gaap--StatementEquityComponentsAxis__custom--WarrantToUnderwritersMayTwoThousandTwentyThreeOneMember_zcqavep0Bx8h" style="text-align: right" title="Number of outstanding warrants">60,476</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_984_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20241231__us-gaap--StatementEquityComponentsAxis__custom--WarrantToUnderwritersMayTwoThousandTwentyThreeOneMember_zMmGhiULMkx" style="text-align: right" title="Number of outstanding warrants">60,476</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_984_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20251231__us-gaap--StatementEquityComponentsAxis__custom--WarrantToUnderwritersMayTwoThousandTwentyThreeOneMember_zk6qVSmDawa4" style="text-align: right" title="Exercise price">2.75</td><td style="text-align: left"> </td><td> </td> <td style="text-align: center"><span id="xdx_900_ecustom--ClassOfWarrantOrRighstMonthYearFromWhichWarrantsOrRightsExercisable_c20250101__20251231__us-gaap--StatementEquityComponentsAxis__custom--WarrantToUnderwritersMayTwoThousandTwentyThreeOneMember_zV6IExvr3zl5" title="Exercisable Through">November 24, 2026</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Warrant to underwriters June 2023</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98C_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20251231__us-gaap--StatementEquityComponentsAxis__custom--WarrantToUnderwritersJuneTwoThousandTwentyThreeMember_zn6pmh7Yo984" style="text-align: right" title="Number of outstanding warrants">35,088</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_987_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20241231__us-gaap--StatementEquityComponentsAxis__custom--WarrantToUnderwritersJuneTwoThousandTwentyThreeMember_zBijD2A82oX5" style="text-align: right" title="Number of outstanding warrants">35,088</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_98E_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20251231__us-gaap--StatementEquityComponentsAxis__custom--WarrantToUnderwritersJuneTwoThousandTwentyThreeMember_z2mLCjm68VE7" style="text-align: right" title="Exercise price">2.67</td><td style="text-align: left"> </td><td> </td> <td style="text-align: center"><span id="xdx_90D_ecustom--ClassOfWarrantOrRighstMonthYearFromWhichWarrantsOrRightsExercisable_c20250101__20251231__us-gaap--StatementEquityComponentsAxis__custom--WarrantToUnderwritersJuneTwoThousandTwentyThreeMember_zdL6PLs41Bjl" title="Exercisable Through">June 2, 2028</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: center"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Warrant to underwriters June 2023</td><td> </td> <td style="text-align: left"> </td><td id="xdx_983_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20251231__us-gaap--StatementEquityComponentsAxis__custom--WarrantToUnderwritersJuneTwoThousandTwentyThreeOneMember_zWOj2rjxEjQf" style="text-align: right" title="Number of outstanding warrants">31,231</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98C_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20241231__us-gaap--StatementEquityComponentsAxis__custom--WarrantToUnderwritersJuneTwoThousandTwentyThreeOneMember_zpdhqSRRmIsa" style="text-align: right" title="Number of outstanding warrants">31,231</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_985_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20251231__us-gaap--StatementEquityComponentsAxis__custom--WarrantToUnderwritersJuneTwoThousandTwentyThreeOneMember_z6BH6J7IZgrl" style="text-align: right" title="Exercise price">4.06</td><td style="text-align: left"> </td><td> </td> <td style="text-align: center"><span id="xdx_90E_ecustom--ClassOfWarrantOrRighstMonthYearFromWhichWarrantsOrRightsExercisable_c20250101__20251231__us-gaap--StatementEquityComponentsAxis__custom--WarrantToUnderwritersJuneTwoThousandTwentyThreeOneMember_zhCthBTXMeld" title="Exercisable Through">June 28, 2028</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: center"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Warrant series E January 2024</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98A_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20251231__us-gaap--StatementEquityComponentsAxis__custom--WarrantSeriesEJanuary2024Member_zf55Ovs0Hkp" style="text-align: right" title="Number of outstanding warrants">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_983_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20241231__us-gaap--StatementEquityComponentsAxis__custom--WarrantSeriesEJanuary2024Member_z9ICJxQ77QA5" style="text-align: right" title="Number of outstanding warrants">1,685,682</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_98A_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20251231__us-gaap--StatementEquityComponentsAxis__custom--WarrantSeriesEJanuary2024Member_zN434DOLjaX9" style="text-align: right" title="Exercise price">1.50</td><td style="text-align: left"> </td><td> </td> <td style="text-align: center"><span id="xdx_905_ecustom--ClassOfWarrantOrRighstMonthYearFromWhichWarrantsOrRightsExercisable_c20250101__20251231__us-gaap--StatementEquityComponentsAxis__custom--WarrantSeriesEJanuary2024Member_zE2844rRw8V6" title="Exercisable Through">July 3, 2029</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Warrant to underwriters January 2024</td><td> </td> <td style="text-align: left"> </td><td id="xdx_989_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20251231__us-gaap--StatementEquityComponentsAxis__custom--WarrantToUnderwritersJanuaryTwoThousandTwentyFourMember_zGuC1kJH4Tf8" style="text-align: right" title="Number of outstanding warrants">84,284</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_984_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20241231__us-gaap--StatementEquityComponentsAxis__custom--WarrantToUnderwritersJanuaryTwoThousandTwentyFourMember_zErIgmLUnLha" style="text-align: right" title="Number of outstanding warrants">84,284</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_98E_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20251231__us-gaap--StatementEquityComponentsAxis__custom--WarrantToUnderwritersJanuaryTwoThousandTwentyFourMember_zLczQ0ZUhAV5" style="text-align: right" title="Exercise price">2.03</td><td style="text-align: left"> </td><td> </td> <td style="text-align: center"><span id="xdx_90C_ecustom--ClassOfWarrantOrRighstMonthYearFromWhichWarrantsOrRightsExercisable_c20250101__20251231__us-gaap--StatementEquityComponentsAxis__custom--WarrantToUnderwritersJanuaryTwoThousandTwentyFourMember_z7aDDZDToVp8" title="Exercisable Through">July 3, 2029</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Warrant series F June 2024</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98D_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20251231__us-gaap--StatementEquityComponentsAxis__custom--WarrantSeriesFJune2024Member_z4tQ3HmaVFE1" style="text-align: right" title="Number of outstanding warrants">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98D_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20241231__us-gaap--StatementEquityComponentsAxis__custom--WarrantSeriesFJune2024Member_zB8FqbWM4uZ4" style="text-align: right" title="Number of outstanding warrants">3,133,338</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_981_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20251231__us-gaap--StatementEquityComponentsAxis__custom--WarrantSeriesFJune2024Member_zPqsFTklohwk" style="text-align: right" title="Exercise price">1.50</td><td style="text-align: left"> </td><td> </td> <td style="text-align: center"><span id="xdx_905_ecustom--ClassOfWarrantOrRighstMonthYearFromWhichWarrantsOrRightsExercisable_c20250101__20251231__us-gaap--StatementEquityComponentsAxis__custom--WarrantSeriesFJune2024Member_zlRlwpoE1Dfb" title="Exercisable Through">June 3, 2026</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Warrant to underwriters June 2024</td><td> </td> <td style="text-align: left"> </td><td id="xdx_981_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20251231__us-gaap--StatementEquityComponentsAxis__custom--WarrantToUnderwritersJuneTwoThousandTwentyFourMember_zIm5qP6hb5Fj" style="text-align: right" title="Number of outstanding warrants">28,102</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_981_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20241231__us-gaap--StatementEquityComponentsAxis__custom--WarrantToUnderwritersJuneTwoThousandTwentyFourMember_zrdgmgCSCqT6" style="text-align: right" title="Number of outstanding warrants">78,333</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_984_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20251231__us-gaap--StatementEquityComponentsAxis__custom--WarrantToUnderwritersJuneTwoThousandTwentyFourMember_zsT7DKy7l5n3" style="text-align: right" title="Exercise price">1.88</td><td style="text-align: left"> </td><td> </td> <td style="text-align: center"><span id="xdx_906_ecustom--ClassOfWarrantOrRighstMonthYearFromWhichWarrantsOrRightsExercisable_c20250101__20251231__us-gaap--StatementEquityComponentsAxis__custom--WarrantToUnderwritersJuneTwoThousandTwentyFourMember_z4liUsqQeotc" title="Exercisable Through">June 3, 2026</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Warrant to underwriters January 2025</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98F_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20251231__us-gaap--StatementEquityComponentsAxis__custom--WarrantToUnderwritersJanuaryTwoThousandTwentyFiveMember_zUthmwdDNBnb" style="text-align: right" title="Number of outstanding warrants">71,750</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_980_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20241231__us-gaap--StatementEquityComponentsAxis__custom--WarrantToUnderwritersJanuaryTwoThousandTwentyFiveMember_z16HcqjbCgr1" style="text-align: right" title="Number of outstanding warrants">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_98F_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20251231__us-gaap--StatementEquityComponentsAxis__custom--WarrantToUnderwritersJanuaryTwoThousandTwentyFiveMember_zR555qGDUas6" style="text-align: right" title="Exercise price">2.19</td><td style="text-align: left"> </td><td> </td> <td style="text-align: center"><span id="xdx_90E_ecustom--ClassOfWarrantOrRighstMonthYearFromWhichWarrantsOrRightsExercisable_c20250101__20251231__us-gaap--StatementEquityComponentsAxis__custom--WarrantToUnderwritersJanuaryTwoThousandTwentyFiveMember_zJG5ThDHGTG7" title="Exercisable Through">January 7, 2027</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Warrant to underwriters January 2025</td><td> </td> <td style="text-align: left"> </td><td id="xdx_988_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20251231__us-gaap--StatementEquityComponentsAxis__custom--WarrantToUnderwritersJanuaryTwoThousandTwentyFiveOneMember_zjRvP9GWXla5" style="text-align: right" title="Number of outstanding warrants">189,428</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98C_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20241231__us-gaap--StatementEquityComponentsAxis__custom--WarrantToUnderwritersJanuaryTwoThousandTwentyFiveOneMember_zLPaZ9xbQdwh" style="text-align: right" title="Number of outstanding warrants">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_987_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20251231__us-gaap--StatementEquityComponentsAxis__custom--WarrantToUnderwritersJanuaryTwoThousandTwentyFiveOneMember_z7REMEYrx6u6" style="text-align: right" title="Exercise price">2.84</td><td style="text-align: left"> </td><td> </td> <td style="text-align: center"><span id="xdx_906_ecustom--ClassOfWarrantOrRighstMonthYearFromWhichWarrantsOrRightsExercisable_c20250101__20251231__us-gaap--StatementEquityComponentsAxis__custom--WarrantToUnderwritersJanuaryTwoThousandTwentyFiveOneMember_zoVvzhS2er86" title="Exercisable Through">January 10, 2027</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Warrant to underwriters January 2025</td><td> </td> <td style="text-align: left"> </td><td id="xdx_980_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20251231__us-gaap--StatementEquityComponentsAxis__custom--WarrantToUnderwritersJanuaryTwoThousandTwentyFiveTwoMember_zovUiuaI9pwh" style="text-align: right" title="Number of outstanding warrants">30,526</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98B_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20241231__us-gaap--StatementEquityComponentsAxis__custom--WarrantToUnderwritersJanuaryTwoThousandTwentyFiveTwoMember_zJKPeh26Wy8h" style="text-align: right" title="Number of outstanding warrants">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_98B_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20251231__us-gaap--StatementEquityComponentsAxis__custom--WarrantToUnderwritersJanuaryTwoThousandTwentyFiveTwoMember_znwsYghAvo3d" style="text-align: right" title="Exercise price">1.88</td><td style="text-align: left"> </td><td> </td> <td style="text-align: center"><span id="xdx_902_ecustom--ClassOfWarrantOrRighstMonthYearFromWhichWarrantsOrRightsExercisable_c20250101__20251231__us-gaap--StatementEquityComponentsAxis__custom--WarrantToUnderwritersJanuaryTwoThousandTwentyFiveTwoMember_zE8KUlCvHNOa" title="Exercisable Through">July 8, 2030</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Warrant to underwriters February 2025</td><td> </td> <td style="text-align: left"> </td><td id="xdx_986_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20251231__us-gaap--StatementEquityComponentsAxis__custom--WarrantToUnderwritersFebruaryTwoThousandTwentyFiveTwoMember_zYDOI8xcLd3b" style="text-align: right" title="Number of outstanding warrants">109,478</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_989_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20241231__us-gaap--StatementEquityComponentsAxis__custom--WarrantToUnderwritersFebruaryTwoThousandTwentyFiveTwoMember_z2mbtLPNY9Ol" style="text-align: right" title="Number of outstanding warrants">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_988_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20251231__us-gaap--StatementEquityComponentsAxis__custom--WarrantToUnderwritersFebruaryTwoThousandTwentyFiveTwoMember_zLMWd19IsAgd" style="text-align: right" title="Exercise price">2.66</td><td style="text-align: left"> </td><td> </td> <td style="text-align: center"><span id="xdx_90E_ecustom--ClassOfWarrantOrRighstMonthYearFromWhichWarrantsOrRightsExercisable_c20250101__20251231__us-gaap--StatementEquityComponentsAxis__custom--WarrantToUnderwritersFebruaryTwoThousandTwentyFiveTwoMember_z9zm23NXLOYc" title="Exercisable Through">June 10, 2027</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Warrant to underwriters September 2025</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98D_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20251231__us-gaap--StatementEquityComponentsAxis__custom--WarrantToUnderwritersSeptemberTwoThousandTwentyFiveMember_zcTA8DkRb3o6" style="text-align: right" title="Number of outstanding warrants">10,362</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98B_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20241231__us-gaap--StatementEquityComponentsAxis__custom--WarrantToUnderwritersSeptemberTwoThousandTwentyFiveMember_zwcKhdLATRf7" style="text-align: right" title="Number of outstanding warrants">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_984_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20251231__us-gaap--StatementEquityComponentsAxis__custom--WarrantToUnderwritersSeptemberTwoThousandTwentyFiveMember_z5TeP6b81ena" style="text-align: right" title="Exercise price">1.88</td><td style="text-align: left"> </td><td> </td> <td style="text-align: center"><span id="xdx_90A_ecustom--ClassOfWarrantOrRighstMonthYearFromWhichWarrantsOrRightsExercisable_c20250101__20251231__us-gaap--StatementEquityComponentsAxis__custom--WarrantToUnderwritersSeptemberTwoThousandTwentyFiveMember_z70YKcYeu16k" title="Exercisable Through">March 16, 2028</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Warrant to underwriters September 2025</td><td> </td> <td style="text-align: left"> </td><td id="xdx_985_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20251231__us-gaap--StatementEquityComponentsAxis__custom--WarrantToUnderwritersSeptemberTwoThousandTwentyFiveOneMember_zhArCiAvPRU7" style="text-align: right" title="Number of outstanding warrants">31,429</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98D_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20241231__us-gaap--StatementEquityComponentsAxis__custom--WarrantToUnderwritersSeptemberTwoThousandTwentyFiveOneMember_z5P3JvbE41ki" style="text-align: right" title="Number of outstanding warrants">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_98A_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20251231__us-gaap--StatementEquityComponentsAxis__custom--WarrantToUnderwritersSeptemberTwoThousandTwentyFiveOneMember_zF2FnAaXM9ma" style="text-align: right" title="Exercise price">2.12</td><td style="text-align: left"> </td><td> </td> <td style="text-align: center"><span id="xdx_907_ecustom--ClassOfWarrantOrRighstMonthYearFromWhichWarrantsOrRightsExercisable_c20250101__20251231__us-gaap--StatementEquityComponentsAxis__custom--WarrantToUnderwritersSeptemberTwoThousandTwentyFiveOneMember_zKg74X9b9qxd" title="Exercisable Through">March 16, 2028</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Warrant to underwriters September 2025</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98E_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20251231__us-gaap--StatementEquityComponentsAxis__custom--WarrantToUnderwritersSeptemberTwoThousandTwentyFiveTwoMember_zw9vQiAzS474" style="text-align: right" title="Number of outstanding warrants">138,906</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_982_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20241231__us-gaap--StatementEquityComponentsAxis__custom--WarrantToUnderwritersSeptemberTwoThousandTwentyFiveTwoMember_zUmDe7RKTp5g" style="text-align: right" title="Number of outstanding warrants">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_980_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20251231__us-gaap--StatementEquityComponentsAxis__custom--WarrantToUnderwritersSeptemberTwoThousandTwentyFiveTwoMember_zHHIGLgdatX4" style="text-align: right" title="Exercise price">2.62</td><td style="text-align: left"> </td><td> </td> <td style="text-align: center"><span id="xdx_907_ecustom--ClassOfWarrantOrRighstMonthYearFromWhichWarrantsOrRightsExercisable_c20250101__20251231__us-gaap--StatementEquityComponentsAxis__custom--WarrantToUnderwritersSeptemberTwoThousandTwentyFiveTwoMember_zy7gKk1ZVQN9" title="Exercisable Through">March 16, 2028</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Warrant to underwriters September 2025</td><td> </td> <td style="text-align: left"> </td><td id="xdx_980_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20251231__us-gaap--StatementEquityComponentsAxis__custom--WarrantToUnderwritersSeptemberTwoThousandTwentyFiveThreeMember_zBLFDW4xLSLf" style="text-align: right" title="Number of outstanding warrants">422,535</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_980_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20241231__us-gaap--StatementEquityComponentsAxis__custom--WarrantToUnderwritersSeptemberTwoThousandTwentyFiveThreeMember_zCOLiEHgPqVe" style="text-align: right" title="Number of outstanding warrants">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_982_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20251231__us-gaap--StatementEquityComponentsAxis__custom--WarrantToUnderwritersSeptemberTwoThousandTwentyFiveThreeMember_zpODHdVn7Lwk" style="text-align: right" title="Exercise price">2.66</td><td style="text-align: left"> </td><td> </td> <td style="text-align: center"><span id="xdx_905_ecustom--ClassOfWarrantOrRighstMonthYearFromWhichWarrantsOrRightsExercisable_c20250101__20251231__us-gaap--StatementEquityComponentsAxis__custom--WarrantToUnderwritersSeptemberTwoThousandTwentyFiveThreeMember_zN885O7SjQe8" title="Exercisable Through">March 16, 2028</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Warrant to underwriters September 2025</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98D_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20251231__us-gaap--StatementEquityComponentsAxis__custom--WarrantToUnderwritersSeptemberTwoThousandTwentyFiveFourMember_zox7alya8Cq4" style="text-align: right" title="Number of outstanding warrants">30,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_985_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20241231__us-gaap--StatementEquityComponentsAxis__custom--WarrantToUnderwritersSeptemberTwoThousandTwentyFiveFourMember_zPujEtkJjYm1" style="text-align: right" title="Number of outstanding warrants">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_982_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20251231__us-gaap--StatementEquityComponentsAxis__custom--WarrantToUnderwritersSeptemberTwoThousandTwentyFiveFourMember_zgjwOxFm4I5i" style="text-align: right" title="Exercise price">2.62</td><td style="text-align: left"> </td><td> </td> <td style="text-align: center"><span id="xdx_908_ecustom--ClassOfWarrantOrRighstMonthYearFromWhichWarrantsOrRightsExercisable_c20250101__20251231__us-gaap--StatementEquityComponentsAxis__custom--WarrantToUnderwritersSeptemberTwoThousandTwentyFiveFourMember_ziHlqgoZYqM1" title="Exercisable Through">March 29, 2028</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Warrant to underwriters September 2025</td><td> </td> <td style="text-align: left"> </td><td id="xdx_984_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20251231__us-gaap--StatementEquityComponentsAxis__custom--WarrantToUnderwritersSeptemberTwoThousandTwentyFiveFiveMember_ztio3Zo0Hnq4" style="text-align: right" title="Number of outstanding warrants">53,758</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_985_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20241231__us-gaap--StatementEquityComponentsAxis__custom--WarrantToUnderwritersSeptemberTwoThousandTwentyFiveFiveMember_z2Oyh8lokeo6" style="text-align: right" title="Number of outstanding warrants">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_986_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20251231__us-gaap--StatementEquityComponentsAxis__custom--WarrantToUnderwritersSeptemberTwoThousandTwentyFiveFiveMember_ztpSMXWRwdDh" style="text-align: right" title="Exercise price">1,88</td><td style="text-align: left"> </td><td> </td> <td style="text-align: center"><span id="xdx_901_ecustom--ClassOfWarrantOrRighstMonthYearFromWhichWarrantsOrRightsExercisable_c20250101__20251231__us-gaap--StatementEquityComponentsAxis__custom--WarrantToUnderwritersSeptemberTwoThousandTwentyFiveFiveMember_zyWPUSd6U1y" title="Exercisable Through">March 16, 2031</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Warrant to underwriters September 2025</td><td> </td> <td style="text-align: left"> </td><td id="xdx_988_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20251231__us-gaap--StatementEquityComponentsAxis__custom--WarrantToUnderwritersSeptemberTwoThousandTwentyFiveSixMember_z9GsrcuUJQj4" style="text-align: right" title="Number of outstanding warrants">146,306</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_983_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20241231__us-gaap--StatementEquityComponentsAxis__custom--WarrantToUnderwritersSeptemberTwoThousandTwentyFiveSixMember_znbSMSQyd97f" style="text-align: right" title="Number of outstanding warrants">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_983_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20251231__us-gaap--StatementEquityComponentsAxis__custom--WarrantToUnderwritersSeptemberTwoThousandTwentyFiveSixMember_zq6mxkZGlRdi" style="text-align: right" title="Exercise price">1.88</td><td style="text-align: left"> </td><td> </td> <td style="text-align: center"><span id="xdx_906_ecustom--ClassOfWarrantOrRighstMonthYearFromWhichWarrantsOrRightsExercisable_c20250101__20251231__us-gaap--StatementEquityComponentsAxis__custom--WarrantToUnderwritersSeptemberTwoThousandTwentyFiveSixMember_ztm91kz5Xfh4" title="Exercisable Through">September 16, 2027</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Warrant to underwriters September 2025</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98E_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20251231__us-gaap--StatementEquityComponentsAxis__custom--WarrantToUnderwritersSeptemberTwoThousandTwentyFiveSevenMember_z4MHSik3OvIh" style="text-align: right" title="Number of outstanding warrants">368,572</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_987_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20241231__us-gaap--StatementEquityComponentsAxis__custom--WarrantToUnderwritersSeptemberTwoThousandTwentyFiveSevenMember_zRlAbU0tyiye" style="text-align: right" title="Number of outstanding warrants">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_985_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20251231__us-gaap--StatementEquityComponentsAxis__custom--WarrantToUnderwritersSeptemberTwoThousandTwentyFiveSevenMember_z4jHEDWQHzCg" style="text-align: right" title="Exercise price">2.12</td><td style="text-align: left"> </td><td> </td> <td style="text-align: center"><span id="xdx_90E_ecustom--ClassOfWarrantOrRighstMonthYearFromWhichWarrantsOrRightsExercisable_c20250101__20251231__us-gaap--StatementEquityComponentsAxis__custom--WarrantToUnderwritersSeptemberTwoThousandTwentyFiveSevenMember_zgHBB2zmcTx1" title="Exercisable Through">September 16, 2027</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Warrant to underwriters September 2025</td><td> </td> <td style="text-align: left"> </td><td id="xdx_988_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20251231__us-gaap--StatementEquityComponentsAxis__custom--WarrantToUnderwritersSeptemberTwoThousandTwentyFiveEightMember_zTN1jdVh00a8" style="text-align: right" title="Number of outstanding warrants">143,723</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_981_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20241231__us-gaap--StatementEquityComponentsAxis__custom--WarrantToUnderwritersSeptemberTwoThousandTwentyFiveEightMember_zvF9qF6r5or8" style="text-align: right" title="Number of outstanding warrants">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_987_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20251231__us-gaap--StatementEquityComponentsAxis__custom--WarrantToUnderwritersSeptemberTwoThousandTwentyFiveEightMember_zm5oe5CKZiC6" style="text-align: right" title="Exercise price">2.63</td><td style="text-align: left"> </td><td> </td> <td style="text-align: center"><span id="xdx_902_ecustom--ClassOfWarrantOrRighstMonthYearFromWhichWarrantsOrRightsExercisable_c20250101__20251231__us-gaap--StatementEquityComponentsAxis__custom--WarrantToUnderwritersSeptemberTwoThousandTwentyFiveEightMember_z3WQBqoGLWOh" title="Exercisable Through">September 16, 2027</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Warrant to underwriters September 2025</td><td> </td> <td style="text-align: left"> </td><td id="xdx_985_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20251231__us-gaap--StatementEquityComponentsAxis__custom--WarrantToUnderwritersSeptemberTwoThousandTwentyFiveNineMember_zNTlBfF8lQ3e" style="text-align: right" title="Number of outstanding warrants">187,794</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98C_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20241231__us-gaap--StatementEquityComponentsAxis__custom--WarrantToUnderwritersSeptemberTwoThousandTwentyFiveNineMember_zAOMOVbNIp5e" style="text-align: right" title="Number of outstanding warrants">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_985_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20251231__us-gaap--StatementEquityComponentsAxis__custom--WarrantToUnderwritersSeptemberTwoThousandTwentyFiveNineMember_ziTHLaNdeMb4" style="text-align: right" title="Exercise price">2.66</td><td style="text-align: left"> </td><td> </td> <td style="text-align: center"><span id="xdx_905_ecustom--ClassOfWarrantOrRighstMonthYearFromWhichWarrantsOrRightsExercisable_c20250101__20251231__us-gaap--StatementEquityComponentsAxis__custom--WarrantToUnderwritersSeptemberTwoThousandTwentyFiveNineMember_zUKmb6k6kXWg" title="Exercisable Through">September 16, 2027</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Warrant series J September 2025</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98C_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20251231__us-gaap--StatementEquityComponentsAxis__custom--WarrantSeriesJSeptemberTwoThousandTwentyFiveMember_zGDPDNPAldql" style="text-align: right" title="Number of outstanding warrants">12,064,627</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_984_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20241231__us-gaap--StatementEquityComponentsAxis__custom--WarrantSeriesJSeptemberTwoThousandTwentyFiveMember_zn6TGRpO80m1" style="text-align: right" title="Number of outstanding warrants">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_983_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20251231__us-gaap--StatementEquityComponentsAxis__custom--WarrantSeriesJSeptemberTwoThousandTwentyFiveMember_zXA3np5OxOAd" style="text-align: right" title="Exercise price">4.50</td><td style="text-align: left"> </td><td> </td> <td style="text-align: center"><span id="xdx_900_ecustom--ClassOfWarrantOrRighstMonthYearFromWhichWarrantsOrRightsExercisable_c20250101__20251231__us-gaap--StatementEquityComponentsAxis__custom--WarrantSeriesJSeptemberTwoThousandTwentyFiveMember_zp1RAop3lgkj" title="Exercisable Through">March 16, 2028</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Warrant series J September 2025</td><td> </td> <td style="text-align: left"> </td><td id="xdx_989_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20251231__us-gaap--StatementEquityComponentsAxis__custom--WarrantSeriesJOneSeptemberTwoThousandTwentyFiveMember_z9YRqWNu8QJ" style="text-align: right" title="Number of outstanding warrants">600,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98D_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20241231__us-gaap--StatementEquityComponentsAxis__custom--WarrantSeriesJOneSeptemberTwoThousandTwentyFiveMember_znCAsPcAsuDd" style="text-align: right" title="Number of outstanding warrants">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_983_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20251231__us-gaap--StatementEquityComponentsAxis__custom--WarrantSeriesJOneSeptemberTwoThousandTwentyFiveMember_zJtFvMqTf2Lc" style="text-align: right" title="Exercise price">4.50</td><td style="text-align: left"> </td><td> </td> <td style="text-align: center"><span id="xdx_906_ecustom--ClassOfWarrantOrRighstMonthYearFromWhichWarrantsOrRightsExercisable_c20250101__20251231__us-gaap--StatementEquityComponentsAxis__custom--WarrantSeriesJOneSeptemberTwoThousandTwentyFiveMember_zUwl2Wfl5aD" title="Exercisable Through">March 29, 2028</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Warrant series J October 2025</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98F_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20251231__us-gaap--StatementEquityComponentsAxis__custom--WarrantSeriesJOctoberTwoThousandTwentyFiveOneMember_znwX9XqCCir8" style="text-align: right" title="Number of outstanding warrants">1,324,488</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_982_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20241231__us-gaap--StatementEquityComponentsAxis__custom--WarrantSeriesJOctoberTwoThousandTwentyFiveOneMember_zgT2ZHSBr13d" style="text-align: right" title="Number of outstanding warrants">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_981_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20251231__us-gaap--StatementEquityComponentsAxis__custom--WarrantSeriesJOctoberTwoThousandTwentyFiveOneMember_z2OGx54bWud5" style="text-align: right" title="Exercise price">4.50</td><td style="text-align: left"> </td><td> </td> <td style="text-align: center"><span id="xdx_905_ecustom--ClassOfWarrantOrRighstMonthYearFromWhichWarrantsOrRightsExercisable_c20250101__20251231__us-gaap--StatementEquityComponentsAxis__custom--WarrantSeriesJOctoberTwoThousandTwentyFiveOneMember_zSwQTLspHRnh" title="Exercisable Through">April 6, 2028</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1pt; text-align: left">Warrant series J October 2025</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: right"> </td><td style="border-bottom: Black 1pt solid; text-align: right" title="Number of outstanding warrants"><p id="xdx_98B_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20251231__us-gaap--StatementEquityComponentsAxis__custom--WarrantSeriesJOctoberTwoThousandTwentyFiveTwoMember_z8cj8kf4Zcg8" style="margin: 0" title="Number of outstanding warrants">66,224</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: right"> </td><td style="border-bottom: Black 1pt solid; text-align: right" title="Number of outstanding warrants"><p id="xdx_989_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20241231__us-gaap--StatementEquityComponentsAxis__custom--WarrantSeriesJOctoberTwoThousandTwentyFiveTwoMember_zdbjXFhsONQi" style="margin: 0" title="Number of outstanding warrants">-</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt; text-align: left">$</td><td style="padding-bottom: 1pt; text-align: right" title="Exercise price"><p id="xdx_985_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20251231__us-gaap--StatementEquityComponentsAxis__custom--WarrantSeriesJOctoberTwoThousandTwentyFiveTwoMember_zB6iVjgA02jh" style="margin: 0" title="Exercise price">2.66</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt; text-align: center"><span id="xdx_901_ecustom--ClassOfWarrantOrRighstMonthYearFromWhichWarrantsOrRightsExercisable_c20250101__20251231__us-gaap--StatementEquityComponentsAxis__custom--WarrantSeriesJOctoberTwoThousandTwentyFiveTwoMember_zIie8aZCfFsh" title="Exercisable Through">April 6, 2028</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: right"> </td><td style="border-bottom: Black 2.5pt double; text-align: right" title="Number of outstanding warrants">16,312,990</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: right"> </td><td id="xdx_982_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20241231_zJKpqHx0fB46" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of outstanding warrants">5,192,335</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt; text-align: right" title="Exercise price"> </td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; text-align: center"> </td></tr> </table>

51125

6.11

October 21, 2027

32778

2.75

November 23, 2026

60476

2.75

November 24, 2026

35088

2.67

June 2, 2028

31231

4.06

June 28, 2028

1685682

1.50

July 3, 2029

84284

2.03

July 3, 2029

3133338

1.50

June 3, 2026

28102

78333

1.88

June 3, 2026

71750

2.19

January 7, 2027

189428

2.84

January 10, 2027

30526

1.88

July 8, 2030

109478

2.66

June 10, 2027

10362

1.88

March 16, 2028

31429

2.12

March 16, 2028

138906

2.62

March 16, 2028

422535

2.66

March 16, 2028

30000

2.62

March 29, 2028

53758

1.88

March 16, 2031

146306

1.88

September 16, 2027

368572

2.12

September 16, 2027

143723

2.63

September 16, 2027

187794

2.66

September 16, 2027

12064627

4.50

March 16, 2028

600000

4.50

March 29, 2028

1324488

4.50

April 6, 2028

66224

2.66

April 6, 2028

16312990

5192335

NOTE 12 - BASIC AND DILUTED NET LOSS PER SHARE The basic and diluted net loss per share and weighted average number of shares of common stock used in the calculation of basic and diluted net loss per share were presented in the consolidated statements of comprehensive loss for the years ended December 31, 2025 and 2024. In the calculation of the basic and diluted net loss, the Company included warrants that would be exercised for no or little consideration and are exercisable with no contingencies. Due to the net loss to common shareholders in each of the periods presented above, diluted loss per share was computed without consideration to potentially dilutive instruments as their inclusion would have been anti-dilutive. As of December 31, 2025 and 2024, potentially dilutive securities excluded from the diluted loss per share calculation are 19,418,605 and 7,689,701, respectively.

19418605

7689701

NOTE 13 - RESEARCH AND DEVELOPMENT EXPENSES, NET <p id="xdx_890_eus-gaap--ScheduleOfResearchAndDevelopmentAssetsAcquiredOtherThanThroughBusinessCombinationTextBlock_zShtIg02vANj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">SCHEDULE OF RESEARCH AND DEVELOPMENT EXPENSES <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%; margin-left: 0.75in; margin-right: 0.5in"> <tr style="display: none; vertical-align: bottom"> <td style="display: none; text-align: center"> </td><td style="display: none; text-align: center; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_49E_20250101__20251231__custom--StatementOfIncomeLocationBalanceAxis__custom--ResearchAndDevelopmentExpensesMember_zMGgdWJsOeE6" style="border-bottom: Black 1pt solid; display: none; font-weight: bold; text-align: center"> </td><td style="display: none; text-align: center; padding-bottom: 1pt; font-weight: bold"> </td><td style="display: none; text-align: center; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_49B_20240101__20241231__custom--StatementOfIncomeLocationBalanceAxis__custom--ResearchAndDevelopmentExpensesMember_zrBr3U7RGIwc" style="border-bottom: Black 1pt solid; display: none; font-weight: bold; text-align: center"> </td><td style="display: none; text-align: center; padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; text-align: center">For the Years Ended December 31,</td><td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: left"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr id="xdx_404_eus-gaap--LaborAndRelatedExpense_iN_di_maRADEzGXN_zRsMpRmuRP0g" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%; text-align: left">Payroll and related expenses</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">(3,688</td><td style="width: 1%; text-align: left">)</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">(3,382</td><td style="width: 1%; text-align: left">)</td></tr> <tr id="xdx_406_eus-gaap--ShareBasedCompensation_iN_di_maRADEzGXN_ztwT8LRn2T6j" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Share-based compensation</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(230</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(292</td><td style="text-align: left">)</td></tr> <tr id="xdx_40F_eus-gaap--CostDirectMaterial_iN_di_maRADEzGXN_zYDvw3DO4Huf" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Materials and subcontractors</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(1,898</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(2,165</td><td style="text-align: left">)</td></tr> <tr id="xdx_409_eus-gaap--RoyaltyExpense_iN_di_maRADEzGXN_zMjXGYR6sU7i" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Patents</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(171</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(178</td><td style="text-align: left">)</td></tr> <tr id="xdx_408_eus-gaap--OtherResearchAndDevelopmentExpense_iN_di_maRADEzGXN_zAYajXWy7yLj" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Rent</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(270</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(225</td><td style="text-align: left">)</td></tr> <tr id="xdx_405_ecustom--OfficeAndMaintenanceExpenses_iN_di_maRADEzGXN_zkqCfotUPNr7" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Office and maintenance expenses</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(122</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(67</td><td style="text-align: left">)</td></tr> <tr id="xdx_401_eus-gaap--Depreciation_iN_di_maRADEzGXN_zPl3t8UaIbDl" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Depreciation</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(43</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(93</td><td style="text-align: left">)</td></tr> <tr id="xdx_40F_eus-gaap--OtherExpenses_iN_di_maRADEzGXN_zY3AR1fhjZEh" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Other</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(357</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(377</td><td style="text-align: left">)</td></tr> <tr id="xdx_40E_ecustom--Grants_msRADEzGXN_zfGmh27MP2f" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1pt">Less - grants</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">496</td><td style="padding-bottom: 1pt; text-align: left"></td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">149</td><td style="padding-bottom: 1pt; text-align: left"></td></tr> <tr id="xdx_406_eus-gaap--ResearchAndDevelopmentExpense_iNT_pn3n3_di_mtRADEzGXN_zDuEJ3cjL5Ai" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 2.5pt">Research and development expense</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(6,283</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(6,630</td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr> </table>

<p id="xdx_890_eus-gaap--ScheduleOfResearchAndDevelopmentAssetsAcquiredOtherThanThroughBusinessCombinationTextBlock_zShtIg02vANj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">SCHEDULE OF RESEARCH AND DEVELOPMENT EXPENSES <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%; margin-left: 0.75in; margin-right: 0.5in"> <tr style="display: none; vertical-align: bottom"> <td style="display: none; text-align: center"> </td><td style="display: none; text-align: center; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_49E_20250101__20251231__custom--StatementOfIncomeLocationBalanceAxis__custom--ResearchAndDevelopmentExpensesMember_zMGgdWJsOeE6" style="border-bottom: Black 1pt solid; display: none; font-weight: bold; text-align: center"> </td><td style="display: none; text-align: center; padding-bottom: 1pt; font-weight: bold"> </td><td style="display: none; text-align: center; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_49B_20240101__20241231__custom--StatementOfIncomeLocationBalanceAxis__custom--ResearchAndDevelopmentExpensesMember_zrBr3U7RGIwc" style="border-bottom: Black 1pt solid; display: none; font-weight: bold; text-align: center"> </td><td style="display: none; text-align: center; padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; text-align: center">For the Years Ended December 31,</td><td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: left"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr id="xdx_404_eus-gaap--LaborAndRelatedExpense_iN_di_maRADEzGXN_zRsMpRmuRP0g" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%; text-align: left">Payroll and related expenses</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">(3,688</td><td style="width: 1%; text-align: left">)</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">(3,382</td><td style="width: 1%; text-align: left">)</td></tr> <tr id="xdx_406_eus-gaap--ShareBasedCompensation_iN_di_maRADEzGXN_ztwT8LRn2T6j" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Share-based compensation</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(230</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(292</td><td style="text-align: left">)</td></tr> <tr id="xdx_40F_eus-gaap--CostDirectMaterial_iN_di_maRADEzGXN_zYDvw3DO4Huf" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Materials and subcontractors</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(1,898</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(2,165</td><td style="text-align: left">)</td></tr> <tr id="xdx_409_eus-gaap--RoyaltyExpense_iN_di_maRADEzGXN_zMjXGYR6sU7i" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Patents</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(171</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(178</td><td style="text-align: left">)</td></tr> <tr id="xdx_408_eus-gaap--OtherResearchAndDevelopmentExpense_iN_di_maRADEzGXN_zAYajXWy7yLj" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Rent</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(270</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(225</td><td style="text-align: left">)</td></tr> <tr id="xdx_405_ecustom--OfficeAndMaintenanceExpenses_iN_di_maRADEzGXN_zkqCfotUPNr7" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Office and maintenance expenses</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(122</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(67</td><td style="text-align: left">)</td></tr> <tr id="xdx_401_eus-gaap--Depreciation_iN_di_maRADEzGXN_zPl3t8UaIbDl" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Depreciation</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(43</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(93</td><td style="text-align: left">)</td></tr> <tr id="xdx_40F_eus-gaap--OtherExpenses_iN_di_maRADEzGXN_zY3AR1fhjZEh" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Other</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(357</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(377</td><td style="text-align: left">)</td></tr> <tr id="xdx_40E_ecustom--Grants_msRADEzGXN_zfGmh27MP2f" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1pt">Less - grants</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">496</td><td style="padding-bottom: 1pt; text-align: left"></td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">149</td><td style="padding-bottom: 1pt; text-align: left"></td></tr> <tr id="xdx_406_eus-gaap--ResearchAndDevelopmentExpense_iNT_pn3n3_di_mtRADEzGXN_zDuEJ3cjL5Ai" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 2.5pt">Research and development expense</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(6,283</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(6,630</td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr> </table>

3688000

3382000

230000

292000

1898000

2165000

171000

178000

270000

225000

122000 67000

43000

93000

357000

377000

496000 149000

6283000

6630000

NOTE 14 – SALES, GENERAL AND ADMINISTRATIVE EXPENSES SCHEDULE OF GENERAL AND ADMINISTRATIVE EXPENSES <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%; margin-left: 0.75in; margin-right: 0.5in"> <tr style="display: none; vertical-align: bottom"> <td style="display: none; text-align: center"> </td><td style="display: none; text-align: center; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_490_20250101__20251231__custom--StatementOfIncomeLocationBalanceAxis__custom--SalesGeneralAndAdministrativeExpensesMember_z6YXgMn1JThe" style="border-bottom: Black 1pt solid; display: none; font-weight: bold; text-align: center"> </td><td style="display: none; text-align: center; padding-bottom: 1pt; font-weight: bold"> </td><td style="display: none; text-align: center; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_493_20240101__20241231__custom--StatementOfIncomeLocationBalanceAxis__custom--SalesGeneralAndAdministrativeExpensesMember_z4nI0JKsYifj" style="border-bottom: Black 1pt solid; display: none; font-weight: bold; text-align: center"> </td><td style="display: none; text-align: center; padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">For the Years Ended December 31,</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: left"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr id="xdx_401_eus-gaap--LaborAndRelatedExpense_iN_di_maGAAEzja1_zHcUUyWe2PVe" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%; text-align: left">Payroll and related expenses</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">(3,747</td><td style="width: 1%; text-align: left">)</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">(1,994</td><td style="width: 1%; text-align: left">)</td></tr> <tr id="xdx_405_ecustom--GovernmentalFees_iN_di_maGAAEzja1_zk9v6WuN8gx7" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Government fees</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(42</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td></tr> <tr id="xdx_409_eus-gaap--ShareBasedCompensation_iN_di_maGAAEzja1_zOb7u4ODLlIb" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Share-based compensation</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(827</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(1,057</td><td style="text-align: left">)</td></tr> <tr id="xdx_40F_eus-gaap--ProfessionalFees_iN_di_maGAAEzja1_zhZJ1jBvRgZg" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Professional services</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(1,971</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(1,059</td><td style="text-align: left">)</td></tr> <tr id="xdx_40A_eus-gaap--GeneralInsuranceExpense_iN_di_maGAAEzja1_zxE6im4SUcqa" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Insurance</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(393</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(442</td><td style="text-align: left">)</td></tr> <tr id="xdx_404_ecustom--PublicAndInvestorRelationsExpenses_iN_di_maGAAEzja1_zYnUt4nJnLDk" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Public and investor relations</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(197</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(132</td><td style="text-align: left">)</td></tr> <tr id="xdx_40A_ecustom--OfficeAndMaintenanceExpenses_iN_di_maGAAEzja1_zz9FOcQY3vfc" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Office and maintenance expenses</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(213</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(74</td><td style="text-align: left">)</td></tr> <tr id="xdx_406_eus-gaap--TravelAndEntertainmentExpense_iN_di_maGAAEzja1_zpVcgujAbfg1" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Travel</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(335</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(84</td><td style="text-align: left">)</td></tr> <tr id="xdx_408_eus-gaap--OtherGeneralAndAdministrativeExpense_iN_di_maGAAEzja1_z4KNsfgTZMFi" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1pt; text-align: left">Other</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(735</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(153</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr> <tr id="xdx_40E_eus-gaap--GeneralAndAdministrativeExpense_iNT_pn3n3_di_mtGAAEzja1_zPamJRyOZ4Ri" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 2.5pt">General and administrative expenses</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(8,460</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(4,995</td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr> </table> MICROBOT MEDICAL INC. NOTES TO CONSOLIDATED FINANCIAL STATEMENTS U.S. dollars in thousands (Except share and per share data) SCHEDULE OF GENERAL AND ADMINISTRATIVE EXPENSES <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%; margin-left: 0.75in; margin-right: 0.5in"> <tr style="display: none; vertical-align: bottom"> <td style="display: none; text-align: center"> </td><td style="display: none; text-align: center; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_490_20250101__20251231__custom--StatementOfIncomeLocationBalanceAxis__custom--SalesGeneralAndAdministrativeExpensesMember_z6YXgMn1JThe" style="border-bottom: Black 1pt solid; display: none; font-weight: bold; text-align: center"> </td><td style="display: none; text-align: center; padding-bottom: 1pt; font-weight: bold"> </td><td style="display: none; text-align: center; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_493_20240101__20241231__custom--StatementOfIncomeLocationBalanceAxis__custom--SalesGeneralAndAdministrativeExpensesMember_z4nI0JKsYifj" style="border-bottom: Black 1pt solid; display: none; font-weight: bold; text-align: center"> </td><td style="display: none; text-align: center; padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">For the Years Ended December 31,</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: left"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr id="xdx_401_eus-gaap--LaborAndRelatedExpense_iN_di_maGAAEzja1_zHcUUyWe2PVe" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%; text-align: left">Payroll and related expenses</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">(3,747</td><td style="width: 1%; text-align: left">)</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">(1,994</td><td style="width: 1%; text-align: left">)</td></tr> <tr id="xdx_405_ecustom--GovernmentalFees_iN_di_maGAAEzja1_zk9v6WuN8gx7" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Government fees</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(42</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td></tr> <tr id="xdx_409_eus-gaap--ShareBasedCompensation_iN_di_maGAAEzja1_zOb7u4ODLlIb" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Share-based compensation</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(827</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(1,057</td><td style="text-align: left">)</td></tr> <tr id="xdx_40F_eus-gaap--ProfessionalFees_iN_di_maGAAEzja1_zhZJ1jBvRgZg" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Professional services</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(1,971</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(1,059</td><td style="text-align: left">)</td></tr> <tr id="xdx_40A_eus-gaap--GeneralInsuranceExpense_iN_di_maGAAEzja1_zxE6im4SUcqa" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Insurance</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(393</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(442</td><td style="text-align: left">)</td></tr> <tr id="xdx_404_ecustom--PublicAndInvestorRelationsExpenses_iN_di_maGAAEzja1_zYnUt4nJnLDk" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Public and investor relations</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(197</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(132</td><td style="text-align: left">)</td></tr> <tr id="xdx_40A_ecustom--OfficeAndMaintenanceExpenses_iN_di_maGAAEzja1_zz9FOcQY3vfc" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Office and maintenance expenses</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(213</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(74</td><td style="text-align: left">)</td></tr> <tr id="xdx_406_eus-gaap--TravelAndEntertainmentExpense_iN_di_maGAAEzja1_zpVcgujAbfg1" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Travel</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(335</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(84</td><td style="text-align: left">)</td></tr> <tr id="xdx_408_eus-gaap--OtherGeneralAndAdministrativeExpense_iN_di_maGAAEzja1_z4KNsfgTZMFi" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1pt; text-align: left">Other</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(735</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(153</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr> <tr id="xdx_40E_eus-gaap--GeneralAndAdministrativeExpense_iNT_pn3n3_di_mtGAAEzja1_zPamJRyOZ4Ri" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 2.5pt">General and administrative expenses</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(8,460</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(4,995</td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr> </table>

3747000

1994000

42000

827000

1057000

1971000

1059000

393000

442000

197000 132000 213000 74000

335000

84000

735000

153000

8460000

4995000

NOTE 15 – SEGMENT REPORTING Segment information is prepared on the same basis that the Company’s chief operating decision maker (“CODM”), the Chief Executive Officer, manages the business, makes business decisions and assesses performance. The Company has one operating and reportable segment, which is the development of robotic devices for endoluminal surgery. See Note 1A for further details. The CODM assesses performance for this segment and decides how to allocate resources based on net loss. The measure of segment assets is reported on the balance sheet as cash and cash equivalents and marketable securities. The chief executive officer performs the assessment of segment performance by using the reported measure of segment loss to monitor actual results. The table below summarizes the significant expense categories regularly reviewed by the CODM for the years ended December 31, 2025 and 2024: SCHEDULE OF STATEMENT OF OPERATION BY SEGMENT <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%; margin-left: 0.75in; margin-right: 0.5in"> <tr style="display: none; vertical-align: bottom"> <td style="display: none"> </td><td style="display: none; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_494_20250101__20251231_zSu7iIjKezOb" style="border-bottom: Black 1pt solid; display: none; font-weight: bold; text-align: center">2025</td><td style="display: none; padding-bottom: 1pt; font-weight: bold"> </td><td style="display: none; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_492_20240101__20241231_zVuOu5xnvbN5" style="border-bottom: Black 1pt solid; display: none; font-weight: bold; text-align: center">2024</td><td style="display: none; padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: left"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Year Ended December 31,</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: left"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Significant segment expenses</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_405_ecustom--PayrollAndPayrollRelated_maNILzcOv_zhWkfl4JK5Qe" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 20pt; width: 60%; text-align: left">Payroll and payroll related</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">(7,435</td><td style="width: 1%; text-align: left">)</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">(5,376</td><td style="width: 1%; text-align: left">)</td></tr> <tr id="xdx_404_ecustom--MaterialsAndSubcontractors_maNILzcOv_zmWHgPSFRQM5" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 20pt; text-align: left">Materials and subcontractors</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(1,898</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(2,165</td><td style="text-align: left">)</td></tr> <tr id="xdx_402_eus-gaap--ShareBasedCompensation_iN_di_msNILzcOv_zkCR8qcfiut2" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 20pt; text-align: left">Share-based compensation</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(1,057</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(1,349</td><td style="text-align: left">)</td></tr> <tr id="xdx_407_eus-gaap--SegmentReportingOtherItemAmount_iN_di_msNILzcOv_z6bCCV7tJsuh" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 20pt; text-align: left; padding-bottom: 1pt">Other segment items (*)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(2,752</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(2,553</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr> <tr id="xdx_406_eus-gaap--NetIncomeLoss_iT_mtNILzcOv_zJMV1NDTDfS1" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; text-align: left; padding-bottom: 2.5pt">Net loss</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(13,142</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(11,443</td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr> </table> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="width: 0.75in"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: right">(*)</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Other segment expense items included within net loss include professional services, patents, overhead and depreciation, travel expenses, financial income, net, other income and other miscellaneous expenses net of grants received. See the consolidated financial statements for other financial information regarding the Company’s operating segment.</td></tr> </table> <p id="xdx_89A_ecustom--ScheduleOfLongLivedAssetsAndOperatingLeaseRightOfUseAssetsByGeographicalAreasTableTextBlock_zJOom3kqr1Uc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.75in; text-align: justify">Long-lived assets and operating lease right-of-use assets by geographical areas were as follows: SCHEDULE OF LONG LIVED ASSETS AND OPERATING LEASE RIGHT OF USE ASSETS BY GEOGRAPHICAL AREAS <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%; margin-left: 0.75in; margin-right: 0.5in"> <tr style="display: none; vertical-align: bottom"> <td style="display: none; font-size: 12pt"> </td><td style="display: none; font-weight: bold"> </td> <td colspan="2" id="xdx_496_20251231_zzA8hm9Izhs7" style="border-bottom: Black 1pt solid; display: none; font-weight: bold; text-align: center">2024</td><td style="display: none; font-weight: bold"> </td><td style="display: none; font-weight: bold"> </td> <td colspan="2" id="xdx_49D_20241231_zOPnu4NbPUl9" style="border-bottom: Black 1pt solid; display: none; font-weight: bold; text-align: center">2023</td><td style="display: none; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: left"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">As of December 31,</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: left"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr id="xdx_40D_ecustom--LongLivedAssetsAndOperatingLeaseRightOfUseAssets_iI_hsrt--StatementGeographicalAxis__country--IL_zsrIbesTIVB7" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; width: 60%">Israel</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">885</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">209</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_407_ecustom--LongLivedAssetsAndOperatingLeaseRightOfUseAssets_iI_hsrt--StatementGeographicalAxis__country--US_zg36VoGR5Nm2" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt">United States</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">41</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">3</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_40A_ecustom--LongLivedAssetsAndOperatingLeaseRightOfUseAssets_iI_zHByftYbQb7k" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 2.5pt">Long lived assets and operating lease right of use assets</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">926</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">212</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table>

The table below summarizes the significant expense categories regularly reviewed by the CODM for the years ended December 31, 2025 and 2024: SCHEDULE OF STATEMENT OF OPERATION BY SEGMENT <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%; margin-left: 0.75in; margin-right: 0.5in"> <tr style="display: none; vertical-align: bottom"> <td style="display: none"> </td><td style="display: none; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_494_20250101__20251231_zSu7iIjKezOb" style="border-bottom: Black 1pt solid; display: none; font-weight: bold; text-align: center">2025</td><td style="display: none; padding-bottom: 1pt; font-weight: bold"> </td><td style="display: none; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_492_20240101__20241231_zVuOu5xnvbN5" style="border-bottom: Black 1pt solid; display: none; font-weight: bold; text-align: center">2024</td><td style="display: none; padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: left"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Year Ended December 31,</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: left"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Significant segment expenses</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_405_ecustom--PayrollAndPayrollRelated_maNILzcOv_zhWkfl4JK5Qe" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 20pt; width: 60%; text-align: left">Payroll and payroll related</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">(7,435</td><td style="width: 1%; text-align: left">)</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">(5,376</td><td style="width: 1%; text-align: left">)</td></tr> <tr id="xdx_404_ecustom--MaterialsAndSubcontractors_maNILzcOv_zmWHgPSFRQM5" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 20pt; text-align: left">Materials and subcontractors</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(1,898</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(2,165</td><td style="text-align: left">)</td></tr> <tr id="xdx_402_eus-gaap--ShareBasedCompensation_iN_di_msNILzcOv_zkCR8qcfiut2" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 20pt; text-align: left">Share-based compensation</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(1,057</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(1,349</td><td style="text-align: left">)</td></tr> <tr id="xdx_407_eus-gaap--SegmentReportingOtherItemAmount_iN_di_msNILzcOv_z6bCCV7tJsuh" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 20pt; text-align: left; padding-bottom: 1pt">Other segment items (*)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(2,752</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(2,553</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr> <tr id="xdx_406_eus-gaap--NetIncomeLoss_iT_mtNILzcOv_zJMV1NDTDfS1" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; text-align: left; padding-bottom: 2.5pt">Net loss</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(13,142</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(11,443</td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr> </table> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="width: 0.75in"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: right">(*)</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Other segment expense items included within net loss include professional services, patents, overhead and depreciation, travel expenses, financial income, net, other income and other miscellaneous expenses net of grants received. See the consolidated financial statements for other financial information regarding the Company’s operating segment.</td></tr> </table>

-7435000 -5376000 -1898000 -2165000

1057000

1349000

2752000

2553000

-13142000

-11443000

<p id="xdx_89A_ecustom--ScheduleOfLongLivedAssetsAndOperatingLeaseRightOfUseAssetsByGeographicalAreasTableTextBlock_zJOom3kqr1Uc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.75in; text-align: justify">Long-lived assets and operating lease right-of-use assets by geographical areas were as follows: SCHEDULE OF LONG LIVED ASSETS AND OPERATING LEASE RIGHT OF USE ASSETS BY GEOGRAPHICAL AREAS <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%; margin-left: 0.75in; margin-right: 0.5in"> <tr style="display: none; vertical-align: bottom"> <td style="display: none; font-size: 12pt"> </td><td style="display: none; font-weight: bold"> </td> <td colspan="2" id="xdx_496_20251231_zzA8hm9Izhs7" style="border-bottom: Black 1pt solid; display: none; font-weight: bold; text-align: center">2024</td><td style="display: none; font-weight: bold"> </td><td style="display: none; font-weight: bold"> </td> <td colspan="2" id="xdx_49D_20241231_zOPnu4NbPUl9" style="border-bottom: Black 1pt solid; display: none; font-weight: bold; text-align: center">2023</td><td style="display: none; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: left"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">As of December 31,</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: left"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr id="xdx_40D_ecustom--LongLivedAssetsAndOperatingLeaseRightOfUseAssets_iI_hsrt--StatementGeographicalAxis__country--IL_zsrIbesTIVB7" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; width: 60%">Israel</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">885</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">209</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_407_ecustom--LongLivedAssetsAndOperatingLeaseRightOfUseAssets_iI_hsrt--StatementGeographicalAxis__country--US_zg36VoGR5Nm2" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt">United States</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">41</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">3</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_40A_ecustom--LongLivedAssetsAndOperatingLeaseRightOfUseAssets_iI_zHByftYbQb7k" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 2.5pt">Long lived assets and operating lease right of use assets</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">926</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">212</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> 885000 209000 41000 3000 926000 212000

NOTE 16 - RELATED PARTIES There were no material related party transactions in each of the years ended December 31, 2025 and 2024 that were outside of the Company’s normal course of business.

NOTE 17 - TAXES ON INCOME The Company is subject to U.S. federal tax rate of <span id="xdx_907_eus-gaap--EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_pid_dp_uPure_c20250101__20251231__us-gaap--IncomeTaxAuthorityNameAxis__custom--USTaxAuthorityMember_zLkkCMbFUczk" title="Corporate income tax rate"><span id="xdx_907_eus-gaap--EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_pid_dp_uPure_c20240101__20241231__us-gaap--IncomeTaxAuthorityNameAxis__custom--USTaxAuthorityMember_zaGAJ8c97zI1" title="Corporate income tax rate">21% for the years ended December 31, 2025 and 2024. The Company has not been audited by the Internal Revenue Service since its incorporation. As of December 31, 2025 and 2024, the Company has generated accumulated net operating losses in the U.S. of approximately $517,992 and $511,371, respectively. The Company has available carryforward net operating losses amounting to approximately $<span id="xdx_90A_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwards_iI_pn3n3_c20251231__us-gaap--IncomeTaxAuthorityNameAxis__custom--USTaxAuthorityMember_zIcUPGXiIOag" title="Operating loss carryforwards">108,969 at the U.S. federal level. This consists of pre-2017 net operating losses subject to a 20-year limitation per Section 382, amounting to approximately $83,848, and post-2017 net operating losses which can be carried forward indefinitely, amounting to approximately $25,121. Utilization of U.S. net operating losses may be subject to substantial annual limitation due to the “change in ownership” provisions of the Internal Revenue Code of 1986 and similar state provisions. The annual limitation may result in the expiration of net operating losses before utilization. Microbot Israel is subject to Israeli corporate tax rate of <span id="xdx_90A_eus-gaap--EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_pid_dp_uPure_c20250101__20251231__us-gaap--IncomeTaxAuthorityNameAxis__us-gaap--IsraelTaxAuthorityMember_zr0m3EAgypOb" title="Corporate income tax rate"><span id="xdx_908_eus-gaap--EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_pid_dp_uPure_c20240101__20241231__us-gaap--IncomeTaxAuthorityNameAxis__us-gaap--IsraelTaxAuthorityMember_zlLR7lJ8Petb" title="Corporate income tax rate">23% for the year ended December 31, 2025 and 2024. Microbot Israel has not received a final tax assessment since 2020. As of December 31, 2025 and 2024, Microbot Israel has generated accumulated net operating losses in Israel of approximately $54,074 and $47,553, respectively, which may be carried forward and offset against taxable income in the future for an indefinite period. MICROBOT MEDICAL INC. NOTES TO CONSOLIDATED FINANCIAL STATEMENTS U.S. dollars in thousands (Except share and per share data) NOTE 17 - TAXES ON INCOME The Company is still in its development stage and has not yet generated revenues, therefore, it is more likely than not that sufficient taxable income will not be available for the tax losses to be utilized in the future. Therefore, a valuation allowance was recorded to reduce the deferred tax assets to its recoverable amounts. SCHEDULE OF DEFERRED TAX ASSETS AND LIABILITIES <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%; margin-left: 0.75in; margin-right: 0.5in"> <tr style="display: none; vertical-align: bottom"> <td style="display: none; text-align: center"> </td><td style="display: none; text-align: center; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_496_20251231_zxz1ATwTuZLe" style="border-bottom: Black 1pt solid; display: none; font-weight: bold; text-align: center"> </td><td style="display: none; text-align: center; padding-bottom: 1pt; font-weight: bold"> </td><td style="display: none; text-align: center; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_49E_20241231_zHjZ2RImTWP5" style="border-bottom: Black 1pt solid; display: none; font-weight: bold; text-align: center"> </td><td style="display: none; text-align: center; padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: left"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">As of December 31,</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: left"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: left"> </td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td></tr> <tr id="xdx_407_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwards_iI_pn3n3_maDTAGzH1x_maDTAGzhML_zbty4JHH0o37" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%; text-align: left">Net operating loss carryforwards</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">121,215</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">118,309</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_408_ecustom--DeferredTaxAssetsOperationLeaseLiabilities_iI_pn3n3_maDTAGzH1x_maDTAGzhML_zP3K1h63Z84j" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Operating lease liabilities</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">198</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">26</td><td style="text-align: left"> </td></tr> <tr id="xdx_404_ecustom--DeferredTaxAssetsAccruedVacationPay_iI_pn3n3_maDTAGzH1x_maDTAGzhML_zdKqJ7q66wt3" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Accrued vacation pay</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">101</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">69</td><td style="text-align: left"> </td></tr> <tr id="xdx_405_ecustom--DeferredTaxAssetsAdvancePaymentFromIia_iI_pn3n3_maDTAGzhML_zMm6zT3Pe9yk" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt">Advance payment from IIA</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">22</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">-</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_401_eus-gaap--DeferredTaxAssetsGross_iTI_pn3n3_maDTANzNI9_mtDTAGzhML_zCMJu2XLyr3d" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Total deferred tax assets</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">121,536</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">118,404</td><td style="text-align: left"> </td></tr> <tr id="xdx_405_eus-gaap--DeferredTaxAssetsValuationAllowance_iNI_pn3n3_di_msDTANzNI9_zNSMsuIGQLKd" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt">Less: valuation allowance</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(121,345</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(118,374</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr> <tr id="xdx_40F_eus-gaap--DeferredTaxAssetsNet_iTI_pn3n3_mtDTANzNI9_maDTLzaPY_zmtaYQ0vwCWa" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1pt">Net deferred tax assets</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">191</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">30</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_404_ecustom--DeferredTaxLiabilitiesOperatingLeasesRightofUseAssets_iNI_pn3n3_di_maDITLzqnl_maDTLzwq6_zxcuwhWwXuF2" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Operating leases, right-of-use assets</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(191</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(30</td><td style="text-align: left">)</td></tr> <tr id="xdx_40E_eus-gaap--DeferredTaxLiabilities_iNTI_di_msDTLzaPY_mtDTLzwq6_zDnHdlL5unUd" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt">Total deferred tax liabilities</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(191</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(30</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr> <tr id="xdx_405_eus-gaap--DeferredTaxAssetsLiabilitiesNet_iTI_mtDTLzaPY_zBf5b25Ns2ne" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 2.5pt">Total net deferred tax assets</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">-</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">-</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> Reconciliation of Income Taxes: The main reconciling item between the statutory tax rate of the Company and the effective tax rate is the recognition of valuation allowance in respect of deferred taxes relating to accumulated net operating losses carried forward due to the uncertainty of the realization of such deferred taxes. SCHEDULE OF RECONCILIATION OF INCOME TAXES <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%; margin-left: 0.75in; margin-right: 0.5in"> <tr style="display: none; vertical-align: bottom"> <td style="padding: 0pt; text-indent: 0pt"> </td><td style="padding: 0pt; font-weight: bold; text-indent: 0pt"> </td> <td colspan="3" id="xdx_49D_20250101__20251231_zwKX0spHxq22" style="border-bottom: Black 1pt solid; padding: 0pt; font-weight: bold; text-align: center; text-indent: 0pt">Tax</td><td style="padding: 0pt; font-weight: bold; text-indent: 0pt"> </td> <td colspan="3" style="border-bottom: Black 1pt solid; padding: 0pt; font-weight: bold; text-indent: 0pt">Rate</td></tr> <tr style="vertical-align: bottom"> <td style="padding: 0pt; text-indent: 0pt"> </td><td style="padding: 0pt; font-weight: bold; text-indent: 0pt"> </td> <td colspan="7" style="border-bottom: Black 1pt solid; padding: 0pt; font-weight: bold; text-align: center; text-indent: 0pt">Year ended December 31, 2025</td></tr> <tr style="vertical-align: bottom"> <td style="padding: 0pt; text-indent: 0pt"> </td><td style="padding: 0pt; font-weight: bold; text-indent: 0pt"> </td> <td colspan="3" style="border-bottom: Black 1pt solid; padding: 0pt; font-weight: bold; text-align: center; text-indent: 0pt">Tax</td><td style="padding: 0pt; font-weight: bold; text-indent: 0pt"> </td> <td colspan="3" style="border-bottom: Black 1pt solid; padding: 0pt; font-weight: bold; text-indent: 0pt">Rate</td></tr> <tr id="xdx_400_ecustom--IncomeTaxReconciliationIncomeTaxExpensesBenefitAtFederalStatutoryIncomeTaxRate_pn3n3_maITEBzqEk_zBjs10lv274" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding: 0pt; width: 60%; text-align: left; text-indent: 0pt">U.S. federal tax rate</td><td style="padding: 0pt; width: 2%; text-indent: 0pt"> </td> <td style="padding: 0pt; width: 1%; text-align: left; text-indent: 0pt">$</td><td style="padding: 0pt; width: 16%; text-align: right; text-indent: 0pt">(2,760</td><td style="padding: 0pt; width: 1%; text-align: left; text-indent: 0pt">)</td><td style="padding: 0pt; width: 2%; text-indent: 0pt"> </td> <td style="padding: 0pt; width: 1%; text-align: left; text-indent: 0pt"> </td><td id="xdx_98C_eus-gaap--EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_pid_dp_uPure_maAAA_c20250101__20251231_zqX8le5Hd6Bl" style="padding: 0pt; width: 16%; text-align: right; text-indent: 0pt" title="Us statutory tax rate, percentage">21</td><td style="padding: 0pt; width: 1%; text-align: left; text-indent: 0pt">%</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding: 0pt; text-indent: 0pt"> </td><td style="padding: 0pt; text-indent: 0pt"> </td> <td style="padding: 0pt; text-align: left; text-indent: 0pt"> </td><td style="padding: 0pt; text-align: right; text-indent: 0pt"> </td><td style="padding: 0pt; text-align: left; text-indent: 0pt"> </td><td style="padding: 0pt; text-indent: 0pt"> </td> <td style="padding: 0pt; text-align: left; text-indent: 0pt"> </td><td style="padding: 0pt; text-align: right; text-indent: 0pt"> </td><td style="padding: 0pt; text-align: left; text-indent: 0pt"> </td></tr> <tr id="xdx_40B_eus-gaap--IncomeTaxReconciliationForeignIncomeTaxRateDifferential_pn3n3_maITEBzqEk_zMMNZ2HpHOPf" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding: 0pt; text-align: left; text-indent: 0pt">Statutory tax rate difference between U.S. and Israel</td><td style="padding: 0pt; text-indent: 0pt"> </td> <td style="padding: 0pt 0pt 1pt; text-align: left; text-indent: 0pt"> </td><td style="padding: 0pt 0pt 1pt; text-align: right; text-indent: 0pt">(130</td><td style="padding: 0pt; text-align: left; text-indent: 0pt">)</td><td style="padding: 0pt; text-indent: 0pt"> </td> <td style="padding: 0pt 0pt 1pt; text-align: left; text-indent: 0pt"> </td><td id="xdx_982_eus-gaap--EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_pid_dp_uPure_maAAA_c20250101__20251231_z0jkb09gAHa1" style="padding: 0pt 0pt 1pt; text-align: right; text-indent: 0pt" title="Statutory tax rate difference between U.S. and Israel, percentage">1</td><td style="padding: 0pt; text-align: left; text-indent: 0pt">%</td></tr> <tr id="xdx_40C_eus-gaap--IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_pn3n3_maITEBzqEk_zXYt3hZznvw4" style="vertical-align: bottom; background-color: White"> <td style="padding: 0pt; text-align: left; text-indent: 0pt">Changes in valuation allowances</td><td style="padding: 0pt; text-indent: 0pt"> </td> <td style="padding: 0pt 0pt 1pt; text-align: left; text-indent: 0pt"> </td><td style="padding: 0pt 0pt 1pt; text-align: right; text-indent: 0pt">2,971</td><td style="padding: 0pt; text-align: left; text-indent: 0pt"> </td><td style="padding: 0pt; text-indent: 0pt"> </td> <td style="padding: 0pt 0pt 1pt; text-align: left; text-indent: 0pt"> </td><td id="xdx_988_eus-gaap--EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_pid_dp_uPure_maAAA_c20250101__20251231_zpw6XV0mMVzc" style="padding: 0pt 0pt 1pt; text-align: right; text-indent: 0pt" title="Changes in valuation allowances, percentage">(22</td><td style="padding: 0pt; text-align: left; text-indent: 0pt">%)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding: 0pt; text-indent: 0pt"> </td><td style="padding: 0pt; text-indent: 0pt"> </td> <td style="padding: 0pt; text-align: left; text-indent: 0pt"> </td><td style="padding: 0pt; text-align: right; text-indent: 0pt"> </td><td style="padding: 0pt; text-align: left; text-indent: 0pt"> </td><td style="padding: 0pt; text-indent: 0pt"> </td> <td style="padding: 0pt; text-align: left; text-indent: 0pt"> </td><td style="padding: 0pt; text-align: right; text-indent: 0pt"> </td><td style="padding: 0pt; text-align: left; text-indent: 0pt"> </td></tr> <tr id="xdx_40A_eus-gaap--IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost_pn3n3_maITEBzqEk_z4STQnq6l27g" style="vertical-align: bottom; background-color: White"> <td style="padding: 0pt; text-align: left; text-indent: 0pt">Share-based compensation</td><td style="padding: 0pt; text-indent: 0pt"> </td> <td style="padding: 0pt 0pt 1pt; text-align: left; text-indent: 0pt"> </td><td style="padding: 0pt 0pt 1pt; text-align: right; text-indent: 0pt">227</td><td style="padding: 0pt; text-align: left; text-indent: 0pt"> </td><td style="padding: 0pt; text-indent: 0pt"> </td> <td style="padding: 0pt 0pt 1pt; text-align: left; text-indent: 0pt"> </td><td id="xdx_984_eus-gaap--EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost_pid_dp_uPure_maAAA_c20250101__20251231_zH9rl90lrA88" style="padding: 0pt 0pt 1pt; text-align: right; text-indent: 0pt" title="Share-based compensation, percentage">(2</td><td style="padding: 0pt; text-align: left; text-indent: 0pt">%)</td></tr> <tr id="xdx_40D_eus-gaap--IncomeTaxReconciliationOtherAdjustments_pn3n3_maITEBzqEk_zsldkPcQ47Xf" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding: 0pt; text-align: left; text-indent: 0pt">Other adjustments</td><td style="padding: 0pt; text-indent: 0pt"> </td> <td style="border-bottom: Black 1pt solid; padding: 0pt; text-align: left; text-indent: 0pt"> </td><td style="border-bottom: Black 1pt solid; padding: 0pt; text-align: right; text-indent: 0pt">(308</td><td style="padding: 0pt; text-align: left; text-indent: 0pt">)</td><td style="padding: 0pt; text-indent: 0pt"> </td> <td style="border-bottom: Black 1pt solid; padding: 0pt; text-align: left; text-indent: 0pt"> </td><td id="xdx_985_eus-gaap--EffectiveIncomeTaxRateReconciliationOtherAdjustments_pid_dp_uPure_maAAA_c20250101__20251231_zIMmeCBqg70l" style="border-bottom: Black 1pt solid; padding: 0pt; text-align: right; text-indent: 0pt" title="Other Adjustments, percentage">2</td><td style="padding: 0pt; text-align: left; text-indent: 0pt">%</td></tr> <tr id="xdx_401_eus-gaap--IncomeTaxExpenseBenefit_iT_pn3n3_mtITEBzqEk_zO7624m4bMpa" style="vertical-align: bottom; background-color: White"> <td style="padding: 0pt; text-align: left; text-indent: 0pt">Effective tax rate</td><td style="padding: 0pt; text-indent: 0pt"> </td> <td style="border-bottom: Black 2.5pt double; padding: 0pt; text-align: left; text-indent: 0pt">$</td><td style="border-bottom: Black 2.5pt double; padding: 0pt; text-align: right; text-indent: 0pt">-</td><td style="padding: 0pt; text-align: left; text-indent: 0pt"> </td><td style="padding: 0pt; text-indent: 0pt"> </td> <td style="border-bottom: Black 2.5pt double; padding: 0pt; text-align: left; text-indent: 0pt"> </td><td id="xdx_982_eus-gaap--EffectiveIncomeTaxRateContinuingOperations_iT_pid_dp_uPure_mtAAA_c20250101__20251231_zOGgDRQUWzKj" style="border-bottom: Black 2.5pt double; padding: 0pt; text-align: right; text-indent: 0pt" title="Effective tax rate, percentage">0</td><td style="padding: 0pt; text-align: left; text-indent: 0pt">%</td></tr> </table> MICROBOT MEDICAL INC. NOTES TO CONSOLIDATED FINANCIAL STATEMENTS U.S. dollars in thousands (Except share and per share data)

0.21

517992000

511371000

108969000

83848000

25121000

0.23

54074000

47553000

SCHEDULE OF DEFERRED TAX ASSETS AND LIABILITIES <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%; margin-left: 0.75in; margin-right: 0.5in"> <tr style="display: none; vertical-align: bottom"> <td style="display: none; text-align: center"> </td><td style="display: none; text-align: center; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_496_20251231_zxz1ATwTuZLe" style="border-bottom: Black 1pt solid; display: none; font-weight: bold; text-align: center"> </td><td style="display: none; text-align: center; padding-bottom: 1pt; font-weight: bold"> </td><td style="display: none; text-align: center; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_49E_20241231_zHjZ2RImTWP5" style="border-bottom: Black 1pt solid; display: none; font-weight: bold; text-align: center"> </td><td style="display: none; text-align: center; padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: left"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">As of December 31,</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: left"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: left"> </td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td></tr> <tr id="xdx_407_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwards_iI_pn3n3_maDTAGzH1x_maDTAGzhML_zbty4JHH0o37" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%; text-align: left">Net operating loss carryforwards</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">121,215</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">118,309</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_408_ecustom--DeferredTaxAssetsOperationLeaseLiabilities_iI_pn3n3_maDTAGzH1x_maDTAGzhML_zP3K1h63Z84j" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Operating lease liabilities</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">198</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">26</td><td style="text-align: left"> </td></tr> <tr id="xdx_404_ecustom--DeferredTaxAssetsAccruedVacationPay_iI_pn3n3_maDTAGzH1x_maDTAGzhML_zdKqJ7q66wt3" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Accrued vacation pay</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">101</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">69</td><td style="text-align: left"> </td></tr> <tr id="xdx_405_ecustom--DeferredTaxAssetsAdvancePaymentFromIia_iI_pn3n3_maDTAGzhML_zMm6zT3Pe9yk" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt">Advance payment from IIA</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">22</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">-</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_401_eus-gaap--DeferredTaxAssetsGross_iTI_pn3n3_maDTANzNI9_mtDTAGzhML_zCMJu2XLyr3d" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Total deferred tax assets</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">121,536</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">118,404</td><td style="text-align: left"> </td></tr> <tr id="xdx_405_eus-gaap--DeferredTaxAssetsValuationAllowance_iNI_pn3n3_di_msDTANzNI9_zNSMsuIGQLKd" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt">Less: valuation allowance</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(121,345</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(118,374</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr> <tr id="xdx_40F_eus-gaap--DeferredTaxAssetsNet_iTI_pn3n3_mtDTANzNI9_maDTLzaPY_zmtaYQ0vwCWa" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1pt">Net deferred tax assets</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">191</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">30</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_404_ecustom--DeferredTaxLiabilitiesOperatingLeasesRightofUseAssets_iNI_pn3n3_di_maDITLzqnl_maDTLzwq6_zxcuwhWwXuF2" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Operating leases, right-of-use assets</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(191</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(30</td><td style="text-align: left">)</td></tr> <tr id="xdx_40E_eus-gaap--DeferredTaxLiabilities_iNTI_di_msDTLzaPY_mtDTLzwq6_zDnHdlL5unUd" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt">Total deferred tax liabilities</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(191</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(30</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr> <tr id="xdx_405_eus-gaap--DeferredTaxAssetsLiabilitiesNet_iTI_mtDTLzaPY_zBf5b25Ns2ne" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 2.5pt">Total net deferred tax assets</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">-</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">-</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table>

121215000

118309000

198000 26000 101000 69000 22000

121536000

118404000

121345000

118374000

191000

30000

191000 30000

191000

30000

The main reconciling item between the statutory tax rate of the Company and the effective tax rate is the recognition of valuation allowance in respect of deferred taxes relating to accumulated net operating losses carried forward due to the uncertainty of the realization of such deferred taxes. SCHEDULE OF RECONCILIATION OF INCOME TAXES <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%; margin-left: 0.75in; margin-right: 0.5in"> <tr style="display: none; vertical-align: bottom"> <td style="padding: 0pt; text-indent: 0pt"> </td><td style="padding: 0pt; font-weight: bold; text-indent: 0pt"> </td> <td colspan="3" id="xdx_49D_20250101__20251231_zwKX0spHxq22" style="border-bottom: Black 1pt solid; padding: 0pt; font-weight: bold; text-align: center; text-indent: 0pt">Tax</td><td style="padding: 0pt; font-weight: bold; text-indent: 0pt"> </td> <td colspan="3" style="border-bottom: Black 1pt solid; padding: 0pt; font-weight: bold; text-indent: 0pt">Rate</td></tr> <tr style="vertical-align: bottom"> <td style="padding: 0pt; text-indent: 0pt"> </td><td style="padding: 0pt; font-weight: bold; text-indent: 0pt"> </td> <td colspan="7" style="border-bottom: Black 1pt solid; padding: 0pt; font-weight: bold; text-align: center; text-indent: 0pt">Year ended December 31, 2025</td></tr> <tr style="vertical-align: bottom"> <td style="padding: 0pt; text-indent: 0pt"> </td><td style="padding: 0pt; font-weight: bold; text-indent: 0pt"> </td> <td colspan="3" style="border-bottom: Black 1pt solid; padding: 0pt; font-weight: bold; text-align: center; text-indent: 0pt">Tax</td><td style="padding: 0pt; font-weight: bold; text-indent: 0pt"> </td> <td colspan="3" style="border-bottom: Black 1pt solid; padding: 0pt; font-weight: bold; text-indent: 0pt">Rate</td></tr> <tr id="xdx_400_ecustom--IncomeTaxReconciliationIncomeTaxExpensesBenefitAtFederalStatutoryIncomeTaxRate_pn3n3_maITEBzqEk_zBjs10lv274" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding: 0pt; width: 60%; text-align: left; text-indent: 0pt">U.S. federal tax rate</td><td style="padding: 0pt; width: 2%; text-indent: 0pt"> </td> <td style="padding: 0pt; width: 1%; text-align: left; text-indent: 0pt">$</td><td style="padding: 0pt; width: 16%; text-align: right; text-indent: 0pt">(2,760</td><td style="padding: 0pt; width: 1%; text-align: left; text-indent: 0pt">)</td><td style="padding: 0pt; width: 2%; text-indent: 0pt"> </td> <td style="padding: 0pt; width: 1%; text-align: left; text-indent: 0pt"> </td><td id="xdx_98C_eus-gaap--EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_pid_dp_uPure_maAAA_c20250101__20251231_zqX8le5Hd6Bl" style="padding: 0pt; width: 16%; text-align: right; text-indent: 0pt" title="Us statutory tax rate, percentage">21</td><td style="padding: 0pt; width: 1%; text-align: left; text-indent: 0pt">%</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding: 0pt; text-indent: 0pt"> </td><td style="padding: 0pt; text-indent: 0pt"> </td> <td style="padding: 0pt; text-align: left; text-indent: 0pt"> </td><td style="padding: 0pt; text-align: right; text-indent: 0pt"> </td><td style="padding: 0pt; text-align: left; text-indent: 0pt"> </td><td style="padding: 0pt; text-indent: 0pt"> </td> <td style="padding: 0pt; text-align: left; text-indent: 0pt"> </td><td style="padding: 0pt; text-align: right; text-indent: 0pt"> </td><td style="padding: 0pt; text-align: left; text-indent: 0pt"> </td></tr> <tr id="xdx_40B_eus-gaap--IncomeTaxReconciliationForeignIncomeTaxRateDifferential_pn3n3_maITEBzqEk_zMMNZ2HpHOPf" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding: 0pt; text-align: left; text-indent: 0pt">Statutory tax rate difference between U.S. and Israel</td><td style="padding: 0pt; text-indent: 0pt"> </td> <td style="padding: 0pt 0pt 1pt; text-align: left; text-indent: 0pt"> </td><td style="padding: 0pt 0pt 1pt; text-align: right; text-indent: 0pt">(130</td><td style="padding: 0pt; text-align: left; text-indent: 0pt">)</td><td style="padding: 0pt; text-indent: 0pt"> </td> <td style="padding: 0pt 0pt 1pt; text-align: left; text-indent: 0pt"> </td><td id="xdx_982_eus-gaap--EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_pid_dp_uPure_maAAA_c20250101__20251231_z0jkb09gAHa1" style="padding: 0pt 0pt 1pt; text-align: right; text-indent: 0pt" title="Statutory tax rate difference between U.S. and Israel, percentage">1</td><td style="padding: 0pt; text-align: left; text-indent: 0pt">%</td></tr> <tr id="xdx_40C_eus-gaap--IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_pn3n3_maITEBzqEk_zXYt3hZznvw4" style="vertical-align: bottom; background-color: White"> <td style="padding: 0pt; text-align: left; text-indent: 0pt">Changes in valuation allowances</td><td style="padding: 0pt; text-indent: 0pt"> </td> <td style="padding: 0pt 0pt 1pt; text-align: left; text-indent: 0pt"> </td><td style="padding: 0pt 0pt 1pt; text-align: right; text-indent: 0pt">2,971</td><td style="padding: 0pt; text-align: left; text-indent: 0pt"> </td><td style="padding: 0pt; text-indent: 0pt"> </td> <td style="padding: 0pt 0pt 1pt; text-align: left; text-indent: 0pt"> </td><td id="xdx_988_eus-gaap--EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_pid_dp_uPure_maAAA_c20250101__20251231_zpw6XV0mMVzc" style="padding: 0pt 0pt 1pt; text-align: right; text-indent: 0pt" title="Changes in valuation allowances, percentage">(22</td><td style="padding: 0pt; text-align: left; text-indent: 0pt">%)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding: 0pt; text-indent: 0pt"> </td><td style="padding: 0pt; text-indent: 0pt"> </td> <td style="padding: 0pt; text-align: left; text-indent: 0pt"> </td><td style="padding: 0pt; text-align: right; text-indent: 0pt"> </td><td style="padding: 0pt; text-align: left; text-indent: 0pt"> </td><td style="padding: 0pt; text-indent: 0pt"> </td> <td style="padding: 0pt; text-align: left; text-indent: 0pt"> </td><td style="padding: 0pt; text-align: right; text-indent: 0pt"> </td><td style="padding: 0pt; text-align: left; text-indent: 0pt"> </td></tr> <tr id="xdx_40A_eus-gaap--IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost_pn3n3_maITEBzqEk_z4STQnq6l27g" style="vertical-align: bottom; background-color: White"> <td style="padding: 0pt; text-align: left; text-indent: 0pt">Share-based compensation</td><td style="padding: 0pt; text-indent: 0pt"> </td> <td style="padding: 0pt 0pt 1pt; text-align: left; text-indent: 0pt"> </td><td style="padding: 0pt 0pt 1pt; text-align: right; text-indent: 0pt">227</td><td style="padding: 0pt; text-align: left; text-indent: 0pt"> </td><td style="padding: 0pt; text-indent: 0pt"> </td> <td style="padding: 0pt 0pt 1pt; text-align: left; text-indent: 0pt"> </td><td id="xdx_984_eus-gaap--EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost_pid_dp_uPure_maAAA_c20250101__20251231_zH9rl90lrA88" style="padding: 0pt 0pt 1pt; text-align: right; text-indent: 0pt" title="Share-based compensation, percentage">(2</td><td style="padding: 0pt; text-align: left; text-indent: 0pt">%)</td></tr> <tr id="xdx_40D_eus-gaap--IncomeTaxReconciliationOtherAdjustments_pn3n3_maITEBzqEk_zsldkPcQ47Xf" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding: 0pt; text-align: left; text-indent: 0pt">Other adjustments</td><td style="padding: 0pt; text-indent: 0pt"> </td> <td style="border-bottom: Black 1pt solid; padding: 0pt; text-align: left; text-indent: 0pt"> </td><td style="border-bottom: Black 1pt solid; padding: 0pt; text-align: right; text-indent: 0pt">(308</td><td style="padding: 0pt; text-align: left; text-indent: 0pt">)</td><td style="padding: 0pt; text-indent: 0pt"> </td> <td style="border-bottom: Black 1pt solid; padding: 0pt; text-align: left; text-indent: 0pt"> </td><td id="xdx_985_eus-gaap--EffectiveIncomeTaxRateReconciliationOtherAdjustments_pid_dp_uPure_maAAA_c20250101__20251231_zIMmeCBqg70l" style="border-bottom: Black 1pt solid; padding: 0pt; text-align: right; text-indent: 0pt" title="Other Adjustments, percentage">2</td><td style="padding: 0pt; text-align: left; text-indent: 0pt">%</td></tr> <tr id="xdx_401_eus-gaap--IncomeTaxExpenseBenefit_iT_pn3n3_mtITEBzqEk_zO7624m4bMpa" style="vertical-align: bottom; background-color: White"> <td style="padding: 0pt; text-align: left; text-indent: 0pt">Effective tax rate</td><td style="padding: 0pt; text-indent: 0pt"> </td> <td style="border-bottom: Black 2.5pt double; padding: 0pt; text-align: left; text-indent: 0pt">$</td><td style="border-bottom: Black 2.5pt double; padding: 0pt; text-align: right; text-indent: 0pt">-</td><td style="padding: 0pt; text-align: left; text-indent: 0pt"> </td><td style="padding: 0pt; text-indent: 0pt"> </td> <td style="border-bottom: Black 2.5pt double; padding: 0pt; text-align: left; text-indent: 0pt"> </td><td id="xdx_982_eus-gaap--EffectiveIncomeTaxRateContinuingOperations_iT_pid_dp_uPure_mtAAA_c20250101__20251231_zOGgDRQUWzKj" style="border-bottom: Black 2.5pt double; padding: 0pt; text-align: right; text-indent: 0pt" title="Effective tax rate, percentage">0</td><td style="padding: 0pt; text-align: left; text-indent: 0pt">%</td></tr> </table>

-2760000

0.21

-130000

0.01

2971000

-0.22

227000

-0.02

-308000

0.02

NOTE 18 – SUBSEQUENT EVENTS <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.75in"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify">A.</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Stock option grants and other compensation:</td></tr> </table> In February 2026, the Company authorized and approved the CEO a total bonus amounting to approximately $<span id="xdx_90B_eus-gaap--EmployeeBenefitsAndShareBasedCompensation_pn3n3_c20260201__20260228__srt--TitleOfIndividualAxis__srt--ChiefExecutiveOfficerMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zndz2IWPg9r6" title="Special bonus paid">556, out of which an approximate amount of $<span id="xdx_906_ecustom--AnnualBonus_pn3n3_c20260201__20260228__srt--TitleOfIndividualAxis__srt--ChiefExecutiveOfficerMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zFO3coEREkZ8" title="Annual bonus">417 is related to fiscal year 2025 and $<span id="xdx_900_eus-gaap--SalariesAndWages_pn3n3_c20260201__20260228__srt--TitleOfIndividualAxis__srt--ChiefExecutiveOfficerMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zX3mJLqjZSd8" title="Special bonus">139 is a special bonus. The company also approved salary increase to the CEO. In February 2026, the Company authorized and approved bonuses to executives and certain employees in the amount of approximately $<span id="xdx_900_eus-gaap--EmployeeBenefitsAndShareBasedCompensation_pn3n3_c20260201__20260228__srt--TitleOfIndividualAxis__custom--ExecutivesAndCertainEmployeesMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zx1tgXCYHaR5" title="Employee benefits and share based compensation">434, related to fiscal year 2025, and approved salary increases to executives and certain employees. Furthermore, in February and March 2026, the Company granted the CEO and executives <span id="xdx_907_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_c20260201__20260228__srt--TitleOfIndividualAxis__srt--ChiefExecutiveOfficerMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zXXFPWovlnq" title="Number of options granted"><span id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_c20260301__20260331__srt--TitleOfIndividualAxis__srt--ChiefExecutiveOfficerMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zRI1SFvgx5Pk" title="Number of options granted">480,000 and <span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_c20260201__20260228__srt--TitleOfIndividualAxis__us-gaap--ExecutiveCommitteeMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zbwukUehruo5" title="Number of options granted"><span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_c20260301__20260331__srt--TitleOfIndividualAxis__us-gaap--ExecutiveCommitteeMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zim3Fg9eEL39" title="Number of options granted">315,000 options, respectively. Additionally, the Company approved to grant <span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_c20260201__20260228__srt--TitleOfIndividualAxis__custom--EmployeesMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zFDN7gB9Jp54" title="Option granted"><span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_c20260301__20260331__srt--TitleOfIndividualAxis__custom--EmployeesMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zrxwaRvcLcX5" title="Option granted">292,500 options to certain employees. <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: top"> <td style="font: 12pt Times New Roman, Times, Serif; padding: 0pt; width: 0.75in; text-indent: 0pt"> </td> <td style="font: 12pt Times New Roman, Times, Serif; padding: 0pt; width: 0.25in; text-align: justify; text-indent: 0pt">B.</td> <td style="font: 12pt Times New Roman, Times, Serif; padding: 0pt; text-align: justify; text-indent: 0pt">Bank guarantee:</td></tr> </table> In February 2026, the Company provided an unconditional bank guarantee on amount of $800. The guarantee was provided to secure the Company’s obligations in respect of purchases made by the subcontractor that manufactures inventory for the Company. The guarantee will be exercised only in the event that the Company fails to settle its payment obligations to the subcontractor for such purchases.

556000

417000

139000

434000

480000

315000

292500

800000 Net of issuance costs in the amount of $661. See note 10F. Net of issuance costs in the amount of $239. Net of issuance costs in the amount of $5,155, of which $101 had not been paid as of December 31, 2025. Net of issuance costs in the amount of $65. Net of issuance costs in the amount of $2,370. Less than $1 Other segment expense items included within net loss include professional services, patents, overhead and depreciation, travel expenses, financial income, net, other income and other miscellaneous expenses net of grants received. See the consolidated financial statements for other financial information regarding the Company’s operating segment.